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Abstract 
eIF4A  
Eukaryotic initiation factor 4A (eIF4A) is an ATP-dependent RNA helicase 
responsible for unwinding the secondary structure of mRNAs. In humans, eIF4A 
exists as three separate paralogs: eIF4AI and eIF4AII possess a high degree of 
homology while eIF4AIII is distinct. Knockdown of eIF4AII had no effect on the 
expression of a reporter construct containing a structured RNA hairpin. 
Knockdown of eIF4AI and treatment with hippuristanol (an eIF4A inhibitor) 
caused a dramatic reduction in the hairpin-mediated gene. This reporter system 
was developed as part of this project to act as a screen for eIF4A activity along 
with an in vitro screening approach. 
 
PDCD4 
The activity of eIF4A is suppressed in vivo by the tumour suppressor PDCD4. The 
fact that loss of PDCD4 function increases the severity of DNA damage is 
probably attributable its eIF4A-suppressive activity.  
 
Alzheimer's Disease 
Based on previous microarray data, it was supposed that eIF4A inhibition may be 
therapeutically beneficial in the treatment of Alzheimer's disease. As part of this 
project, it was demonstrated that eIF4A suppression significantly reduced the 
H[SUHVVLRQRIUHSRUWHUJHQHVSUHFHGHGE\ WKH·875VRIJHQHVSUHGLFWHG WRSOD\
KDUPIXO UROHV LQ$O]KHLPHU·VGLVHDVH7KHH[SUHVVLRQ of reporter genes preceded 
E\ WKH·875VHTXHQFHVRIJHQHVSUHGLFWHG WREHEHQHILFLDO LQ$O]KHLPHU
VZHUH
not affected by this suppression. 
 
Cancer 
5HSRUWHU SODVPLGV FRQWDLQLQJ WKH · 875 VHTXHQFHV RI WKH RQFRJHQHV 2'&
EGFR and VEGFA have high requirements for eIF4A as estimated using 
hippuristanol. eIF4A inhibition did not significantly affect the reporters 
FRQWDLQLQJWKH·875VRIQRQ-SDWKRJHQLFJHQHV7KH(*)5·875ZDVIRXQGWR
contain an IRES which explains why EGFR is upregulated in response to hypoxia.  
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Chapter 1. Introduction 
 
Part 1. 
An Introduction to Translation 
 
 
1.1.1. Background 
In biology, translation is the process by which the nucleotide sequence of a 
messenger RNA (mRNA) directs the synthesis of a specific peptide (Reviewed in: 
(Gray and Wickens, 1998)). The machinery of translation is highly conserved 
across organisms but there are differences between eukaryotes, prokaryotes and 
archaea (Noller, 2004). Translation in archaea bears a resemblance to that in 
eukaryotic organisms, particularly in the structure of the ribosome (Allers and 
Mevarech, 2005; Dennis, 1997). It is this difference in ribosomal composition that 
allows a large number of antibiotics (e.g. chloramphenicol) to be specific in their 
disruption of bacterial translation without damaging eukaryotic cells (Pestka, 
1974). 
Prokaryotic translation is mechanistically similar to eukaryotic although it only 
requires the action of three main factors as opposed to the large number (>12) 
often required by eukaryotes (Kozak, 1999; Myasnikov et al., 2009).  
The canonical nature of many of the factors and processes of translation has led to 
the postulation that it was highly evolved even before the divergence of the three 
main groups of life (Woese, 2002). The relative simplicity of prokaryotic 
translation, combined with the fact that bacteria are very easy to culture in the 
laboratory made prokaryotes the model organism for studying translation in the 
early years of the discipline (Goldstein, 1970).  
Although the study of translation in prokaryotes has had a head start, there is 
now a large body of information about translation in eukaryotes (Reviewed in: 
(Jackson et al., 2010)).  
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1.1.2. The Stages of Translation 
Translation is divided into four stages: initiation, elongation, termination and 
recycling (Reviewed in: (Pestova et al., 2001)). The initiation of translation 
requires a large number of proteins termed initiation factors (Reviewed in: 
(Kozak, 1999)). These factors act in concert to bind the ribosome to a mRNA and 
allow it to scan for the translation start codon (usually AUG) (Kozak, 1984a). The 
ribosome is an organelle consisting of a collection of protein and ribosomal RNA 
(rRNA) molecules divided into small and large subunits; its function is to facilitate 
the synthesis of a peptide using the amino acid sequence defined by the mRNA 
(Figure 1.1.) (Reviewed in: (Ramakrishnan, 2002)).  
 
 
 
 
 
 
 
 
GGCGGCCGCCGCCGCCCAGACCGGATGACAGGCCACCTC 
  
 
 
Figure 1.1. The complete ribosome. The diagram shows the complete ribosome 
engaged in the elongation stage of translation. 
 
Translation initiation is a significant regulatory element in the expression of 
many genes (Reviewed in: (Sonenberg and Hinnebusch, 2009; Thach, 1991). 
Regulation occurs at a number of stages of gene expression, for example at the 
level of transcription, but the regulation of translation is an increasingly 
interesting field as it has implications in a range of diseases (Gingras et al., 1999; 
Hollams et al., 2002). 
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1.1.3. Transcription 
A pre-mRNA is generated initially when RNA polymerase II transcribes a copy of 
WKH UHOHYDQW VHFWLRQ RI WKH FHOO·V JHQRPH 5HYLHZHG LQ (Nikolov and Burley, 
1997)). As the mRNA is synthesised, it is subject to modifications that protect it 
from exonuclease degradation and allow it to be efficiently translated (Reviewed 
in: (Erkmann and Kutay, 2004)). The following sections outline these 
modifications. 
 
7KH·&DS 
7KH · HQGRI WKH SUH-P51$ LV PRGLILHG E\ WKH DGGLWLRQ RI WKH · FDS VWUXFWXUH
((Reddy et al., 1974), Reviewed in: (Banerjee, 1980)7KH WHUPLQDO·SKRVSKDWH
group of the RNA backbone is removed by hydrolysis performed by a phosphatase, 
followed by the action of guanosyl transferase which leads to the creation of a 
GLSKRVSKDWH · HQG 7KH · HQG WKHQ DWWDFNV WKH ǂ-phosphorous atom of the 
JXDQRVLQH WULSKRVSKDWH *73 WR IRUP WKH ·-· WULSKRVSKDWH ERQG 5HYLHZHG LQ
(Kapp and Lorsch, 2004)). The nitrogen atom at position 7 on the guanine cap is 
methylated by guanine methyltransferase which transfers a methyl group from S-
adenosyl methionine (Yamada-Okabe et al., 1999). The methylated guanine 
triphosphate is referred to as 7-methylguanosine (or simply m7G) (Perry and 
Kelley, 1974).  
In addition to protecting the mRNA molecule from degradation by exonuclease 
enzymes, the cap provides a binding site for factors involved in the initiation of 
translation.  
 
1.1.5. Polyadenylation of an RNA 
7KH·WHUPLQXVLVDOVRVXEMHFWWRPRGLILFDWLRQ7KH51$VWUDQGLVFOHDYHGZLWKLQ
WKH · XQWUDQVODWHG UHJLRQ E\ DQ HQGRQXFOHDVH WKDW UHFRJQLVHV WKH VHTXHQFH
AAUAAA and cuts the molecule at a site 30 nucleotides downstream (Fitzgerald 
and Shenk, 1981). The excised fragment is replaced by a polyadenylate (poly(A)) 
tail consisting of an average of 250 adenylate residues (Wickens, 1990). As it is 
synthesised, poly(A)-binding proteins (PABPs) become associated with the 
polyadenylate tail (Sachs et al., 1986). PABP-binding proteins PAIP1 and PAIP2 
bind both the RNA-associated domain of PABP and also the carboxy terminus and 
serve to regulate the level of total protein synthesis (Craig et al., 1998). Binding of 
PAIP2 to PABP causes PABP to dislocate from the RNA. When PABP levels are 
depleted E3 ubiquitin ligase degrades PAIP2, this mechanism is believed to even 
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out fluctuations and maintain consistent protein homeostasis (Khaleghpour et al., 
2001; Yoshida et al., 2006). 
Like the cap, the poly(A) tail also facilitates the translation of a mRNA as well as 
stabilising the molecule (Walther et al., 1998). It is believed that mRNA molecules 
are circularised by the binding of PABP DQG 3$,3 WR · FDS-associated 
translation initiation factors, a phenomenon which stimulates translation (Craig 
et al., 1998; Roy et al., 2002; Yazaki et al., 2000). 
 
1.1.6. mRNA Splicing and Editing 
The non-coding intron sequences are spliced out of an mRNA molecule and the 
coding exons are ligated together (Berget et al., 1977; Black, 2003). Some introns 
are self-splicing but the splicing of most introns is mediated by the spliceosome 
complex (Cech, 1990). The spliceosome consists of small nuclear RNAs (snRNA) 
and a collection of over 150 polypeptides (Reviewed in: (Kramer, 1996; Zhou et al., 
2002)). This complex assembles on the mRNA and recognises the introns by the 
presence of the splice donor and acceptor sites (Reviewed in: (Robin, 1996)). The 
GRQRUVLWHDWWKH·HQGRIWKHLQWURQLVXVXDOO\FKDUDcterised by the presence of 
WKHVHTXHQFH*8ZKLOHWKHDFFHSWRUVLWHDWWKH·HQGLVXVXDOO\FKDUDFWHULVHGE\
the sequence: AG (Reviewed in: (Berget, 1995)). Upstream of the acceptor site is a 
polypyrimidine tract and upstream of this is a conserved adenosine residue known 
as the branch point (Patton et al., 1991; Smith et al., 1989). The spliceosome 
brings together and ligates the donor and acceptor sites (Anderson and Moore, 
2000)7KLVSURFHVVFDXVHVWKH51$WRIRUPDORRSRU¶ODULDW·ZKLFKXQGHUJRHVVHOI-
cleavage once the exons have been ligated (Agback et al., 1993; Anderson and 
Moore, 2000).  
Alternative splicing of exons offers a mechanism by which a single mRNA can 
code for different proteins (Chow et al., 1977). Introns are either spliced out of the 
mRNA or left in (Black, 2003; Modrek and Lee, 2002). An intron sequence will be 
translated along with the rest of the mRNA if it is left un-spliced and the protein 
generated will therefore be different to the one generated by the spliced mRNA 
(Black, 2003; Modrek and Lee, 2002). 
One further method by which mRNA processing may occur is termed RNA editing, 
this process involves the changing of the nucleotide sequence of the RNA and it 
confers similar advantages to the cell as alternative splicing (Benne et al., 1986; 
Covello and Gray, 1993). 
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1.1.7. The Untranslated Regions (UTRs) 
The mRNA does not only encode the order in which the amino acids are to be 
bonded, it also directs the translation machinery as to when to start and stop the 
process of translation. The start codon is usually AUG while the stop codon is 
UAG, UAA or UGA (Brenner et al., 1967; Brenner et al., 1965; Hinnebusch, 2011). 
7KHP51$PROHFXOHH[WHQGVEH\RQGWKHVWDUWFRGRQLQWKH·GLUHFWLRQDQGEH\RQG
the stop codon in tKH · GLUHFWLRQ 7KHVH GLVWDO VHTXHQFHV DUH WHUPHG WKH ·
XQWUDQVODWHGUHJLRQ·875DQGWKH·XQWUDQVODWHGUHJLRQ·875UHVSHFWLYHO\
7KHEHVWFKDUDFWHULVHGIXQFWLRQRIWKH·875LVWRUHJXODWHWKHH[SUHVVLRQRIWKH
downstream coding sequence (Kozak, 1987)6RPHP51$VSRVVHVV¶ZHDN··875V
these are more difficult to translate due to their length and secondary structure 
(De Benedetti and Graff, 2004). Many of the genes involved in proliferation are 
regulated in this way (De Benedetti and Graff, 2004). 
 
 
1.1.8. Cis-Acting RNA Elements 
 
The Iron Response Element (IRE) 
7KH · 875 PD\ DOVR PD\ DFW DV DQ RSHUDWRU PDNLQJ WKH H[SUHVVLRQ RI WKH
downstream open reading frame (ORF) dependent upon the fulfilment of a certain 
condition (Aisen et al., 2001))RUH[DPSOHDVKRUW51$VWHPORRSIRUPVLQWKH·
RU · 875V RI D QXPEHU RI JHQHV LQYROYHG LQ LURQ PHWDEROLVP DQG SURYLGHV D
binding site for iron response proteins (IRPs) (Aisen et al., 2001; Hentze, 1995; 
Hentze et al., 1987; Hentze and Kuhn, 1996). L ferritin is an example of an IRE-
regulated gene involved in the solubilisation and storage of iron (Figure 1.2.) 
(Reviewed in: (Torti and Torti, 2002)7KH·875RI/IHUULWLQFRQWDLQVDVLQJOH
stem loop that acts as a binding site for the iron response proteins (IRPs) (Theil, 
1990). Binding of the IRPs in low iron concentrations causes the translational 
repression of the mRNA (Figure 1.2.) (Reviewed in: (Piccinelli and Samuelsson, 
2007; Rouault, 2012)). This system ensures that L ferritin expression varies with 
cellular iron concentration. Under low iron conditions, resources are not wasted 
manufacturing this iron storage protein and under high iron conditions the excess 
iron does not cause toxicity as it is stored by L ferritin (Reviewed in: (Piccinelli 
and Samuelsson, 2007; Rouault, 2012)). 
Transferrin receptor expression is also regulated by an iron response element. The 
·875RIWKHWUDQVIHUULQUHFHSWRUP51$FRQWDLQVILYH51$ORRSVWKDWELQGWKH
iron response proteins (Figure 1.3.) (Testa et al., 1993). Unlike the IRE in L 
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ferritin, the binding of IRPs to the transferrin receptor mRNA causes it to be 
translationally upregulated as the IRPs stabilise the mRNA allowing it to be 
translated for longer (Srai and Sharp, 2012). An increase in iron concentration 
causes the IRPs to dissociate which results in the degradation of the mRNA 
(Figure 1.3.) (Testa et al., 1993). Upregulation of transferrin receptor expression 
in response to low iron conditions is consistent with its involvement in the 
importing of iron into the cell (Testa et al., 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L Ferritin Coding Sequence 
Iron response protein ELQGV/IHUULWLQ¶875DQG
represses the translation of the coding sequence 
RNA Stem Loop 
/)HUULWLQ¶875 
Low Iron Concentration 
L Ferritin Coding Sequence 
Iron response protein GLVVRFLDWHVIURP/IHUULWLQ¶875
which permits the translation of the coding sequence 
RNA Stem Loop 
/)HUULWLQ¶875 
High Iron Concentration 
Figure 1.2. The L ferritin iron response element. In low-iron conditions, the 
iron response protein (IRP) represses L ferritin translation by binding the stem 
loop in its 5' UTR. L ferritin expression is permitted in high-iron conditons by the 
dissociation of IRP.  
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Transferrin Receptor Regulation 
 
 
  
Iron response proteins dissociate 
IURPWKHWUDQVIHUULQ¶875ZKLFK
causes the mRNA to degrade 
 
High Iron Concentration 
Transferrin Receptor Coding Sequence 
Iron response proteins bind the 
WUDQVIHUULQ¶875and stabilise the 
mRNA 
Five RNA Stem Loops 
7UDQVIHUULQ5HFHSWRU¶875 
Low Iron Concentration 
Figure 1.3. The transferrin receptor iron response element. In low-iron conditions, the iron 
response proteins bind to the iron response elements and stabilise the transferrin receptor 
mRNA.  High iron conditions cause the iron response proteins to dissociate and therefore the 
transferrin receptor mRNA to degrade. 
The transferrin mRNA degrades when the iron 
response proteins dissociate 
7UDQVIHUULQ5HFHSWRU¶875  Transferrin Receptor Coding Sequence 
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Riboswitches 
A riboswitch is a region of an mRNA that directly binds a specific small molecule 
(Mironov et al., 2002). This binding (which occurs at the aptamer region of the 
riboswitch) causes the expression platform of the riboswitch to undergo structural 
changes (Tucker and Breaker, 2005; Wachter, 2010). These changes alter the rate 
at which the mRNA is expressed (Tucker and Breaker, 2005; Wachter, 2010). 
  
uORFs  
The first start codon encountered by the ribosomal subunit complex as it scans the 
·875 LVQRW DOZD\V WKDWRI WKHPDLQRSHQUHDGLQJ IUDPH 25)RI WKHP51$
(Reviewed in: (Calvo et al., 2009)). Upstream open reading frames (uORFs) 
generally inhibit the expression of the primary ORF (pORF) as the ribosome may 
translate the uORF and then stall (Kozak, 1991b). For the pORF to be expressed 
the ribosome must either reinitiate at the pORF start codon after translating the 
uORF or it must fail to recognise the uORF start codon (a process called leaky 
scanning) (Miller and Hinnebusch, 1990; Morris and Geballe, 2000). 
 
7KH·XQWUDQVODWHGUHJLRQDOVR VHUYHV WR UHJXODWH WKH expression of the gene by 
providing binding sites for proteins or micro-RNAs that may stabilise or 
destabilise the mRNA (Lai, 2002; Mazumder et al., 2003).  
 
1.1.9. mRNA Export and Pioneer Translation 
The first step in the translation of a mature mRNA molecule is the binding of the 
nuclear cap-binding complex (CBC) WR WKH· FDS (Kataoka et al., 1994; Lewis et 
al., 1996). As transcription occurs in the nucleus and translation does not, the 
mature mRNA must be exported into the cytoplasm (Kapp and Lorsch, 2004). 
Although translation does usually occur in the cytoplasm, there is a contested 
body of evidence that suggests that translation may also occur in the nucleus  
(Iborra et al., 2004). Normally however, the heterodimeric cap-binding complex 
facilitates mRNA export from the nucleus via the nuclear pore complex (Bastos et 
al., 1996). The nuclear cap-binding complex is also believed to play a role in 
stabilising the poly(A) tail and in the splicing of the mRNA (Flaherty et al., 1997). 
Once out of the nucleus and in either the cytoplasm or the endoplasmic reticulum 
(ER), the P51$XQGHUJRHVD¶SLRQHHU·URXQGRIWUDQVODWLRQ with the cap binding 
complex still in place (Chiu et al., 2004; Lerner and Nicchitta, 2006). If the mRNA 
is exported into the ER, the signal recognition particle (SRP) recognises the signal 
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sequence of the nascent peptide emerging from the ribosome and facilitates the 
binding of the ribosome to the SRP receptor (Gilmore et al., 1982; Keenan et al., 
2001; Walter and Blobel, 1983). The SRP receptor anchors the RNA-ribosome 
complex to the ER membrane thereby aiding in the secretion of the nascent 
peptide (Wiedmann et al., 1987). 
The pioneer round of translation is believed to facilitate the nonsense mediated 
decay of mRNAs containing premature translation termination codons which 
would otherwise lead to the synthesis of potentially harmful truncated peptides 
(Behm-Ansmant et al., 2007). As part of the mRNA splicing pathway exon 
junction complexes (EJCs) bind the mRNA upstream of points where exons have 
been ligated together (Reviewed in: (Chang et al., 2007)). EJCs are displaced from 
an mRNA by the ribosome as it performs the pioneer round of translation (Figure 
1.4.). When the ribosome reaches a stop codon it dissociates from the mRNA. If a 
mutation causes the introduction of a stop codon upstream of the wild-type stop 
codon then the ribosome will dissociate at this point. The EJCs downstream of 
this point will therefore remain attached to the mRNA and provide binding sites 
for UPFs (regulator of nonsense transcripts) which trigger the decay of the mRNA 
molecule (Reviewed in: (Chang et al., 2007)). 
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Exon Junction Complex 
Exon 1 Exon 2 
Mutant 
Stop Codon 
Ribosome dissociates at mutant stop 
codon and downstream exon junction 
complex remains bound to RNA   
Start Codon Stop Codon 
Exon 1 Exon 2 
The remaining EJCs provide binding 
sites for UPFs which trigger the decay 
of the mutant mRNA molecule 
Mutant mRNA  
Mutant 
Stop Codon 
Start Codon Stop Codon 
Exon Junction Complex 
Exon 1 Exon 2 
eIF4AIII* 
Ribosome engaged in pioneer 
round of translation moving from 
the start codon to the stop codon  
Start Codon Stop Codon 
Exon Junction Complex dislodged 
by ribosome  
Exon 1 Exon 2 
Normal mRNA  
Figure 1.4. The nonsense mediated decay pathway. *eIF4AIII is 
believed to act as the RNA clamp of the complex (this will be discussed 
further in the eIF4A Paralogs section). 
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After the pioneer round of translation, the cap-binding complex is replaced by the 
eukaryotic initiation factor 4 E (eIF4E) which acts together with a number of 
other factors to initiate steady-state translation (see next section) (Lee et al., 
2008).  
 
1.1. . Translation Initiation Factors 
 
Factor 
Name 
Size* 
(kDa) Function Reference 
eIF2 126 When associated with GTP, eIF2 binds Met-tRNAi 
(Kimball, 
1999) 
eIF2B 294 Exchanges eIF2-associated GDP with GTP (Gomez et al., 2002) 
eIF1 12 Facilitate the binding of eIF2-GTP-Met-
tRNAi to 40S ribosomal subunit and aid in 
the recognition of the start codon 
(Passmore et 
al., 2007) eIF1A 17 
eIF5 58 (Chaudhuri et al., 1994) 
eIF3 800 Stabilises the above complex and also the 
cap-binding complex 
(LeFebvre et 
al., 2006) 
eIF4E 24 %LQGVWKH·FDS (Rhoads, 2009) 
eIF4A 46 8QZLQGVWKHVWUXFWXUHRIWKH·875 (Rogers et al., 2002a) 
eIF4B 80 Stimulate eIF4A activity (Rogers et al., 2001b) eIF4H 25 
eIF4G 154 Acts as a scaffold for eIF4A and aids in the circularisation of the mRNA 
(Lamphear et 
al., 1995) 
eIF5B 139 
Facilitates the binding of the 60S ribosomal 
subunit to the 40S-Met-tRNAi-mRNA 
complex 
(Rasheedi et 
al., 2007) 
 
Table 1. The main eukaryotic initiation factors. * The size refers to the approximate 
size of the protein in mammals. 
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1.1.11. Translation Initiation 
The following figures show how the translation initiation factors (Table 1.) 
IDFLOLWDWH WKH ELQGLQJ RI WKH VPDOO 6 ULERVRPDO VXEXQLW WR WKH · FDS RI WKH
mRNA and allow the 48S ribosomal subunit complex to scan for and recognise the 
start codon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eIF2 
eIF2B GTP GDP 
Met-tRNAi 
40S Ribosomal Subunit 
eIF3 
Met-tRNAi 
eIF2 
eIF1 
eIF1A eIF5 
Figure 1.5. The Formation of the Ternary Complex. When it is associated with 
guanosine triphosphate (GTP), eIF2 forms part of the cap-binding complex (Kimball, 
1999). The transition from eIF2-GDP (guanosine diphosphate) to eIF2-GTP is catalysed 
by the heteropentameric translation initiation factor eIF2B (Williams et al., 2001). eIF2-
GTP then forms a ternary complex with Met-tRNAi. Met-tRNAi is the transfer RNA / amino 
acid complex complementary to the AUG translation start codon (Kimball, 1999). 
 
Figure 1.6. The 43S Complex. If eIF2 is not phosphorylated and it is associated with 
triple-phosphorylated guanosine then it is free to become part of the ternary complex 
(Berg et al., 2002; Kimball, 1999). The attachment of the ternary complex (eIF2-GTP-
Met-tRNAi) to the 40S ribosomal subunit is facilitated by eIF1, eIF1A, eIF5 and stabilised 
by eIF3, this leads to the formation of the 43S pre-initiation complex (LeFebvre et al., 
2006; Lomakin et al., 2003).  
eIF3 is a large multi-subunit initiation factor, it is believed to have a number of regulatory 
functions that are yet to be explained (Hershey and Merrick, 2000). However, one 
subunit of eIF3 (p170) is strongly implicated in regulating the cell cycle and proliferation 
(Dong et al., 2004). 
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40S Ribosomal Subunit 
eIF3 
Met-tRNAi 
eIF2 
eIF1 
eIF1A eIF5 
eIF4E 
eIF4G 
eIF4A 
¶&DS 
mRNA 
Figure 1.7. The 48S Complex. eIF3 and the cap-bound eIF4E are linked by the large 
scaffold protein eIF4G (Pyronnet et al., 1999). eIF4G binds eIF4E at its N terminal third 
and binds both eIF3 and eIF4A at its C terminal two thirds (Pyronnet et al., 1999). 
eIF4A is a bidirectional RNA helicase that binds eIF4G and catalyses the processing of 
WKH VHFRQGDU\ VWUXFWXUH RI WKH P51$ ¶ XQWUDQVODWHG UHJLRQ LQ DQ $73 GHSHQGHQW
manner, a process which facilitates ribosome recruitment (Grifo et al., 1984; Ray et al., 
1985; Rozen et al., 1990; Svitkin et al., 2001). eIF4A is an abundant cytoplasmic 
protein, at over three copies per ribosome in HeLa cells it is the most abundant 
translation initiation factor (Bordeleau et al., 2006; Duncan et al., 1987; Lin et al., 
2008). 
When complexed together, eIF4A, eIF4E and eIF4G are referred to as eIF4F. Once 
associated with the cap-bound eIF4F, the 43S pre-initiation complex is now termed the 
48S pre-initiation complex. eIF4B and eIF4H both serve to stimulate the helicase 
activity of eIF4A and make it more processive (Richter-Cook et al., 1998; Richter and 
Sonenberg, 2005; Richter et al., 1999; Rogers et al., 1999a). eIF4B and eIF4H share a 
binding site on eIF4A so their activity is likely to be mutually exclusive (Rozovsky et al., 
2008). eIF4B (in combination with eIF4G) stimulates the ATPase activity of eIF4A 
(Nielsen et al., 2011). eIF4H has been proposed to contribute to the RNA affinity of 
eIF4A (Rozovsky et al., 2008). 
eIF4B possesses an RNA recognition motif at its N terminus and an 18S ribosomal 
RNA (rRNA) binding domain at its C terminus (Methot et al., 1996). eIF4B also binds 
eIF3, suggesting that it acts as an intermediary between eIF3 and both the ribosome 
and mRNA (Methot et al., 1996). 
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eIF4E 
eIF4G 
mRNA PAIP1 eIF4A 
¶&DS 
Figure 1.8. mRNA Circularisation. The poly(A) tail binding protein (PABP) remains bound to the 
poly(A) tail while also binding eIF4G thereby creating a mRNA loop that is believed to stimulate 
translation and also to play a role in the regulation of the expression of certain transcripts 
(Mazumder et al., 2001; Sachs et al., 1986; Wakiyama et al., 2000). There is also evidence to 
suggest that the circularised structure may be strengthened by the binding of PABP to eIF4A via 
PAIP1 (Craig et al., 1998). 
It has been proposed that circularisation of the mRNA could serve the same purpose as 
nonsense mediated decay in that it only allows the expression of intact mRNAs at the expense of 
the expression of potentially harmful truncated peptides (Searfoss et al., 2001). For example: 
stop codons introduced into the mRNA upstream of the wild-type stop codon by mutation 
(nonsense mutations) will lead to the dissociation of the ribosome before it can reach the start 
codon again thereby repressing the translation of the mutated mRNA (Wilkinson and Shyu, 
2002). 
 
Proof of in vivo mRNA Circularisation 
The fact that PABP directly binds eIF4G is consistent with the existence of this phenomenon in 
living cells but alone it is not strong evidence (Tarun, 1996). Stronger evidence comes from the 
visualisation of cellular mRNAs; polysomes (multiple ribosomes associated with a single mRNA) 
appear as a ring on electron micrographs and atomic force microscopy of in vitro RNA-protein 
complexes also reveals circular shapes (Tarun and Sachs, 1996; Wells et al., 1998; Yazaki et al., 
2000).   
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40S Ribosomal Subunit 
eIF3 
eIF2 
eIF1 
eIF1A eIF5 
Met-tRNAi 
eIF4E 
eIF4G 
eIF4A 
mRNA 
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Figure 1.9. 7KHQH[WVWDJHLVWKHVFDQQLQJRIWKH6FRPSOH[DORQJWKHP51$LQD¶
WR¶GLUHFWLRQXQWLOLWUHDFKHVWKHAUG start codon (Kozak, 1989). The context of the start 
codon plays an important role in regulating the expression of the downstream open reading 
frame (Kozak, 1984b). The Kozak consensus sequence is: (gcc)gccRccAUGG (where R is 
either A or G) (Kozak, 1984b). If the AUG sequence is encountered by the 48S pre-initiation 
complex in the configuration shown above, the consensus would act as a strong initiator of 
translation (Kozak, 1984b). Variations in the sequence weaken the ability of the start codon 
to initiate translation (Kozak, 1984b). This differential confers varying degrees of initiation 
strength to different genes, thereby regulating the relative amount of their encoded protein 
produced (Kozak, 1984b). The consensus may even be weak enough that the ribosome does 
not recognise it as the translation start point at all; this is called leaky scanning (Kozak, 
1989). Although the Kozak consensus sequence exhibits variation, the start codon itself is an 
AUG codon in 99.9% of all eukaryotic genes (prokaryotes use non AUG start codons more 
commonly) (Sugiharas et al., 1990; Tikole and Sankararamakrishnan, 2006). Once the start 
codon has been found, the initiator Met-tRNAi in the ternary complex is base paired to the 
RNA. This event triggers eIF5 to facilitate GTP hydrolysis by eIF2 by acting as a GTPase-
activating protein (Asano et al., 2001). eIF1 aids in the recognition of the AUG start codon by 
dissuading base pairing of the Met-tRNAi to inappropriate triplets and inhibiting the GTPase 
activating function of eIF5 in the absence of an AUG triplet (Lomakin et al., 2003; Unbehaun 
et al., 2004). The 48S subunit contains three sites that function as part of protein synthesis; 
these are termed: A, P and E (Garrett, 2000). Site A binds tRNA that is aminoacylated 
(charged with an amino acid), site P binds tRNA attached to the amino acid which is 
becoming part of the peptide and site E binds the exiting non-bound tRNA (Woodcock et al., 
1991). Hydrolysis of eIF2-GTP (to form eIF2-GDP) releases the initiator methionine tRNA into 
the P site of the ribosomal subunit, the eIF2-GDP then dissociates to be recycled into eIF2-
GTP (Campbell et al., 2005). Also believed to dissociate from the ribosome complex at this 
stage are eIF1, eIF1A, eIF3, eIF4F and eIF5 (Pestova et al., 2001).  
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1.1.12 Examples of the Regulation of Gene Expression at the Level of Translation  
 
Regulation of the rate at which mRNAs are recruited to the endoplasmic 
reticulum 
Insulin synthesis was found to increase in pancreatic islets with increasing 
glucose concentration. Despite this increase in insulin expression, the 
concentration of the insulin mRNA remained constant (Itoh and Okamoto, 1980). 
It was shown that insulin mRNA molecules localise at the endoplasmic reticulum 
(where insulin is synthesised) when glucose concentrations are higher (Welsh et 
al., 1986). The fact that supplemental signal recognition particle introduced into 
cells exposed to high glucose concentrations increased the rate of insulin mRNA 
localisation at the ER is consistent with the signal recognition particle being 
involved in this response (Welsh et al., 1986). 
 
eIF2 and eIF2B Regulation 
Since eIF2-GTP is critical for successful translation (Figure 1.5.), it is logical that 
the activity of eIF2B is a regulator of translation (Webb and Proud, 1997). 
Mutations in the gene encoding eIF2B have been strongly linked to the disease 
¶OHXNRHQFHSKDORSDWK\ZLWKYDQLVKLQJZKLWHPDWWHU· (VWM) (Li et al., 2004). It is 
not yet apparent the exact mechanism by which the loss of eIF2B function causes 
Figure 1.10. After the initiation factors dissociate, the ribosome-dependent 
GTPase activity of eIF5B facilitates the binding of the 60S ribosomal subunit to 
the 40S-Met-tRNAi-mRNA complex (Pestova et al., 2000). With the 80S 
ribosome now complete and in its correct position on the mRNA, the process of 
translation initiation is over and elongation can begin. 
 
«&&&**&*&$*&*&**&&*AUGCAGCCUCCGCCCCC« 
40S Ribosomal Subunit 
60S Ribosomal Subunit 
mRNA 
80S Ribosome 
Met-tRNAi 
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the pathology but it is known that inhibition of eIF2B causes a decrease in global 
protein synthesis (Kimball et al., 1998). Despite this general suppression, 
translation of mRNAs with start codons iQ WKH ·XQWUDQVODWHG UHJLRQ increases 
(Hinnebusch, 2000). Interestingly, one such mRNA encodes CHOP which is a 
transcription factor responsible for inducing the transcription of a set of stress 
response genes (Harding et al., 2000; Ubeda and Habener, 2000). This means that 
loss of either eIF2 or eIF2B function, possibly by natural phosphorylation or 
pathogenic mutation, will lead to the upregulation of the CHOP-mediated stress 
response (Harding et al., 2000; Ubeda and Habener, 2000). The relationship 
between uAUG-mediated gene upregulation in VWM and the disease phenotype is 
unknown but the fact that prolonged CHOP expression causes apoptosis in 
astrocytes (as well as other cell types) is consistent with this upregulation being 
important in the disease (Reviewed in: (Proud, 2011)). 
Translation may be suppressed by the phosphorylation oI WKHǂ VXEXQLWRI H,)
(Kimball, 1999). This phosphorylation converts eIF2 from a substrate of eIF2B to 
a competitive inhibitor (Kimball, 1999). Downregulation of global protein 
synthesis by the phosphorylation of eIF2 is induced in response to a range of 
cellular stresses and performed by a range of different kinases (Kimball, 1999). 
One example of such a response is the activity of GCN2 (eIF2 kinase general 
control non-derepressible-2) which is induced by the presence of uncharged tRNA 
and, as such serves to suppress translation under conditions of amino acid 
starvation (Wek et al., 2004). Another example is PERK ((RNA-dependent protein 
kinase)-like endoplasmic reticulum kinase) which phosphorylates eIF2 in 
response to the presence of misfolded proteins in the endoplasmic reticulum 
(Kaufman, 2004). 
 
eIF4E Regulation 
A number of conditions must be fulfilled for eIF4E to be able to participate in 
translation initiation (Raught and Gingras, 1999). The fact that eIF4E is 
generally the least common initiation factor in terms of numbers of molecules per 
cell (eIF4A is generally the most common (Duncan and Hershey, 1983)) makes it 
an ideal target for regulation (Hiremath et al., 1985). eIF4E is phosphorylated in 
response to certain stimuli, one example of which is the hormone insulin 
(Makkinje et al., 1995). One of the main kinases responsible for phosphorylating 
H,)( LV ¶0$3NLQDVH-DFWLYDWHGSURWHLQNLQDVH·01.ZKLFKDFFHVVHVH,)(E\
binding eIF4G (Li et al., 2001). This phosphorylation increases the affinity of 
H,)(IRUWKH·FDSDQGDOVRFRQWULEXWHVWRDPRUHVWDEOHH,))FRPSOH[ (Bu et 
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al., 1993; Minich et al., 1994). The binding of eIF4E to eIF4G and hence 
translation initiation is inhibited by competition for the site on eIF4E by a family 
of three proteins called eIF4E binding proteins (4E-BPs) which possess a similar 
4E-binding domain to eIF4G (Haghighat et al., 1995). The ability of the 4E-BPs to 
interfere with eIF4E binding is regulated by their phosphorylation state; 
underphosphorylated forms can bind to eIF4E while hyperphosphorylated forms 
cannot (Pause et al., 1994a). The 4E-BPs can become hyperphosphorylated in 
response to growth factors, environmental stimuli or hormones (Fleurent et al., 
1997; Lin et al., 1994; Pause et al., 1994a). When the protein PHAS-I 
(phosphorylated heat-acid stabled) is hypophosphorylated it also binds eIF4E but 
in response to the presence of mitogenic compounds MAP (mitogen activated) 
kinase rapidly phosphorylates PHAS-I causing it to dissociate from eIF4E (Lin et 
al., 1994). The released eIF4E can then upregulate translation initiation to meet 
the increased demands for protein of the process of mitosis (Lin et al., 1994). 
 
1.1.13. Cap-Independent Translation Initiation 
An internal ribosomal entry site (IRES) is a VHTXHQFH FRQWDLQHG ZLWKLQ WKH ·
untranslated region of a mRNA that recruits the ribosome and initiates 
WUDQVODWLRQ ZLWKRXW WKH XVH RI WKH · FDS and even, in some instances (e.g. the 
cricket paralysis virus IRES) without the use of translation initiation factors 
(Fraser et al., 2004; Jang et al., 1988; Kaminski et al., 1995). Originally identified 
in picornavirus mRNA in 1988, insight into the properties of IRESs was provided 
when WKH SROLRYLUXV · 875 ZDV FORQHG LQWR D dicistronic plasmid and found to 
allow the expression of the downstream cistron (Pelletier and Sonenberg, 1988). It 
became apparent that an IRES could facilitate translation initiation in the 
DEVHQFH RI HLWKHU D · RU · HQG ZKHQ LW ZDV VKRZQ WR be able to recruit the 
ribosome to a circular mRNA (Chen and Sarnow, 1995).  
A number of different viruses including poliovirus, coxsackievirus, human 
rhinovirus and foot and mouth disease virus (FMDV) encode a protease in their 
genome which cleaves eIF4G rendering it unable to bind eIF4E (Borman et al., 
1997). This severely impairs cap-dependent translation initiation and thereby 
increases the ability of the cell to translate the non-cap-dependent IRES-mediated 
viral genes (Borman et al., 1997). While the cap-associated eIF4E is redundant in 
IRES-mediated translation initiation, a significant role for eIF4A has become 
apparent (see next section) (Pause et al., 1994b).  
The first eukaryotic mRNA that was found to contain an IRES was BiP (HSPA5); 
an immunoglobulin heavy chain binding protein present in B lymphocytes 
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(Sarnow, 1989). It was discovered when expression levels of BiP remained 
consistent in cells infected with poliovirus. This was in contrast to the majority of 
proteins in the cell, the expression of which was inhibited by the cleavage of 
eIF4G by the virus (Sarnow, 1989). This technique was used to identify more 
cellular mRNAs that contained IRES elements (Johannes et al., 1999). 68 viral 
and 115 eukaryotic cellular IRESs have been identified and catalogued in a 
repository (http://iresite.org/, 2012). Despite the increasing numbers of IRESs 
discovered, a common sequence motif that may be used to accurately predict the 
presence of an IRES within a sequence has proved elusive (Le and Maizel, 1997). 
This fact points to the importance of RNA secondary and tertiary structure in the 
function of an IRES (Xia and Holcik, 2009). Also in support of the idea that the 
precise three dimensional composition of an IRES is critical to its function is the 
idea that a single nucleotide change to its sequence can have significant impact on 
its ability to initiate translation (Fernandez et al., 2005). Where structure is 
important, for example in ribosomal RNA (rRNA), if a mutation occurs that 
changes the structure, often a compensatory mutation will arise that will restore 
the original configuration of the molecule (Hancock et al., 1988). 
The fact that IRESs exhibit such variation has been used in support of the 
hypothesis that they have emerged independently over the course of evolutionary 
time (Martinez-Salas et al., 2001). Contrary to this idea is the theory that cap-
independent translation initiation evolved first and was superseded by cap-
dependent initiation (Hernández, 2008). The main argument in favour of extant 
IRES elements being very ancient sequences is the fact that eIF4E and eIF4G 
were among the last translation initiation factors to evolve (Hernández, 2008).  
IRES-mediated translation initiation combined with eIF4G cleavage is a useful 
mechanism for viral attack, it is also well established that the cellular IRES 
elements are used in a regulatory capacity (Borman et al., 1997; Stoneley and 
Willis, 2004). An example of an IRES-UHJXODWHGJHQHLV¶type I insulin-like growth 
factor receptor· (IGF-IR) (Meng et al., 2008). 
Cap-independent translation initiation has been thoroughly studied in the myc 
transcription factors with c-myc, L-myc and N-myc mRNAs all demonstrated to 
contain IRESs (Jopling et al., 2004; Jopling and Willis, 2001; Stoneley et al., 
1998). Despite the similar functions of these genes, their IRES elements have 
differing requirements for the translation initiation factors (Spriggs et al., 2009). 
For example, the L-myc IRES requires PABP and eIF3 in association with eIF4G 
while the N- and c-myc IRESs only require the C-terminal domain of eIF4GI and 
eIF3 but not necessarily complexed (Spriggs et al., 2009). As part of the same 
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study, hippuristanol treatment of cells transfected with reporter plasmids 
containing the IRESs revealed that they all have a significant requirement for 
eIF4A (Spriggs et al., 2009). The IRES element belonging to N-myc was shown to 
have a differential expression pattern in laboratory cell lines of different origins 
with higher expression in neuronally-derived SH-SY5Y cells (Jopling and Willis, 
2001). 
IRES trans acting factors (ITAFs) may also be responsible for the differing 
strengths, initiation factor requirements and cell-type specific effects of different 
IRESs (Lewis and Holcik, 2007). ITAFs are proteins that act as accessories to 
cellular IRESs, facilitating their association with the ribosome (Mitchell et al., 
2005). The mechanism of action of the recently discovered ITAFs is not yet clear 
but it has been suggested that they may act as a physical bridge between 
ribosome and RNA or that they enable the RNA to form the structural 
conformation necessary for ribosomal entry (Mitchell et al., 2005; Yaman et al., 
2003). Some ITAFs are associated with most cellular IRESs, for example 
polypyrimidine tract binding protein (PTB) which is particularly active during 
apoptosis (Bushell et al., 2006; Mitchell et al., 2005; Spriggs et al., 2005). In 
general however, IRESs have varying requirements for different ITAFs (Cobbold 
et al., 2008). 
 
The IRES families and their requirements 
IRESs are organised into four IDPLOLHV RU ¶JURXSV· RU ¶W\SHV· EDVHG RQ WKH
conservation of their structure (Reviewed in: (Pacheco and Martinez-Salas, 2010)). 
Picornaviridae are divided into two main types. Type I includes enterovirus (e.g. 
poliovirus) and rhinovirus (e.g. human rhinovirus) and type II includes 
aphthovirus (e.g. foot and mouth disease virus) and cardiovirus (e.g. 
encephalomyocarditis virus) (Beales et al., 2003; Jackson et al., 1990).  
IRES type III contains hepatitis A virus (a member of the Flaviviridae family) and 
type IV contains hepatitis C virus (also a member of the Flaviviridae family). 
Types I and II require eIF4A, eIF4G (the central domain), eIF4B, eIF2, ATP and 
eIF3 but not eIF1, eIF1A or eIF4E (de Breyne et al., 2009; Kolupaeva et al., 1998; 
Pestova et al., 1996a; Pestova et al., 1996b).  
The requirement for the activity of eIF4A in the expression of one of the (type II) 
IRES-mediated genes from encephalomyocarditis virus has been demonstrated 
(Pause et al., 1994b). Mutant eIF4A with a non-functional HRIGRXXR domain 
(believed to be required for RNA binding and ATP hydrolysis) failed to initiate the 
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translation of the gene encoding the EMC virion in rabbit reticulocyte lysate, 
unlike the addition of functional eIF4A (Pause et al., 1993; Pause et al., 1994b).  
The role of eIF4A in the expression of EMCV IRES-mediated genes may also be 
structural (Lomakin et al., 2000). It was found that the interaction between eIF4A 
and eIF4G was able to increase the expression of an EMCV IRES-mediated gene 
even in the absence of ATP. It was proposed that eIF4A may provide binding sites 
that induce the IRES to form a structure that is better able to initiate translation 
(Kolupaeva et al., 2003; Lomakin et al., 2000).  
The type III IRES belonging to hepatitis A virus (HAV) is unusual as it has been 
shown to require eIF4E and eIF4G (Ali et al., 2001). However, like the 
picornavirus IRESs, the HAV IRES also has a strong requirement for functional 
eIF4A (Fletcher et al., 2002). 
The type IV IRES of hepatitis C virus (HCV) only requires eIF3 and the ternary 
complex to form a successful 48S complex (Otto and Puglisi, 2004; Tsukiyama-
Kohara et al., 1992). 
 
1.1.14. Elongation and Termination 
Whether initiation occurs in a cap-dependent or cap-independent manner, the 
next step in the translation of a mRNA is elongation. This process is assisted by 
just two (elongation) factors which facilitate the reciprocating action of the 
ribosome by positioning an aminoacyl-tRNA at the ribosomal A site, catalysing 
the condensation reaction that forms the peptide bond between amino acids and 
shifting the mRNA on by three nucleotides (Reviewed in: (Greganova et al., 2011; 
Riis et al., 1990)). There may be more than one ribosome engaged in translation of 
a single mRNA at any one time in order to increase the amount of protein 
produced per mRNA, multiple ribosomes are collectively referred to as a polysome 
(Warner et al., 1963). 
The process of elongation continues until the ribosome encounters a stop codon, at 
which point, release factors associate with the large ribosomal subunit and cleave 
the ester bond between the final amino acid residue and the tRNA (Kisselev et al., 
2003). Both the ribosomal subunits dissociate from the mRNA and translation is 
terminated. The poly(A) tail serves to stimulate the increased translation rate of a 
mRNA (Munroe and Jacobson, 1990). Circularisation of a mRNA by the joining of 
eIF4G to the PABPs as part of translation initiation means that a ribosome that 
has reached the stop codon will be physically closer to the start codon and 
therefore readily available for reinitiation should it be required (Asselbergs et al., 
1978; Craig et al., 1998). 
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1.1.14. mRNA Recycling 
Factors that influence the rate at which the mRNA degrades (such as miRNAs) 
are used as a mechanism to control the level of the protein that the mRNA 
encodes (Valencia-Sanchez et al., 2006). The fact that mRNAs encoding different 
proteins have different half-lives naturally introduces a further differential 
between the length of time over which their products are expressed (Tucker and 
Parker, 2003). Genes that are regulated in this manner tend to be involved in 
critical cellular functions that require rapid adjustment in response to dynamic 
environmental conditions (McCarthy, 1998). The main contributor to mRNA 
stability and longevity is the poly(A) tail, mRNAs do not degrade readily with the 
tail in place (Decker and Parker, 1993). The activity of deadenylases, which cleave 
adenine residues from the tail, PD\EHHQKDQFHGE\VHTXHQFHVLQWKH·875RIWKH
mRNA, for example, the AU-rich element (ARE) (Schiavi et al., 1992). These 
sequences are notably found to be mutated in oncogenic alleles of WKH·875RIc-
fos (Schiavi et al., 1992).  
Complete deadenylation of a mRNA leaves the molecule vulneraEOH WR ·
exonucleolytic digestion by the exosome complex (Wilusz et al., 2001). More 
commonly, once deadenylation has occurred, GHJUDGDWLRQSURJUHVVHV LQD· WR·
direction IROORZLQJWKHUHPRYDORIWKH·FDS(Badis et al., 2004).  
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Part  
Eukaryotic Initiation Factor 4 A (eIF4A) 
 
1.2.1. The helicase families 
eIF4A belongs to a larger family of helicases (Rogers et al., 2002a). The DEAD box 
helicases are named after their conserved Aspartic acid, Glutamic Acid, Alanine, 
Aspartic acid (DEAD) motif (Rogers et al., 2002a). Also conserved between family 
members are nine general motifs: the Q-motif, motif 1, motif 1a, motif 1b, motif II, 
motif III, motif IV, motif V, and motif VI (Linder et al., 1989). The DEAD sequence 
LV FRQWDLQHG ZLWKLQ PRWLI ,, DOVR FDOOHG WKH ¶:DONHU %· PRWLI PRWLI , LV DOVR
VRPHWLPHVFDOOHGWKH¶:DONHU$·PRWLI (Linder et al., 1989). Motifs 1, II, Q and VI 
are involved in ATP hydrolysis, while motifs, 1a, 1b, III, IV, and V are responsible 
for RNA interaction (Figure 1.11.) (Tanner et al., 2003). 
 
 
           Q              I            Ia       Ib       II      III       IV     V          VI 
[F][GAxxPoxxQ][AxxGsGKT][PTRELA][TPGR][DEAD][SAT]----[LIV][ARGID][HRxGRxGR] 
                        N-terminal Domain         C-terminal Domain 
Colour Key: Involved in ATP usage, RNA binding, Linker region 
 
 
The DEAD box helicases are closely related to the DEAH and the Ski2 helicases 
(Wang et al., 2005; Xu et al., 2002). Together these three families are referred to 
as DExD/H (Rocak and Linder, 2004). The DExD/H family fits into the 
classification of all helicase proteins as part of superfamily II (Rocak and Linder, 
2004). There exist three large super-families (I-III) and two smaller families, they 
are divided along parameters of structure, such as the conserved DEAD motif, 
rather than function e.g. DNA or RNA specificity (Gorbalenya and Koonin, 1993). 
The substrate for all DExD/H helicases is RNA (Rocak and Linder, 2004). The 36 
DEAD box helicases predicted to occur in humans are believed to function as part 
of the processes of: transcription, translation initiation, ribosome biogenesis, 
mitochondrial gene expression, RNA splicing, RNA transport and mRNA 
degradation (Abdelhaleem et al., 2003; Cordin et al., 2006; Rocak and Linder, 
2004). It has also been proposed that the RNA binding activity of the DEAD box 
Figure 1.11. The conserved sequence motifs of the DEAD-box helicase family 
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helicases could be used in the disruption of unfavourable RNA-protein 
interactions (Rocak and Linder, 2004).  
H,)$ LV RIWHQ GHVFULEHG DV WKH ¶SURWRW\SLFDO· RU ¶DUFKHW\SLFDO· '($' box RNA 
helicase, this is due to the fact that it was the first to be discovered and it does not 
contain the C terminal and N terminal extensions seen in many helicases (Rogers 
et al., 2002a; Sonenberg et al., 1988). 
Although DEAD box helicases are found in a large number of species, both 
prokaryotic and eukaryotic, they are not entirely ubiquitous (Rocak and Linder, 
2004). Notable for their total lack of DEAD box helicases are the bacterial species 
Chlamydia and Borrelia and the archaea Pyrococcus and Halobacterium (Rocak 
and Linder, 2004). The reason for the absence of DEAD box helicases in these 
organisms is not known. 
The conservation of DEAD box helicases across archaea, bacteria and eukaryotes 
indicates that eIF4A may be the most ancient translation initiation factor 
(Hernández, 2008; Kyrpides and Woese, 1998).  
 
1.2.2. Paralogs 
In humans, there exist three paralogs of eIF4A termed eIF4AI (eIF4A1), eIF4AII 
(eIF4A2) and eIF4AIII (eIF4A3) (Li et al., 1999). eIF4AI and II are structurally 
similar, with 90-95% homology at the amino acid level (Bordeleau et al., 2005; 
Conroy et al., 1990). In an early study of translation initiation factors in rabbit 
reticulocyte lysate, separation of the eIF4F complex revealed the presence of 
proteins with Dalton masses of: 220,000, 24,000 and 46,000. The 220 kDa protein 
was eIF4G and the 24 kDa protein eIF4E (Conroy et al., 1990). The 46 kDa 
protein consisted of both eIF4AI and eIF4AII, present in a 4:1 ratio respectively 
(Conroy et al., 1990).  
As part of the eIF4F complex, eIF4A I and II are referred to as eIF4Ac 
¶FRPSOH[HG·) as opposed to eIF4Af ¶IUHHIRUP· (Yang et al., 2003). When not 
complexed, eIF4AI and II are present in the cytoplasm with no particular 
localisation (Yang et al., 2003).  
eIF4AI and eIF4AII were found to exhibit the same level of RNA processing 
activity in vitro (Conroy et al., 1990; Yoder-Hill et al., 1993). The coding sequences 
of eIF4AI and II (from NCBI, RefSeq IDs NM_001416 for eIF4AI and NM_001967 
for eIF4AII) have 77% homology (based on the Smith-Waterman algorithm). Until 
fairly recently, it was supposed that the amino acid similarity of eIF4AI and II, 
combined with the fact that they both form part of the eIF4F complex meant that 
they were functionally identical (Bordeleau et al., 2006). 
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Foot and Mouth Disease Virus (FMDV) 3C protease cleaves eIF4AI but not 
eIF4AII, this suggests the possibility of a functional difference between the 
paralogs (Li et al., 2001). It remains to be explained why FMDV should cleave one 
paralog and not the other (Li et al., 2001). The use of this example as an argument 
for the functional distinction of the two paralogs must be treated sceptically as it 
may be coincidence that the site of viral cleavage is unique to paralog I (Belsham, 
2000).  
Also consistent with the theory that paralogs I and II are functionally distinct is 
the finding that the mRNA levels of the two genes vary between tissues with the 
highest amounts of II/I recorded in the kidney and the lowest in the thymus in 
mouse (Nielsen and Trachsel, 1988). 
In support of the idea that eIF4AII is functionally important in humans is the fact 
that there often exist more than one paralog in other species, although this 
multiplicity is conserved, the reason for the presence of the second paralog in any 
organism remains to be satisfactorily explained (Kato et al., 2001). This argument 
relies upon the paradigm that evolutionary conservation across species is often 
associated with functional importance (Boffelli et al., 2004; Dermitzakis et al., 
2005). Contrary to the argument that the presence of a biological structure within 
an extant organism must mean that it is important is the existence of vestigial 
features (e.g. junk DNA) which serve no known purpose but do not represent a 
significant evolutionary disadvantage (Reviewed in: (Biemont and Vieira, 2006)). 
As well as eIF4AI and eIF4AII, a third variant of eIF4A exists, eIF4AIII (Li et al., 
1999). eIF4AIII shares only 65% amino acid similarity with eIF4AI, the main 
difference occurring in the N terminal 30 amino acid residues (Li et al., 1999). 
Despite this difference, eIF4AIII can also act as an ATP-dependent RNA helicase 
and, like eIF4AI, an RNA-dependent ATPase, the activity of which may be 
enhanced by eIF4B (Li et al., 1999). Although eIF4AIII is able to perform the 
same RNA processing function as eIF4AI, it was found to be unable to bind to the 
ribosome (via eIF4G) and to have an inhibitory effect on translation in general in 
rabbit reticulocyte lysate (Li et al., 1999). It was concluded that eIF4AIII inhibited 
translation by competing for the eIF4A binding site on eIF4G but only partially 
associating with eIF4G when it did bind, eIF4AI binds the central and the C 
terminus of eIF4G while eIF4AIII only binds the central (Li et al., 1999).  
While eIF4AI and eIF4AII are located in the cytoplasm, eIF4AIII localises in the 
nucleus in ¶VSHFNOHGRPDLQV·(Holzmann et al., 2000). 
The role of eIF4AIII in translation (if any) is unclear, although it has been 
strongly implicated in both nonsense mediated decay (NMD) and mRNA splicing, 
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both of which are consistent with the fact that eIF4AIII is found in the nucleus 
(Ferraiuolo et al., 2004; Holzmann et al., 2000). It was proposed that the helicase 
activity of eIF4AIII could aid in the process of splicing (Ballut et al., 2005; 
Ferraiuolo et al., 2004). RNA interference knockdown of eIF4AIII, but not eIF4AI 
or eIF4AII was found to inhibit nonsense mediated decay in HeLa cells 
(Ferraiuolo et al., 2004). Within the EJC the ATP binding activity of eIF4AIII is 
stimulated by the protein MLN51 (Noble and Song, 2007). The ATPase activity of 
eIF4AIII in the EJC is inhibited by MAGOH (protein mago nashi homolog) and 
Y14 (Shibuya et al., 2004). This causes eIF4AIII to act as an RNA clamp, 
anchoring the EJC to the mRNA (Shibuya et al., 2004).  
EJC-associated eIF4AIII also provides a binding site for UPF3, one of the factors 
responsible for triggering the degradation of the mRNA (Ballut et al., 2005).  
As part of the function of eIF4AIII in the EJC and in NMD, it is a key regulatory 
element in suppressing the translation of dendritic mRNAs (Giorgi et al., 2007). 
Knockdown of eIF4AIII in HeLa and PC-12 cells caused an increase in the product 
of the neuronal gene ARC which encodes a protein that mediates neuronal 
plasticity and is also involved in the consolidation of long-term memory (Giorgi et 
al., 2007). 
In Drosophila, eIF4AIII is involved in the localisation of mRNAs in the 
development phase of the organism; this phenomenon has yet to be observed in 
mammalian cells however (Palacios et al., 2004). 
Neatly combining the hypotheses that eIF4AIII is involved in both development 
and the regulation of elements of the nervous system, it was found that 
knockdown of eIF4AIII in Xenopus laevis embryos resulted in full body paralysis 
with phenotypic abnormalities in sensory neurons, pigment cells and the heart 
(Haremaki et al., 2010). The mechanism by which loss of eIF4AIII function caused 
such significant phenotypic defects became clearer when it was found that 
knockdown of other critical components of the exon junction complex also caused 
such effects (Haremaki et al., 2010). 
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2.3. Structure 
eIF4AI is a protein of 406 amino acid residues with a predicted relative molecular 
mass of 46,153 (Belsham, 2000; Chang et al., 2009). 
 
 
 
 
 
 
 
  
Figure 1.12. Ribbon diagram of the structure of both domains of yeast eIF4A 
(Caruthers et al., 2000). The structure of eIF4A in yeast has been approximated 
using X-ray crystallographic analysis, (Caruthers et al., 2000). To the left, coloured 
gold is the carboxyl terminal domain and to the right, coloured silver, is the amino 
terminus. The proximal linker, coloured black, consists of 11 amino acid residues. 
The blue regions of the diagram represent motif I (the Walker A motif), amino acid 
sequence: ASQSGTGKT, residues number 65-72. The yellow region is motif Ia, 
amino acid sequence: PTRELA, residues 97-102. The red region within the silver 
carboxyl terminal domain represents the Walker B motif (motif II) which contains 
the DEAD sequence, residues 169-172. The green region is motif III, amino acid 
sequence SAT, residues 200-202.  
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H,)$ KDV D ¶GXPEEHOO· VKDSH (Figure 1.12.) (Caruthers et al., 2000). X-ray 
crystallographic analysis revealed that the molecule has a total length of 80Å 
while the proximal linker section is 18Å (Caruthers et al., 2000). Although the 
conserved motifs are identified in the diagram, their arrangement does not seem 
to corroborate their known function (Caruthers et al., 2000). As part of the 
analysis, it was concluded that this meant that eIF4A can be distended in solution 
and that the linker must possess a degree of flexibility (Caruthers et al., 2000). It 
was also concluded that ATP binding must cause a conformational change in the 
shape of the molecule (Caruthers et al., 2000). 
 
2 . Function 
The ability of a mRNA to recruit and bind the ribosome is in inverse proportion to 
the extent and stability of the secondary structure of LWV · 875 (Kozak, 1980; 
Svitkin et al., 2001). This secondary structure was proposed to aid the ribosome in 
the recognition of the AUG start codon (Kozak, 1980). This was largely disproven 
when the study presented data demonstrating that reovirus mRNA which was 
irreversibly unfolded (by bisulfite treatment in denaturing conditions) retained 
the ability to bind to wheat germ ribosomes (Kozak, 1980). The same study 
proposed that the secondary structure may, instead, modulate gene expression; a 
large number of subsequent studies support this hypothesis (Kozak, 1980; 
Takimoto and Kuramoto, 1994). 
In many instances, it is energetically more favourable for a mRNA molecule, 
which is single stranded, to form secondary structure than to remain linear due to 
the hydrogen bond forming tendency of the hydroxyl groups in the ribose sugar 
(Doty et al., 1959; Higgs, 2000). The nucleotides of an RNA molecule determine its 
structural conformation by base pairing in a number of different ways. (Mathews, 
2006a). Watson-Crick pairing refers to the interaction between adenine and 
thymine (uracil in RNA) or the interaction between cytosine and guanine (Watson 
and Crick, 1953). Wobble base pairing is a type of non-Watson-Crick interaction, 
in mRNA wobble pairing can occur between guanine and uracil or between 
guanine and adenine (Crick, 1966; Gautheret et al., 1994). Inosine is a modified 
adenine residue that can form non Watson-Crick hydrogen bonds with cytosine, 
guanine and uracil (Crick, 1966). The presence of this residue in tRNA has been 
well documented, it is only more recently that it has been proposed to be present 
in mRNA (Grosjean et al., 1996; Paul and Bass, 1998). The effect of these 
interactions on the structure of the RNA molecule is approximately the same as if 
they were Watson-Crick (Sugimoto et al., 1986). 
37 
 
Hydrogen bonds can form between any of the edges of the nucleotides in a mRNA 
molecule (Figure 1.13.., left panel) (Hoogsteen, 1963). Since the interactions may 
form in cis or trans orientations (Figure 1.13..., right panel), there is the potential 
for the nucleotides to form 10 non-Watson-Crick configurations (e.g. cis 
Hoogsteen-Sugar Edge, trans Hoogsteen-Hoogsteen etc.) (Reviewed in: (Leontis et 
al., 2002)). Each of these interactions is comparable in strength to Watson-Crick 
parings (Nikolova et al., 2011). 
Another factor that contributes to the stability of the structure of an RNA 
molecule is the non-covalent interaction between the aromatic rings of the 
nucleotides, a phenomenon known as stacking (Reviewed in: (äSRQHUHWDO)). 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. From: (Leontis et al., 2002). Left Panel: the names of the edges of the 
RNA nucleotides according to the pairings they form. Right Panel: The orientation of 
the pairings may be either cis or trans 
 
Due to the complexity of the process of predicting RNA folding patterns in silico, 
the role of the tertiary structure of a mRNA in the process of translation initiation 
largely remains to be explored (Westhof and Auffinger, 2006). Tertiary structure 
has been identified as important in the function of the internal ribosome entry site 
(IRES) of the hepatitis C virus, although, as was discussed in the background 
section, this IRES has no requirement for eIF4A (Fraser et al., 2004; Kieft et al., 
2002). 
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Although RNA tertiary structure is difficult to predict, secondary structure can be 
approximated with a degree of confidence in silico (Mathews, 2006b).  
The secondary structure formed by an RNA hairpin used as part of this project to 
investigate the activity of eIF4A was predicted (Figure 1.14.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gibbs free energy Ʀ* is defined as the ability of a thermodynamic system to do 
work (Gibbs, 1873). 7KH IDFW WKDW SURJUDPV OLNH PIROG DVFULEH D QHJDWLYH Ʀ* WR
RNA structures is consistent with the fact that energy input is required to break 
the hydrogen bonds and other interactions that stabilise the molecule (Deng and 
Figure 1.14. The ODC1 Hairpin. The 
VWDEOHKDLUSLQ51$VWUXFWXUHǻ*-82.20 
.FDOPRO WKDW IRUPV SDUW RI WKH ¶
untranslated region of the human 
ornithine decarboxylase  mRNA 
(NM_002539), as predicted by mfold 
(Zuker, 2003). 
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Cieplak, 2010; Zuker, 2003). In performing this reaction in living cells, ATP is the 
source of energy and an RNA helicase enzyme is the catalyst (Rocak and Linder, 
2004). As early as 1982, it was demonstrated that mammalian eIF4A bound RNA 
in an ATP-depended manner (Grifo et al., 1982).  
The fact that eIF4A can function in vitro means that RNA strand separation 
assays may be performed (Rozen et al., 1990). One such assay involved the in vitro 
transcription of RNA molecules of varying lengths in which the cytosine residues 
were radiolabelled with 32P (Rogers et al., 2001a). These radiolabelled strands 
were hybridised to unlabelled equivalents (Rogers et al., 2001a). The addition of 
purified eIF4A to the reaction, along with the relevant buffers and ATP, was 
found to cause the strands to separate when visualised using polyacrylamide gel 
electrophoresis followed by autoradiogram detection (Figure 1.15.) (Rogers et al., 
2001a). 
 
  
Figure 1.15. From: (Rogers et al., 2001a). Helicase assay results showing the 
separation of a partially radiolabelled RNA duplex. The lanes third and fourth from the 
left show the difference in the state of the RNA duplex in the absence and presence of 
eIF4A respectively. Without eIF4A, the duplex remains 92% annealed but with eIF4A, after 
the same length of time it is only 15% annealed. The four lanes furthest to the right indicate 
that the predicted free energy of the duplex, ranging from 17.9 kcal/mol to 23.3 kcal/mol, 
dictates the rate at which it is unwound by eIF4A (Rogers et al., 2001a). Although this study 
was not the first to demonstrate the functional properties of eIF4A in vitro; it is included 
here because it is replicated as part of this project using similar conditions. The results also 
show that eIF4A can unwind an RNA duplex in vitro (Rogers et al., 2001a).  
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With regard to the in vivo function of eIF4A, the RNA substrate i.e. the messenger 
RNA molecule may be more than two orders of magnitude larger than the 13 
nucleotide duplex and therefore able to form much more stable structures (Figure 
1.15.) (Davuluri et al., 2000). Although the entirety of the mRNA has the potential 
to form secondary structure, including the coding sequence, eIF4A is believed only 
to be involved in processing the ·XQWUDQVODWHGUHJLRQas it dissociates when the 
80S ribosome is formed, an event which occurs at the start codon at the end of the 
·875(Favre et al., 1975; Kapp and Lorsch, 2004). 
It was discovered, in bacteria that structure within the coding region of a mRNA 
did not inhibit the elongation phase of translation because the ribosome itself has 
RNA helicase activity (Lingelbach and Dobberstein, 1988; Takyar et al., 2005). 
This activity was found to be ATP-independent, therefore differing from the way 
in which eIF4A functions (Takyar et al., 2005). It was also found that this activity 
was not observable until after the process of translation initiation had occurred 
(Takyar et al., 2005).  
The hypothesis is that eIF4A is responsible for processing the secondary structure 
RI WKH · XQWUDQVODWHG UHJLRQ in an ATP dependent manner to allow the 40S 
ribosomal subunit to bind and scan for the start codon (Takyar et al., 2005). At 
this point the 60S ribosomal subunit binds and the helicase activity of the 
completed ribosome is used to process the secondary structure of the coding 
sequence (Takyar et al., 2005). 
As discussed in the background section, there is a large degree of variation 
between the · untranslated regions of different genes and the distribution of this 
variation across the transcriptome is not random, it is used as a regulatory 
mechanism (Day and Tuite, 1998). An analysis of 699 vertebrate mRNAs found 
WKDW WKH DYHUDJH OHQJWK RI WKH · 875 ZDV EHWZHHQ  DQG  QXFOHRWLGHV IRU
three quarters of the cohort while the remaining quarter possessed ·875VORQJHU
than 100 nucleotides (Kozak, 1991a). A more recent bioinformatics approach 
GHWHUPLQHG WKDW WKH PHGLDQ OHQJWK RI · 875V LQ KXPDQV LV  nucleotides 
(Pesole et al., 2000). 
$·875WKDWLVYHU\VKRUW(<10) nucleotides is inhibitory to the expression of the 
downstream coding sequence as it does not provide adequate room for the 
ribosome to bind at the cap and recognise the start codon (Kozak, 1987). 
Conversely, a ORQJ·875GRHVQRWQHFHVVDULO\PHDQWKDWLWZLOOEH inhibitory to 
translation initiation (Kozak, 1987). This idea is supported by the fact that a 13 
nucleotide duplex is unwound at almost the same rate as one that is 16 
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nucleotides as they both have roughly the same predicted free energy stability 
(Figure 1.15.) (Rogers et al., 2001a).  
Apparent from the study of the 699 vertebrate sequences was the fact that proto-
RQFRJHQHV WHQGHG WR SRVVHVV DW\SLFDOO\ ORQJ · UTRs (Kozak, 1987). Proto-
oncogenes also tended to differ in their number of upstream open reading frames 
(uORFs), with an average of two in three containing at least one AUG codon 
withLQWKH·875 (usually more than one) (Kozak, 1987). This is consistent with 
examples like Her2, the expression of which is normally suppressed by a uORF 
but under certain conditions in cancer cells, this suppression is bypassed (Mehta 
et al., 2006). 
 
2.5. Genes 
In Homo sapiens, the gene encoding eIF4AI is located on chromosome 17 (p13) 
(GenBank, 2010). It has a mRNA 1844 nucleotides in length which is divided into 
a 103 nucleotide · UTR (Table 2.), 1221 nucleotide coding sequence and a 520 
nucleotide ·875 (GenBank, 2010).  
eIF4AII differs in that it is located on chromosome 3 (q28) and has a slightly 
longer mRNA at 1905 nucleotides (GenBank, 2010). Also in contrast to eIF4AI is 
the fact that WKH·875RIeIF4AII is only 39 nucleotides in length (Table 2.). The 
·875LVVLPLODUWReIF4AI, being 642 nucleotides in length (GenBank, 2010). 
The gene encoding eIF4AIII also belongs to chromosome 17 (q25.3), it has a 1734 
nucleotide mRNA with a 222 nucleotide ORQJ · 875 (Table 2.) and a 276 
nucleotide ·UTR (GenBank, 2010). 
 
Table 2. Details of the 5' UTRs of the eIF4A paralogs and the hairpin 
 
 
Name 
 
 
Length 
(nucleotides) 
GC 
Content 
(%) 
 
Predicted 
Free Energy 
(kcal/mol) 
 
 
Accession # 
 
eIF4AI 103 66 -39.20 NM_001416.2 
eIF4AII 39 53 -7.00 NM_001967 
eIF4AIII 222 74 -75.90 NM_014740 
Hairpin 137 74 -82.20 NM_002539 (ODC1) 
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1.2.6. Small Molecule Inhibitors of eIF4A 
 
Pateamine A 
 
 
Figure 1.16. The structure of Pateamine A. (Website Reference 1.) 
 
A high-throughput screen of over 90,000 natural products for inhibitors of 
eukaryotic translation initiation resulted in a single positive hit (Bordeleau et al., 
2005). The thiazole-containing polyene bis-lactone pateamine A (PatA) was 
originally isolated from the marine sponge Mycale found off the coast of New 
Zealand (Romo et al., 1998). Pateamine A enhances the ability of eIF4A to bind to 
ATP and mRNA, stimulates RNA-dependent ATP hydrolysis and also acts as an 
agonist of the helicase activity of eIF4A (Bordeleau et al., 2005). Pateamine does 
not affect the complexed eIF4A (eIF4Ac) but overstimulation of the free cytosolic 
eIF4A (eIF4Af) causes impromptu, non-specific unwinding of mRNA templates 
resulting in interference of translation initiation and elongation (Bordeleau et al., 
2005). Alongside this activity, pateamine also causes eIF4Af to become tightly 
bound to the RNA template so that the helicase is eventually sequestered away 
from its cytosolic reservoir and therefore unavailable to form the eIF4F complex 
necessary for effective translation initiation (Bordeleau et al., 2005). Pateamine A 
has a high specificity for eIF4A even among the DEAD box helicase family; it was 
found to have no affinity for the Ded1p helicase, a close relative of eIF4A 
(Bordeleau et al., 2005).   
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Hippuristanol 
 
 
Figure 1.17. The structure of Hippuristanol (Website Reference 2.) 
 
Hippuristanol was identified initially as an in vitro inhibitor of eIF4A as part of a 
high-throughput screen of small molecules (Bordeleau et al., 2006). The molecule 
itself is a 462.66 g mol-1 cytotoxic polyoxygenated steroid which was originally 
isolated from the gorgonian coral Isis hippuris found off the coast of Okinawa, 
Japan (Bordeleau et al., 2006). It was flagged by the screen as a potent and highly 
specific inhibitor of cap-dependent translation; it was found that a dose of 1 Ǎ0
was sufficient to reduce translation by 60% in Krebs-2 extracts (Bordeleau et al., 
2006). Hippuristanol acts by weakening the ability of eIF4A to bind to RNA by 
binding in a reversible manner to a number of conserved motifs (IV ² VI) within 
the C terminus of eIF4A (Bordeleau et al., 2006). ATP hydrolysis and mRNA 
binding are believed to be the responsibility of motif IV while V and VI form the 
active closed conformation of eIF4A (Bordeleau et al., 2006). 
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Silvestrol 
 
 
 
 
 
 
 
 
 
 
 
 
A further small molecule inhibitor of eIF4A was discovered more recently. The 
cyclopenta benzofuran flavagline silvestrol was originally isolated from the fruits 
and twigs of Aglaia silvestris, a species of plant belonging to the mahogany family 
(Meliaceae) (Hwang et al., 2004). It was identified as an inhibitor of eIF4A as part 
of another high-throughput screen of natural products (Bordeleau et al., 2008b). 
It was established, as part of the same study, that silvestrol acts as a chemical 
inducer of dimerization causing eIF4Af (free-form) to bind strongly to RNA upon 
contact negating its subsequent use as eIF4Ac (complexed-form) (Bordeleau et al., 
2008b). Silvestrol and its synthetic analogue episilvestrol were previously tested 
for chemotherapeutic effects against a number of human cancer cell lines before 
their specific function as translation inhibitors was established (Hwang et al., 
2004). These studies generated promising results including an apparent 63.2% 
reduction in human KB (carcinoma) cell numbers implanted into mouse 
peritoneum (Kim et al., 2006).  
  
Figure 1.18. The structure of Silvestrol (Website Reference 3.) 
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1.2.10. Cellular molecules that interact with eIF4A  
 
Programmed cell death protein 4 (PDCD4) 
 
 
Figure 1.19. Ribbon diagram of PDCD4 (Website Reference 12.). 
 
 
As discussed in the background section, the processive helicase activity of eIF4A 
is stimulated by eIF4B and eIF4H (Richter-Cook et al., 1998; Richter et al., 1999; 
Rogers et al., 2001b). Contrary to this action is the activity of PDCD4 which 
suppresses the function of eIF4A (Yang et al., 2003).  
PDCD4 was first discovered as part of a study into the proteins expressed as part 
of apoptosis (Shibahara et al., 1995). The mRNA of what was then termed simply 
MA-3 was found to be expressed in a number of cell lines belonging to different 
species in which apoptosis can be induced (Shibahara et al., 1995).  
In general, PDCD4 is a 485 amino acid, 64 kDa protein that is expressed in the 
nucleus of primarily liver cells during the G0 phase of the cell cycle and during 
apoptosis (Goke et al., 2002; Onishi et al., 1998; Yoshinaga et al., 1999). 
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The link between PDCD4 and eIF4A was discovered when it was found that 
PDCD4 shared a significant degree of homology with both isoforms of eIF4G 
(Goke et al., 2002). PDCD4 inhibits the helicase activity of eIF4A and its ability to 
bind to the C terminal region of eIF4G by forming a complex itself with eIF4G 
(Goke et al., 2002; Yang et al., 2003). The fact that PDCD4 acts by interfering 
with eIF4G may explain why it inhibits the translational activity of eIF4A 
paralogs I and II but not III (Yang et al., 2003).  
The JB6 paired mouse cell lines are commonly used in the study of PDCD4, these 
are individually susceptible and resistant to neoplastic transformation (Cmarik et 
al., 1999). Knockdown of the constitutively expressed PDCD4 in JB6 P- cells 
rendered them susceptible to transformation; this revealed that PDCD4 plays 
some role in tumour-suppression (Cmarik et al., 1999). PDCD4 was found to be 8-
10 times less highly expressed in the transformation-susceptible JB6 variant 
(termed P+) (Cmarik et al., 1999). The hypothesis that PDCD4 is an effective 
tumour suppressor gains further support in light of the fact that artificially 
elevated levels of PDCD4 in P+ JB6 induces resistance to transformation as 
induced by 12-O-tetradecanoylphorbol-13-acetate treatment (Bernstein et al., 
1992; Yang et al., 2001). This carcinogen works by increasing the binding of the 
transcription factor AP-1 (activator protein 1) to its target sequences which occur 
in gene promoters and also by inducing the activation of AP-1-regulated proteins 
in a posttranslational manner (Bernstein et al., 1992; Yang et al., 2001). The large 
array of proteins regulated by AP-1 tend to be involved in proliferation, 
differentiation and apoptosis (Ameyar et al., 2003).  
The regulation of the expression of PDCD4 is complex, involving both 
transcriptional and translational elements (Vikhreva et al., 2010). An example of 
the latter is the fact that PDCD4 expression is downregulated in response to 
microRNA-21 (miR-ZKLFKELQGVWRLWV·875(Asangani et al., 2007; Davis et 
al., 2008). This is consistent with the finding that miR-21 is typically 
overexpressed in solid tumours, wherein it induces invasion and metastasis 
(Frankel et al., 2008).  
It has recently been shown that PDCD4 is involved in the cellular response to 
DNA damage in chicken DT40 cells as knockout of PDCD4 impaired the recovery 
response by an unknown mechanism (Singh et al., 2009). The opposite effect was 
observed in human cells, with suppression of PDCD4 causing a reduction in 
apoptosis and an increase in survival (Bitomsky et al., 2008). However, when p53 
was also suppressed, the same effect as for chicken cells was observed (Bitomsky 
et al., 2008). 
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-PGJ2 
 
Figure 1.20. Diagram of 15d-PGJ2 (Website Reference 13.). 
 
15d-PGJ2 (15-deoxy-delta 12,14-prostaglandin J2) is a cyclopentenone 
prostaglandin that endogenously inhibits inflammatory responses (Lawrence et 
al., 2002; Straus and Glass, 2001). 15d-PGJ2 acts as an agonist of the pro-
inflammatory transcription factors NF-ǋ% DQG 33$5Ǆ SHUR[LVRPH SUROLIHUDWRU
DFWLYDWHGUHFHSWRUǄ(Straus et al., 2000). The link between 15d-PGJ2 and eIF4A 
was first discovered when it was noticed that 15d-PGJ2 causes stress granule 
formation in un-stressed cells (Kim et al., 2007). Stress granules consist of 
proteins from the translation pre-initiation complex along with various other 
proteins that bind RNA; they form in response to stresses such as heat and amino 
acid starvation (Anderson and Kedersha, 2006). Stress granules also incorporate 
TRAF2 (TNF receptor-associated factor 2) which binds eIF4GI in such situations 
(Kim et al., 2005). The normal role of TRAF2 is to stimulate TNF-ǂ WXPRXU
necrosiV IDFWRU ǂ ZKLFK LV D SUR-inflammatory cytokine (Kim et al., 2007). 
Therefore stress granule formation contributes to the suppression of inflammation 
(Kim et al., 2007). Pull-down experiments in HeLa cells revealed that eIF4AI was 
a binding target of 15d-PGJ2, this effect was corroborated by in vitro experiments 
conducted as part of the same study (Kim et al., 2007). 15d-PGJ2 was found to 
enhance the RNA-binding activity of eIF4A and also, by binding the cysteine 
residue at position 264 on eIF4A, 15d-PGJ2 interferes with the formation of the 
eIF4G-eIF4A complex (Kim et al., 2007). 
15d-PGJ2 has been proposed as a potential therapeutic anti-metastatic agent due 
to the fact that it modifies cytoskeletal structure, a property that was found to 
attenuate the migration of adenocarcinoma cells (Diers et al., 2010). he study 
outlined above presents strong evidence that 15d-PGJ2 binds and inhibits eIF4A, 
however the biological relevance of these finding, although consistent with what is 
known about translation suppression during inflammation, must be questioned 
(Ma and Hendershot, 2003). Intracellular prostaglandin concentration is difficult 
to measure as it requires the molecules to be conjugated to proteins but 15d-PGJ2 
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is believed to have an EC50 (effective concentration) in the low nM range  (Powell, 
2003). As part of the study, HeLa cells were treated with 50µM 15d-PGJ2, it is 
unknown whether this reflects the concentration normally found in HeLa cells 
however (Kim et al., 2007). Therefore, the biological relevance of the interaction 
between 15d-PGJ2 and eIF4A remains to be established (Powell, 2003). 
 
HuD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HuD (ELAV4) belongs to the Hu family of RNA-binding proteins, the function of 
which is to stabilise mRNAs containing adenine / uridine rich elements 
(Deschênes-Furry et al., 2006). It was recently shown, initially using co-
immunoprecipitation, then by mutagenesis that HuD directly binds eIF4A (Fukao 
et al., 2009). This study found that HuD stimulated translation but only when the 
cap and poly(A) structures were present (Fukao et al., 2009). It was concluded 
that this effect may be due to HuD attaching the poly(A) tail of a mRNA to the cap 
(via eIF4A), thereby contributing to the circularisation of the mRNA (a 
phenomenon known to stimulate translation) (Fukao et al., 2009; Wells et al., 
1998). It was also suggested that HuD may act by stimulating the activity of 
eIF4A (Fukao et al., 2009). It is not known whether HuD stimulates translation 
indiscriminately or only acts on a certain population of mRNAs, for example, 
those with adenine / uridine rich elements (to which HuD binds) or those with 
high eIF4A requirements (Chen and Shyu, 2009; Fukao et al., 2009). 
Figure 1.21. Ribbon diagram of HuD 
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1.2.11. Aims of the eIF4A section of the project 
 
New high throughput screens for small molecule inhibitors of eIF4A  
Pateamine A, hippuristanol and silvestrol were all identified as inhibitors of 
translation by high throughput screens of large libraries of small molecules. One 
of the aims of this project is to develop new screening strategies to be used in the 
search for new inhibitors of eIF4A. The current range of eIF4A inhibitors has been 
used to reveal much about the biology of translation initiation. In addition to this, 
due to the involvement of eIF4A in cancer, all of the known inhibitors are being 
considered for use in a chemotherapeutic context. Discovery of another inhibitor 
that potentially functions in a different way could be useful in future studies of 
eIF4A and may ultimately form the basis of a treatment for cancer and other 
diseases. 
Two different screens were created as part of this project, one cell-based (in vivo) 
and the other in vitro. 
 
Investigating the properties of the three paralogs of eIF4A  
The cell-based screen was used to distinguish more clearly the function of the 
distinct paralogs of eIF4A. RNA interference was used to suppress the expression 
of each paralog independently and the effect on the screen was recorded. 
7KH·875VRIWKHWKUHHparalogs are different in terms of length and structure 
(Table 2.). In order to determine whether these sequences are involved in feedback 
regulation of the expression of the genes they precede, they were cloned into a 
reporter system.  
 
PDCD4 
Previous studies have implicated PDCD4 as being involved in the cellular 
response to DNA damage. One of the aims of this project is to determine the 
extent to which the role of PDCD4 as a suppressor of eIF4A activity contributes to 
this response.  
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Part  
Alzheimer's Disease  
 
1.3.1. Background 
Alzheimer's disease (AD) is a neurodegenerative disease characterised by the 
aggregation of protein plaques and tangles in the neurons of the brain, together 
with an increase in oxidative stress and neuronal apoptosis (Shimohama, 2000).  
Although the pathophysiology of AD has been extensively studied, there is 
considerable disagreement among experts in the field regarding the importance of 
certain characteristics of the disease. 
 
1.3.2. The molecular basis of Alzheimer's disease 
The trigger for the onset of AD is unknown but age is the most significant risk 
factor with only a small percentage of people developing the early onset (<65 
years) form of the disease (Campion et al., 1999).  
In either form, there is strong evidence implicating the transmembrane amyloid 
precursor protein (APP) as being important in the establishment of the pathology 
(Bayer et al., 1999). The exact function of APP is not known but it is believed to be 
involved in iron metabolism, synaptic formation, neuronal repair and plasticity 
(Duce et al., 2010; Priller et al., 2006; Turner et al., 2003). Aberrant cleavage of 
APP leads to the generation of peptides between 39-43 amino acids in length 
known as DP\ORLGEHWD$ǃ(Small and Duff, 2008). These peptides aggregate in 
the intracellular environment to form amyloid plaques RU¶VHQLOHSODTXHV· (Perry 
et al., 1978). The way in which these plaques damage cells is not yet known but it 
has been suggested that they cause apoptosis by disrupting calcium homeostasis 
and also that they increase oxidative stress within mitochondria (Chen and Yan, 
2006; Yankner et al., 1990). APP is strongly implicated in AD by the fact that 
sufferers of Down·V syndrome generally develop the disease by the age of 40 or 50 
(Mann et al., 1984). This correlation is believed to be caused by the fact that APP 
is located on chromosome 21, which is present in triplicate in Down·V syndrome 
patients (Burt et al., 1998; Heyman et al., 1984; Suchowersky and Hayden, 1984). 
Mutations affecting the gene encoding APP were found to be strong risk factors 
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for AD in a study of Alzheimer's in a Swedish family (Citron et al., 1994). This 
collection of missense mutations was VXEVHTXHQWO\WHUPHGWKH¶6ZHGLVKPXWDWLRQ· 
² although this is a singular term, it is commonly used in the literature to refer to 
all the mutations identified by the original study (e.g. (Haass et al., 1995)). It was 
determined that the Swedish mutation caused a disruption in the cellular 
localisation of recycled APP, making it more susceptible to pathological cleavage 
leading to the formation of the amyloid beta peptides (Citron et al., 1994; Haass et 
al., 1995). 
The aberrant cleavage of APP is mediated by a number of enzymes and cofactors 
(Nunan and Small, 2000). ¶Beta site of APP cleaving enzyme 1· (BACE1) is a ǃ 
secretase that cleaves the transmembrane APP, leaving a membrane bound 
protein (C99) and an extracellular peptide (Hussain et al., 1999; Lin et al., 2000; 
Sinha et al., 1999; Yan et al., 1999). This initial cleavage step may also be 
performed by the ǂ VHFUHWDVH ¶GLVLQWHJULQ DQG PHWDOORSURWHLQDVH GRPDLQ-
FRQWDLQLQJSURWHLQ·$'$0, which cleaves closer to the cell membrane than 
BACE1 (Figure 1.22.) (Lammich et al., 1999; Sisodia, 1992). The next stage 
involves the cleavage of the transmembrane section of APP by a large complex of 
proteins including a Ǆ secretase (Figure 1.22.) (Edbauer et al., 2003). If the APP 
molecule was previously cleaved E\ $'$0 RU DQRWKHU ǂ secretase) then 
FOHDYDJH E\ WKH Ǆ VHFUHWDVH ZLOO UHVXOW LQ WKH JHQHUDWLRn of harmless protein 
fragments (Lammich et al., 1999). However, if the APP was cleaved by BACE1 
initially then cleavage by the ǄVHFUHWDVHZLOOgenerate $ǃ (Figure 1.22.) (Hussain 
et al., 1999; Lin et al., 2000; Sinha et al., 1999; Yan et al., 1999).  
  
52 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22. The cleavage of APP. IW WDNHV WKH FRPELQHG DFWLRQ RI %$&( DQG Ȗ
secretase to release the $ȕSHSWLGHwhich then aggregates and forms the pathogenic 
plaques. 
 
The imprecision of WKHǄ VHFUHWDVH HQ]\PH LVUHVSRQVLEOH IRU WKHYDULDWLRQ LQ$ǃ
peptide length between 39-43 amino acids (Figure 1.22..) (Hardy, 1997). 7KH Ǆ
secretase complex contains the proteins: nicastrin, ¶DQWHULRUSKDU\Q[-GHIHFWLYH·
(APH1), the two presenilin proteins and presenilin enhancer 2 (PEN2) (Kaether et 
al., 2006). The presenilins PS1 (PSEN1) and PS2 (PSEN2) were implicated in AD 
when it was discovered that mutations in their encoding genes were a significant 
risk factor (Sherrington et al., 1995). The mutant presenilin proteins increase the 
amount of the more pathogenic 42 amino acid form of the $ǃ peptide relative to 
the 39, 40 and 41 amino acid IRUPV ZLWKRXW DIIHFWLQJ WKH WRWDO DPRXQW RI $ǃ
produced (Citron et al., 1997).  
The proteins clusterin (Clu) and complement receptor 1 (CR1) were first identified 
as potentially involved in Alzheimer's disease by a Genome-Wide Association 
Study (GWAS) that screened almost 4000 sufferers and 4000 control individuals 
from Belgium, Finland, Italy and Spain (Lambert et al., 2009). High levels of Clu 
in the blood correlated with increased disease severity but did not act as a 
predictor for AD (Schrijvers et al., 2011). It was suggested that Clu may act as a 
PROHFXODUFKDSHURQHIRU$ǃ, allowing it to form more efficiently (Thambisetty et 
al., 2010). The GWAS mutant search identified CR1 as implicated in AD possibly 
Ȗ6HFUHWDVH&XW6LWHV 
BACE1 Cut Site 
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Cell Interior 
APP 
Released 
$ȕ3ODTXH 
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due to its function as part of the immune system, with it potentially having a role 
LQWKHLPPXQRORJLFDOFOHDUDQFHRIDJJUHJDWHG$ǃ(Lambert et al., 2009). 
/LNH $33 WKH ¶PLFURWXEXOH DVVRFLDWHG SURWHLQ WDX· 0$37 also acts as a 
precursor for a protein aggregate that causes damage as part of Alzheimer's 
disease (Tolnay and Probst, 1999). The normal function of MAPT is to stabilise 
microtubules, particularly those belonging to cells of the nervous system (Goedert 
et al., 1988). In AD, MAPT becomes hyperphosphorylated by a largely unknown 
mechanism, causing it to leave the microtubules which degrade in its absence 
(Hampel et al., 2010). It is believed that over-activity of glycogen synthase kinase 
3 (GSK3) may be partially responsible for this hyperphosphorylation (Hooper et 
al., 2008). $ǃdirectly stimulates the hyperphosphorylation and therefore release 
of MAPT (Busciglio et al., 1995). Free MAPT is insoluble and aggregates together 
to form structures called ¶tau tangles· (Hampel et al., 2010).  
Oxidative stress in the tissues of the brain, which increases with age, causes an 
increase in the production of amyloid plaques and tau tangles (Christen, 2000). 
The increased concentration of these aggregates stimulates further oxidative 
stress (Christen, 2000; Markesbery, 1997). This stress causes severe damage to 
neuronal protein and fats and mitochondrial DNA (Hensley et al., 1995; Mecocci 
et al., 1994; Palmer and Burns, 1994). Superoxide dismutase 1 (SOD1) is 
frequently found associated with amyloid plaques and tau tangles (Pappolla, 
1992). SOD1 forms part of the cellular defence against oxidative stress by 
converting the superoxide radical to molecular oxygen and hydrogen peroxide 
(Pappolla et al., 1992). One mechanism by which amyloid plaques perpetuate 
oxidative stress is by blocking the activity of SOD1 (Yoon et al., 2009). Another 
antioxidative process involves the expression of the protein thioredoxin (TXN), 
which is oxidised in preference to other cellular components (e.g. mitochondrial 
DNA), then subsequently reduced by the enzyme thioredoxin reductase (Wollman 
et al., 1988). The thioredoxin pathway is particularly important in AD as it is 
impaired in the neuronal tissues of sufferers of the disease (Lovell et al., 2000).  
Studies into the brains of sufferers of Alzheimer's disease taken from biopsy and 
autopsy revealed that the neurotransmitter acetylcholine consistently depleted 
compared to control samples (Davies and Verth, 1977; Muir, 1997). 
The cholinergic deficit in Alzheimer's disease is consistent with the fact that 
GSK3 reduces acetylcholine synthesis (Hooper et al., 2008; Hooper et al., 2007). 
This reduction in acetylcholine may be responsible for a number of the symptoms 
of Alzheimer's disease as acetylcholine has a definite role in the consolidation of 
new memory (Hasselmo, 2006). 
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As part of normal neurotransmission, acetylcholine is broken down by 
acetylcholinesterase (AChE) (Muir, 1997). In order to maintain levels of 
acetylcholine in the brains of Alzheimer's sufferers, acetylcholinesterase is 
pharmaceutically inhibited in the treatment of the disease (see next section).  
 
1.3.3. Treatments 
Unsurprisingly, given that little is known and less still agreed upon regarding the 
causes and progression of AD, at present there is no cure and few 
chemotherapeutic treatments that are beneficial. There are currently three main 
drugs licensed for the treatment of AD in the UK. All of these inhibit the action of 
acetylcholinesterase (AChE) which normally catalyses the degradation of the 
neurotransmitter acetylcholine (Shen et al., 2002). Inhibition of this degradation 
is intended to slow mental decay as the disease progresses but the effectiveness of 
drugs that act in this way is disappointing with a slight improvement observed in 
only half of the patients treated with them (Website Reference 5.). 
Many of the therapies currently in development focus on reducing the production 
of the amyloid plaques and the tau tangles or else on reducing oxidative stress 
(Godemann et al., 2009; Mancuso et al., 2007; Su et al., 2003).  
 
1.3.4. Translational control in Alzheimer's disease via ·875s  
7KH·875RIthe mRNA encoding APP contains an iron response element (IRE) 
that causes its upregulation in response to increased concentrations of cellular 
iron (Rogers et al., 1999b; Rogers et al., 2002b). The function of this response is 
unknown but it is consistent with the fact that free iron in the brain increases 
with age and that iron is particularly concentrated in the brains of AD sufferers 
(Bartzokis et al., 1997; Lovell et al., 1998; Smith et al., 1998). The APP ·875
also contains an internal ribosome entry site (IRES) (Beaudoin et al., 2008). Like 
the IRE, the reason for the presence of the IRES cannot be currently explained 
(Beaudoin et al., 2008). The IRES contributes to the severity of the pathology by 
upregulating the expression of APP in response to the ischemic conditions often 
associated with Alzheimer's disease (Kalaria, 2000).  
7KH · 875 RI the mRNA encoding BACE1 is important in the translational 
control of its expression, one of the functions of the highly structured 461 
nucleotide sequence is to suppress the translation of the protein (Lammich et al., 
2004). The inhibitory effect of the BACE1 ·875is enhanced by the presence of 
four upstream open reading frames (uORFs) (Mihailovich et al., 2007; Zhou and 
Song, 2006). There is currently debate as to the relative importance of the uORFs 
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verses the secondary structure of the BACE1 ·875LQLWVVXSSUHVVLYHIXQFWLRQ
with different studies arriving at different conclusions (Mihailovich et al., 2007). 
The majority of the data support the idea that the uORFs are more inhibitory 
than the structure, with the second AUG being particularly inhibitory 
(Mihailovich et al., 2007). It is unclear how the ribosome ultimately bypasses the 
uORFs in this context, whether it is by reinitiation or leaky scanning (De Pietri 
Tonelli et al., 2004). Stresses such as hypoxia (e.g. caused by ischemia following a 
stroke) or viral infections WKDWFDXVHH,)ǂSKRVSKRU\ODWLRQLQFUHDVHWKHrelative 
translation rate of BACE1 as repression of H,)ǂweakens the inhibitory ability of 
the uORFs (Ill-Raga et al., 2011; Sun et al., 2006). The BACE1 ·875ZDVDOVR
found to be able to undergo alternative splicing under certain conditions with the 
removal of three of the four uORFs (De Pietri Tonelli et al., 2004). Like the 
PDMRULW\RIWKHVHTXHQFHWKHX25)VLQWKH%$&(·875DUHKLJKO\FRQVHUYHG
across species (Figure 1.23.). The importance of translational control in the 
expression of BACE1 is consistent with the finding that it is often upregulated in 
AD without an increase in its mRNA level (Marcinkiewicz and Seidah, 2000; 
Preece et al., 2003).  
 
 
 
 
 
 
 
The ·875RIWKHP51$HQFRGLQJADAM10 is similar to the BACE1 ·875LQ
terms of length, GC content and predicted free energy (Table 3.) but not in terms 
of sequence (Lammich et al., 2010; Lammich et al., 2004). Also like the BACE1 
sequence, the ADAM10 ·875represses the expression of the downstream open 
reading frame (Lammich et al., 2010). The highly structured · VHFWLRQ and the 
two uORFs are important in this function (Lammich et al., 2010). For BACE1 and 
ADAM10 UHPRYDO RI WKHLU · 875V UHVXOWs in significant increases in their 
expression levels in vivo, and inclusion of the sequences into luciferase reporter 
constructs significantly decreases the level of reporter activity observed (Lammich 
et al., 2010; Lammich et al., 2004). In contrast to BACE1, the suppressive nature 
Figure 1.23. 7KH%$&(¶875IURPGLIIHUHQWVSHFLHVZDVDOLJQHGXVLQJ
ClustalX 2.1. &DQRQLFDOEDVHVDUHLQGLFDWHGE\DVWHULVNV7KHWRSSDQHOVKRZVWKH¶
UHJLRQRIWKHVHTXHQFHVDQGWKHERWWRPSDQHOVKRZQWKH¶UHJLRQ 
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of the ADAM10 ·875ZDVPRVWO\DWWULEXWHGWRLWVSUHGLFWHGVHFRQGDU\VWUXFWXUH
and less to its uORFs, which are in unfavourable contexts (Lammich et al., 2010). 
The uORFs of ADAM10 are highly conserved but unlike those belonging to 
BACE1 which are all conserved, one is unique to humans among the species 
referenced (Figure 1.24.). 
 
 
 
 
 
 
 
Name 
 
Length 
(nucleotides) 
GC 
Content 
(%) 
Predicted 
Free 
Energy 
(kcal/mol) 
Predicted 
Consequence 
if 
Overexpressed 
uORF(s) IRES(s) 
APP 194 76 -101.10 Harmful 0 1 
BACE1  461 76 -226.70 Harmful 4 0 
ADAM10 444 68 -215.90 Beneficial 3 0 
PS1 284 56 -99.60 Harmful 0 0 
PS2 427 57 -157.50 Harmful 0 0 
Clu2 305 59 -128.60 ? 0 0 
CR1 140 50 -35.10 ? 0 0 
MAPT 320 74 -132.50 Harmful 0 1 
SOD1 148 64 -58.70 Beneficial 0 0 
TXN 80 54 -24.50 Beneficial 0 0 
AChE 139 81 -78.50 Harmful 0 0 
Table 3. Details of the 5' UTRs of the AD-associated genes studied as part of 
this project 
 
Figure 1.24. 7KH $'$0 ¶ 875 IURP  GLIIHUHQW VSHFLHV ZDV DOLJQHGXVLQJ
ClustalX 2.1. &DQRQLFDOEDVHVDUHLQGLFDWHGE\DVWHULVNV7KHWRSSDQHOVKRZVWKH¶
UHJLRQRIWKHVHTXHQFHVDQGWKHERWWRPSDQHOVKRZQWKH¶UHJLRQ 
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1.3.5. $LPVRIWKH$O]KHLPHU·VGLVHDVHVHFWLRQRIWKLVSURMHFW 
The aim of this section is to investigate further the translational control of a 
number of the genes involved in Alzheimer's GLVHDVH7KH·875VRIa selection of 
such genes were cloned into luciferase reporter plasmids (Table 3.). This collection 
of reporters was used to estimate the inhibitory or stimulatory nature of the 
sequences on the expression of the downstream reporter gene. The eIF4A 
UHTXLUHPHQWRIHDFKRIWKH·875VZas determined by treating cells transfected 
with the reporter plasmids with hippuristanol.  
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Part 4. 
Oncogenes 
 
1.4.1. Background 
Cancer results from abnormal or uncontrolled cellular proliferation (Reviewed in: 
(Hanahan and Weinberg, 2011)). A mutation arising in one or more of a specific 
cohort of genes may trigger this process. These genes are termed proto-oncogenes 
in their pre-mutated state and simply oncogenes post-mutation. Another 
mechanism by which a proto-oncogene may become oncogenic is by its 
overexpression. The fact that there are a number of proto-oncogenes means that 
there are a number of different pathways by which a cancer may arise.  
 
1.4.2. Causes of Cancer 
Once a cancer has developed, more often than not, the original cause of the 
mutation(s) that led to its establishment will never be discovered. There are 
several known factors capable of causing neoplastic mutations, including 
environmental risk factors that increase the probability of such a mutation 
occurring (Lichtenstein et al., 2000). 
It is possible that an error may occur in the cell cycle. For example, during 
mitosis, translocation of portions of chromosomes may occur (Hartwell and 
Kastan, 1994). A t(11;14)(q13;q32) translocation event causes part of the enhancer 
region of IgH to become adjacent to the gene encoding cyclin D1, a protein 
involved in the progression of the cell cycle (Chesi et al., 1996; Gabrea et al., 
1999). This drives higher levels of cyclin D1 expression than normal which results 
in mantle-cell lymphoma or multiple myeloma (Chesi et al., 1996; Gabrea et al., 
1999). 
Part of the reason ZK\¶PLVWDNHV·RQO\RFFXUUHODWLYHO\LQIUHTXHQWO\ is the presence 
of ¶SURRI UHDGLQJ·DQG checking mechanisms that serve to increase the fidelity of 
DNA replication, repair genetic faults and initiate the programmed death of the 
cell if the damage is deemed irreversible (Enoch and Norbury, 1995). 
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p53 (TP53) upregulates the expression of p21 which binds and inactivates cyclin-
dependent kinase 2 (CDK2) (J. et al., 1993). CDK2 is involved in the progression 
of the cell cycle from G1 to S phase (Levkau et al., 1998).  
Genetic susceptibility is a strong contributing factor in some types of cancer, for 
example Li-Fraumeni syndrome is the name given to the predisposition towards a 
range of cancers caused by a familial mutation in the gene encoding p53 (Li and 
Fraumeni, 1969; Malkin, 2011).  
The example of Li-Fraumeni syndrome also highlights the importance of tumour 
suppressors (of which p53 is a well-studied example). On average, p53 is believed 
to be mutated in half of all human cancers (Hollstein et al., 1991). 
Radiation is another risk factor for cancer, the most commonly experienced 
example of radiation is ultraviolet (UV) light, a component of sunlight that has a 
wavelength between 295 and 400 nm (English et al., 1997). UV exposure causes 
damage to the chromosomal DNA of skin cells by inducing the formation of 
cyclobutyl pyrimidine dimers (Roza et al., 1991). Although there are mechanisms 
designed to repair these lesions, namely photoreactivation or enzymatic excision, 
these do not prevent all the mutations from causing eventual harm (Yarosh et al., 
1992). 
'LHWDQGSK\VLFDODFWLYLW\FRQWULEXWHWRDSHUVRQ·VULVNRIGHYHORSLQJFDQFHULQD
number of different ways, for example excessive ethanol consumption in alcoholic 
drinks increases the concentration of its carcinogenic breakdown product 
acetaldehyde in the liver (Homann et al., 2006; Lambert and He, 1988). The link 
between obesity and cancer has been thoroughly established although the 
underlying biology of this relationship remains unclear (Pischon et al., 2008). 
Whilst cancer is not generally transmissible horizontally in humans (there is 
evidence that certain animal tumours are however (Bostanci, 2005)), situations in 
which an infection causes cancer may make its epidemiological profile resemble 
that of a transmissible disease (Perz et al., 2006). It may be argued that cancer 
may be transmitted horizontally between humans by organ transplantation (Buell 
et al., 2001). An example of a potentially carcinogenic infectious agent is Human 
Papillomavirus (HPV) which can cause cancer of the cervix (Munoz et al., 1992). 
Similar to other viruses, persistent HPV infection (usually >10 years) results in 
inflammation which involves a high rate of cell division, thereby increasing the 
chances of an oncogenic mutation occurring (Ohshima and Bartsch, 1994). 
Inflammation is frequently associated with increased oxidative stress within the 
affected tissue, this is characterised by the formation of reactive oxygen species 
(ROS) which interfere with enzyme function and gene expression and also cause 
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damage to proteins, membranes and DNA, potentially inducing mutations 
(Ohshima and Bartsch, 1994). In addition to causing inflammation, HPV directs 
the synthesis of proteins E6 and E7 which inactivate the tumour suppressors p53 
and pRb (Retinoblastoma protein) respectively (Thomas et al., 1996). This may 
benefit the virus by suppressing the ability of its host cell to undergo apoptosis 
(Munger et al., 1992). 
Like p53, pRb stalls the cell cycle at G1 phase before it can progress to S phase 
(Reviewed in: (Munro et al., 2012)). pRb inactivates transcription factors 
belonging to the E2F family, the targets of which are involved in inducing the cell 
to leave the G1 phase of the cell cycle and enter S phase (Reviewed in: (Munro et 
al., 2012)). If pRb function was lost by mutation rather than by viral-protease 
degradation, it was shown that both alleles of pRb have to be mutated (Knudson, 
1971). This paradigm represents an interesting distinction between oncogenes and 
tumour suppressors; oncogenes are frequently activated by mutations occurring in 
a single allele (i.e. a dominant) whereas tumour suppressors generally need to be 
defective at both alleles (i.e. recessive) (Reviewed in: (Berger et al., 2011)). This is 
because the amount of protein expressed as a result of the wild-type allele is 
sufficient to perform the function of the diploid amount of protein (Reviewed in: 
(Berger et al., 2011)). Haploinsufficiency does occur in some cases however, for 
example the level of the tumour suppressor PTCH resulting from a single 
functional allele is not enough to prevent the formation of medulloblastoma in 
mice (Zurawel et al., 2000).  
The precise mechanisms by which the immune system contributes to cancer 
prophylaxis are yet to be determined (de Visser et al., 2006). However, the fact 
that HIV infection increases the risk of many different cancers developing is 
consistent with the immune system being an important line of defence against 
cancer (Reiche et al., 2004). While very common cancers among HIV carriers such 
DV .DSRVL·V VDUFRPD DQG FHUYLFDO FDQFHU are most commonly of viral origin (a 
strain of herpesvirus and HPV respectively for the examples here); non-viral 
cancers are also more prevalent, for example lung cancer is 2.5 to 7.5 times more 
frequent (Bower et al., 2003). 
 
1.4.3. The mechanisms by which cancer causes harm 
Regardless of its conception, if the cellular proliferation is allowed to progress 
unchecked, a tumour may develop (Hanahan and Weinberg, 2011). Cancer is not 
always associated with the presence of a solid tumour, for example leukaemia 
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consists of neoplastic white blood cells spread throughout the blood  (Teitell and 
Pandolfi, 2009). 
Tumours may be either benign or malignant. A benign tumour is one which does 
not have the potential to metastasise (Kwee et al., 1982; Russell, 1940). 
Metastasis is the budding of the primary tumour and the spread of single or 
groups of cells around the body (Liotta et al., 1991; Prall, 2007). Benign tumours 
can also be harmful, for example, a uterine fibroid can interrupt reproductive 
system function and cause pelvic pressure or pain (Stewart, 2001). 
Whether benign or malignant, a tumour may cause harm E\LWV¶PDVVHIIHFW·; this 
LVWKHSK\VLFDO LQIOXHQFHRIWKHWXPRXU·VSUHVHQFHRQQHDUE\RUgans and tissues, 
for example, compression of blood vessels causing ischemia (Duncan et al., 2005). 
A cancer becomes more harmful if it metastasises, Such satellite cells can be 
transported by the circulatory or lymphatic system and each has the potential to 
form a new tumour (Bostick et al., 1998). If metastatic secondary tumours form in 
the liver, their bulk can cause the severe disruption of hepatic function which may 
lead to death (Andreas et al., 2005). Frequently, the only treatment for this 
consequence is a liver transplant which is not often deemed appropriate as there 
is a strong chance that the new liver may be also populated by secondary tumours 
(Andreas et al., 2005).  
It is possible for neoplastic cells to permeate the blood-brain barrier, so primary 
tumours derived in any part of the body may spread to the brain and vice-versa 
(Deeken and Löscher, 2007). The spread of tumours from the brain to the body is 
only rarely documented (Sanerkin, 1962). Perhaps contrary to expectations, it was 
found that clumps of neoplastic cells were able to pass through the barrier more 
readily than individual cells; possibly because these clumps cause damage to the 
barrier (Zhang et al., 1992). 
Once in the brain, the mass effect can easily prove fatal as there is only a finite 
space for the tumour to grow within the skull (Behin et al., 2003). 
 
1.4.  Treatments for Cancer 
There are currently four categories of intervention used in the management of 
cancer, these are: radiotherapy, surgery, chemotherapy and biological therapy 
(Edwards et al., 2005). Chemotherapy is further divided by the mechanism of 
action of the chemotherapeutic agent; traditional drugs may be broadly divided 
into either: anthracyclines antimetabolites, alkaloid-derived compounds, 
topoisomerase inhibitors or alkylating agents (DeVita and Chu, 2008). All of these 
primarily work by damaging actively growing cells, for example; alkylating agents 
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(e.g. treosulfan, topotecan and melphalan) work by crosslinking guanine 
nucleobases thereby making DNA unable to separate and therefore unable to 
replicate (Meier et al., 2009). The non-specificity of alkylating agents represents a 
serious limitation to their use, the fact that they target any dividing cell means 
that the immune system, hair follicles, the gastrointestinal tract, the skin and 
elements of the reproductive system are severely compromised (Batchelor, 2001; 
Hall et al., 1991; Jain et al., 2011; Rezvanfar et al., 2008). 
Unlike the majority of cancer-chemotherapeutics which target the cell cycle, 
XVXDOO\ E\ GDPDJLQJ WKH FHOO·V'1$ LQ VRPH ZD\YLQFULVWLQH D YLQFD DONDORLG
binds to tubulin, rendering it unable to act as a component of the cytoskeleton 
which eventually causes the death of the cell (Lobert et al., 1996) Despite this 
differing mechanism, vinca alkaloids are also associated with debilitating side 
effects including: seizures, orthostatic hypotension, secretion of antidiuretic 
hormone and exacerbation of pre-existing neurological disease (Rosenthal and 
Kaufman, 1974). 
Biological therapies target cancer cells specifically by interfering with molecules 
involved in carcinogenesis (Reviewed in: (Sawyers, 2004)). Biological therapy may 
be in the form of an antibody against a specific oncoprotein or a small molecule. 
Cetuximab is an example of an antibody that is used to treat cancer (Baselga, 
2001; Pahl et al., 2012). It works by binding the extracellular domain of EGFR 
(epidermal growth factor receptor) thereby blocking its activation (Baselga, 2001). 
Some cancer cells express higher levels of EGFR than non-cancerous cells; this 
contributes to their abnormal proliferative capacity (Bigner et al., 1990; Ekstrand 
et al., 1991; Humphrey et al., 1990; Schlegel et al., 1994; Schwechheimer et al., 
1995; Wikstrand et al., 1998; Yamazaki et al., 1990). Attenuation of EGFR 
signalling in this way therefore has a more inhibitory effect on the growth of some 
cancer cells than normal cells (Tsuchihashi et al., 2005). 
 The drug Imatinib represents a new class of targeted therapy; it acts by 
inhibiting the activity of ABL1 (Abelson murine leukaemia viral oncogene 
homolog 1) (van Oosterom et al., 2001). The normal function of this tyrosine 
kinase is to induce cell differentiation, division and adhesion in response to Cyclin 
dependent kinase 1 signalling (Bueno et al., 2008). A translocation mutation event 
between chromosomes 9 and 22 leads to the creation of the ¶Philadelphia 
Chromosome· which encodes a mutant version of ABL1 which is constitutively 
activated and therefore induces excessive cell division (Kurzrock et al., 2003). This 
increased proliferation leads to chronic myelogenous leukaemia (CML), a cancer of 
the blood originating in the myeloid cells of the bone marrow (Druker, 2008). 
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Imatinib binds competitively to the active (TK) site of ABL1 thereby reducing its 
ability to phosphorylate its targets (one of which is ¶growth factor receptor-bound 
protein 2·) (Warmuth et al., 1997). The introduction of this drug in 2001 turned 
CML from a terminal disease into a true chronic condition. Before 2000, the seven 
year survival rate of patients with CML was less than 50%, it is now nearly 90% 
(Website Reference 6.). 
 
1.4.  eIF4A and cancer 
While there has been only a moderate amount of research specifically focusing on 
the role of eIF4A in cancer and its potential as a drug target, there is much in the 
literature to implicate it as an important factor in neoplasia (Silvera et al., 2010).  
mRNAs with long or highly-VWUXFWXUHG·875Vare not as readily translated as 
those with short or XQVWUXFWXUHG · UTRs (Kozak, 1980; Pickering and Willis, 
2005). Genes involved in cancer often possess PRUH LQKLELWRU\ · UTRs (Kozak, 
1987; Kozak, 1989; Pickering and Willis, 2005; Willis, 1999).   
7KHLPSRUWDQFHRIWKH·875LQWKHUHJXODWLRQRIWKHH[SUHVVLRQRIgenes involved 
in cancer is exemplified by BRCA1 (breast cancer type 1 susceptibility protein). 
BRCA1 is a tumour suppressor (Bishop, 1999). $ PXWDWLRQ LQ WKH · 875 RI
BRCA1 that often occurs in breast cancers changes the context of the start codon 
putting it in a weaker Kozak consensus (Signori et al., 2001). This causes the 
downregulation of the expression of BRCA1 which results in the cancer becoming 
resistant to apoptosis (Signori et al., 2001).  
It is reasonable to assume that oncogenes and hence cancer will have a higher 
dependency on eIF4A than non-cancerous cells since it is known that the 
requirement for eIF4A in translation is in direct proportion to the extent of mRNA 
·VHFRQGDU\VWUXFWXUH(Svitkin et al., 2001). 
Although this paradigm is often discussed in the literature, there has been little 
statistical and structural analysis into the relationship between gene function 
HJRQFRJHQHKRXVHNHHSLQJJHQHHWFDQG·875OHQJWKDQGVWUXFWXUHLess still 
is known about the role of eIF4A in the expression of tumour suppressor genes. As 
outlined in the Cancer section, a mutation that deactivates a tumour suppressor is 
more likely to occur than a mutation that activates an oncogene (Reviewed in: 
(Hanahan and Weinberg, 2011)). If the expression of tumour suppressor genes is 
reduced by inhibition of eIF4A then this may mean that targeting of eIF4A could 
promoter rather than inhibit neoplasia.  
In order to briefly address this idea as part of this project, a table of the properties 
RI WKH · 875V RI D VHOHFWLRQ RI KRXVHNHHSLQJ JHQHV RQFRJHQHV DQG WXPRXU
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suppressor genes was compiled (Table 4.). The housekeeping genes chosen were 
the control genes for this project (ǃDFWLQ, ǃWXEXOLQ and GAPDH). The oncogenes 
and tumour suppressor genes are those used as examples in (Hanahan and 
Weinberg, 2000). This review article covers the main hallmarks of cancer; the 
genes it references are therefore representative of cancer as a whole. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4'HWDLOVRIWKH¶875VRIDVHOHFWLRQRI
housekeeping, oncogenes and tumour suppressor 
genes  
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It is apparent from Table 4 and Table 5 that oncogenes tend to possess longer and 
PRUHKLJKO\VWUXFWXUHG·875Vthan tumour suppressor and housekeeping genes 
DQG WKDW WXPRXUVXSSUHVVRUJHQH·875VDUH ORQJHUDQGPRUHVWUXFWXUHG WKDQ
those belonging to housekeeping genes. It must be acknowledged that this is a 
very small sample size, considering that the total number of oncogenes is believed 
to be well over 200 (Chandeck and Mooi, 2010). Although the sample size limits 
the confidence with which conclusions may be made based on these data, they 
suggest that eIF4A inhibition would decrease the expression of oncogenes to a 
greater extent than it would tumour suppressor genes and housekeeping genes.  
As with eIF4A, it is accepted that inhibition of eIF4E results in the selective 
VXSSUHVVLRQ RI P51$V ZLWK ORQJ KLJKO\ VWUXFWXUHG · 875V compared to those 
ZLWK VKRUW XQVWUXFWXUHG · 875V D SKHQRPHQRQ RQFH UHIHUUHG WR DV P51$
discrimination (Graff et al., 2008). eIF4E has been strongly implicated in 
contributing to the pathology of a number of cancers.  It was found that 
overexpression of eIF4E could induce neoplasia (Graff et al., 2008; Lazaris-
Karatzas et al., 1990). Phosphorylation of the 4E-BPs in cancers is often 
associated with poor patient survival rates (O'Reilly et al., 2009). 
Suppression of cancer growth by eIF4E inhibition is achieved without apparent 
toxicity (Graff et al., 2007). The eIF4E inhibitor ribavirin is currently at the phase 
I / II stage of clinical trials in the USA for treatment of advanced breast cancer 
(Pettersson et al., 2011). 
Initially, eIF4E seems a better choice of drug target in the treatment of cancer 
than eIF4A as eIF4E is rate limiting in translation initiation whereas eIF4A is 
the most abundant translation initiation factor in terms of number of molecules 
per cell (Lin et al., 2008). However, there is evidence to support the idea that 
eIF4A suppression could be at least as effective as eIF4E suppression. 
The level of mRNA encoding eIF4AI is elevated in primary human hepatocellular 
carcinoma tissues, along with that of eIF4E (Shuda et al., 2000). Another study 
 
Average 
Length 
S.D. 
Average 
Predicted 
Free 
Energy 
S.D. 
Median 
Length 
Median 
Predicted 
Free Energy 
Housekeeping 104.3 7.3 -22.5 21.6 102 -21.9 
Onco- 408.1 369.8 -179.3 196.9 286.0 -134.0 
Tumour 
Suppressor 
257.2 217.2 -115.6 121.6 203.0 -81.0 
Table 5. Summary of the data presented in Table 4. 
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showed that the eIF4AI mRNA was on average 5.6 times more abundant in a 
panel of melanoma cell lines compared to normal human melanocytes (Eberle et 
al., 1997). Unlike the hepatocellular carcinoma study, the study into melanoma 
did not find any increase in the eIF4E (or eIF4AII, eIF4B or eIF4G) mRNAs 
(Eberle et al., 1997). A further advantage of targeting eIF4A rather than eIF4E is 
the fact that the expression of many oncogenes is IRES-mediated (review: (Silvera 
et al., 2010)). In cap-independent translation initiationH,)(ZKLFKELQGVWKH·
cap) is bypassed, whereas many IRESs have high eIF4A requirements (Bordeleau 
et al., 2006; Jackson, 1988). This means that eIF4A could be more relied-upon by 
oncogenes for their expression than eIF4E.  
In the paper describing the discovery of silvestrol, it was shown that eIF4A 
suppression LQ PLFH VXIIHULQJ IURP (Ǎ-Myc lymphoma was able to render the 
cancer susceptible to doxorubicin chemotherapy (Bordeleau et al., 2008b). The 
mice in this study were closely monitored for any potential side effects of the 
eIF4A inhibition. Eight days of daily injections of silvestrol did not cause the mice 
to lose weight or exhibit detectible levels of impaired liver function or 
immunosuppression (Bordeleau et al., 2008b).  
In a subsequent study by the same group, it was found that silvestrol treatment 
could not only sensitise cancers to chemotherapy but also dramatically suppress 
the growth of both lung and pancreatic cancer xenografts in mice (Cencic et al., 
2009). The major difference between these two studies was the type of cancer 
treated; the first study (Bordeleau et al., 2008a) investigated lymphoma whereas 
the second (Cencic et al., 2009) focused on a solid tumour lung cancer xenograft 
model. The increased susceptibility of the solid tumour to eIF4A suppression was 
attributed to the increased reliance of tumours of this type on angiogenesis 
(Cencic et al., 2009). Human umbilical vein endothelial cells exposed to silvestrol 
and pro-angiogenic stimuli simultaneously did not undergo angiogenesis (Cencic 
et al., 2009). The fact that eIF4A inhibitors suppress angiogenesis is consistent 
with the fact that many of the genes involved in these pathways are 
translationally controlled e.g. VEGF and FGF-2 (Cencic et al., 2009).  
The fact that PDCD4 is a negative regulator of eIF4A function is consistent with 
the involvement of eIF4A in cancer (Yang et al., 2003). As outlined in the PDCD4 
section (page 42), PDCD4 is upregulated during apoptosis and it has been 
demonstrated that elevated levels of the protein can suppress the growth of cancer 
cells (Shibahara et al., 1995).  
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1.4.6. Control genes for this project: ǃDFWLQ ǃWXEXOLQ and GAPDH  
ǃDFWLQ (ACTB) is an important cytoskeletal protein, involved in cell structure and 
motility (Reviewed in: (Engqvist-Goldstein and Drubin, 2003)). ǃWXEXOLQ (TUBB) 
forms part of the microtubules which are important in both cell structure and 
intracellular transport (Reviewed in: (Dutcher, 2001)). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) is involved in glycolysis, aiding in the 
production of ATP (Reviewed in: (Barber et al., 2005)). ǃ DFWLQ, ǃ WXEXOLQ and 
GAPDH all are often used as loading controls e.g. in western blotting 
(Stürzenbaum and Kille, 2001). Given the frequency of the use of these genes in 
this capacity, a number of studies have investigated the possible problems of 
WUHDWLQJWKHPDVVLPSO\¶KRXVHNHHSLQJ·JHQHV7KHVHstudies generally support the 
accepted idea that these genes can be used as relevant controls, particularly when 
all three are used in combination as they are in this project (Bauer et al., 2009; 
Ferguson et al., 2005). 7KH · UTR sequences of each of these genes (Table 6.) 
were cloned into reporter vectors as part of this project. 
 
1.4.7. Ornithine Decarboxylase 1 (ODC1) 
ODC1 is the rate limiting enzyme in the generation of polyamines (Russell and 
Snyder, 1968). It is overexpressed in certain human cancers, particularly 
oesophageal (Yoshida et al., 1992). Polyamines have been implicated as agonists 
in a large number of pathways that contribute to cancer formation and 
perpetuation (Gerner and Meyskens, 2004). 7KH·875RIKXPDQODC1 (Table 6.) 
contains a uORF, a very stable hairpin structure and an IRES (Danner, 2002). 
The hairpin structure has been used out of context in a number of studies to 
investigate structured RNA sequences; LWLVVRPHWLPHVUHIHUUHGWRDVWKH¶2'&+3·
RU¶KS· (Bottley et al., 2010). These studies thoroughly support the accepted idea 
that a structure such as this represents a significant obstacle to the translation of 
the downstream coding region and has a high requirement for the activity of 
eIF4A (Svitkin et al., 2001).  
The function of this hairpin is to repress the expression of ODC1 in conditions 
that are generally unfavourable (Mathews et al., 2007; Sergeevich Spirin, 1999). 
The uORF is believed to be present in order to contribute to the translational 
repression of the transcript, this effect is predicted to be minimal, however, as the 
uAUG is in an unfavourable context (Grens and Scheffler, 1990). Deletion of the 
uAUG was found to make little difference to the properties of the UTR (Grens and 
Scheffler, 1990). The ODC1 uORF is highly conserved across species as is the 
hairpin sequence (Figure 1.25.). 
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Figure 1.25. 7KH 2'& ¶ 875 IURP QLQH GLIIHUHQW VSHFLHV ZDV DOLJQHG XVLQJ
ClustalX 2.1. &DQRQLFDOEDVHVDUHLQGLFDWHGE\DVWHULVNV7KHWRSSDQHOVKRZVWKH¶
UHJLRQRIWKHVHTXHQFHVDQGWKHERWWRPSDQHOVKRZQWKH¶UHJLRQ 
 
7KH·875RIODC1 was suspected to contain an IRES following the discovery 
that the ODC1 protein was upregulated during the late G2 and mitosis phases of 
the cell cycle, phases which are typically associated with cap-dependent but not 
cap-independent translation inhibition (Bonneau and Sonenberg, 1987; Fredlund 
et al., 1995; Huang and Schneider, 1991). Translation initiation of the mRNA 
encoding ODC1 occurs in a cap-dependent manner during the G1 and S phases of 
the cell cycle, only progressing by cap-independent initiation during G2 and 
mitosis (Pyronnet et al., 2000). This indicates that the ODC1 IRES has weak 
activity since it is out-competed for the translation machinery by the cap which is 
followed shortly by the unfavourable stable hairpin (Pyronnet et al., 2000). Since 
polyamines are involved in cellular proliferation and ODC1 has a very short 
cellular half-life, it is unsurprising that it is beneficial for the cell to elevate the 
expression level of ODC1 during mitosis (Pyronnet et al., 2000; Tabor and Tabor, 
1984).  
 
1.4.  Epidermal Growth Factor Receptor (EGFR) 
EGFR is a transmembrane glycoprotein tyrosine kinase (Reviewed in: (Roy S, 
2004) and (Herbst, 2004)). Its function is to stimulate, primarily Akt-, MAPK- or 
JNK-mediated cellular proliferation in response to a range of ligands including 
WUDQVIRUPLQJJURZWKIDFWRUǂ7*)ǂDQGWKHIDPLO\RIHSLGermal growth factors 
(EGFs) (Oda et al., 2005). 
Overexpression of EGFR has been strongly linked to poor prognosis in head, neck, 
ovarian, cervical, bladder and oesophageal cancers and implicated in a large 
number of other cancers (Nicholson et al., 2001). Mutations in EGFR are also 
important, particularly in instances of glioblastoma multiforme, with ~25% 
predicted to possess a constitutively active truncated version (EGFRvIII) 
(Wikstrand et al., 1998). Although there is a strong relationship between the 
presence of this mutation and poor prognosis, it does not seem to be as significant 
as the overexpression of EGFR, with 40-50% of the glioblastomas assayed for the 
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presence of the vIII mutant displaying significantly elevated levels of the wild-
type receptor (Bigner et al., 1990; Ekstrand et al., 1991; Humphrey et al., 1990; 
Schlegel et al., 1994; Schwechheimer et al., 1995; Wikstrand et al., 1998; 
Yamazaki et al., 1990). 
The primary mechanism by which EGFR is overexpressed is gene amplification, 
as demonstrated in colorectal, pulmonary, bile duct and soft tissue cancers (Dacic 
et al., 2006; Dobashi et al., 2004; Nakazawa et al., 2005; Ooi et al., 2004). In each 
of these instances however, amplification was not the only cause of the 
overexpression, with a discrepancy between gene dosage and EGFR expression 
(Kersting et al., 2004). A SHUFHQWDJH RI WKLV ¶H[WUD· RYHUH[SUHVVLRQ PD\ EH
attributable to mutations that cause the transcriptional upregulation of the EGFR 
gene (Chi et al., 1992; Gebhardt et al., 1999; Haley and Waterfield, 1991; 
Maekawa et al., 1989). The transcription factor ¶early growth response factor · 
(Egr-1 RU ¶(*5·) is responsible for upregulating the expression of EGFR in 
response to stress (Nishi et al., 2002). The existence of this relationship partly 
explains why EGFR expression is upregulated in response to hypoxia (Appl and 
Klempnauer, 2002; Laderoute et al., 1992; Nishi et al., 2002; Swinson and 
O'Byrne, 2006). 
There has been little research into the possible contribution of translational 
regulation to EGFR overexpression in cancer. One study, however, demonstrated 
that EGFR was upregulated in response to both hypoxia and the activation of 
hypoxia-LQGXFLEOH IDFWRU ǂ +,)ǂ RU ¶(3$6·) without observing either 
mutational events or changes in EGFR mRNA levels (Franovic et al., 2007). 
Cancer cells overexpressing EGFR in hypoxic conditions have a significant 
survival advantage and tend to be more resistant to chemotherapy (Clarke et al., 
2001; Swinson and O'Byrne, 2006; Warburton et al., 2004; Yokoi and Fidler, 
2004). This is due to the EGFR signalling via the phosphatidylinositol 3-kinase 
(PI3K) and MAPK pathways which are associated with cell survival, for example, 
activation of PI3K leads to the induction of VEGF which stimulates 
vascularisation (Clarke et al., 2001). 
 
1.4.9. Vascular Endothelial Growth Factor A (VEGFA) 
The normal function of VEGFA is to stimulate angiogenesis as part of embryonic 
development, wound healing and reproductive functions (Folkman, 1990; Folkman 
and Klagsbrun, 1987; Plouët et al., 1989). The expression of VEGFA is strongly 
induced by hypoxia which occurs in the tumour microenvironment (Plate et al., 
1992; Shweiki et al., 1992). Part of this response was attributed to upregulation 
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by the transcription factor hypoxia-inducible factor 1 (HIF-1) and also by the 
hypoxia-induced stabilisation of the normally rapidly degraded VEGFA mRNA 
(Forsythe et al., 1996; Levy et al., 1996).  
Translational control was implicated in the hypoxic stimulation of VEGFA 
H[SUHVVLRQZKHQLWZDVGLVFRYHUHGWKDWLWV·875ZDVDEOHWRLQLWLDWHWUDQVODWLRQ
in a cap-independent manner (Huez et al., 1998). The very long (491 nucleotide) 
VEGFA ·875FRQWDLQV WZR independent IRES elements (Huez et al., 1998). It 
has been proposed that these two IRESs regulate the expression of two different 
splice variants of VEGFA (Bornes et al., 2004). The VEGFA · 875 FRQVLVWV RI
¶,5(6 %· IROORZHG E\ D &8* LQLtiation codon in frame of the coding region, 
IROORZHGE\¶,5(6$· (Bornes et al., 2004). The upstream start codon, regulated by 
IRES B drives the expression of L-VEGF IRU ¶large· VEGF), a variant which 
possesses an extra 180 amino acids (Bornes et al., 2004). The function of this 
larger version is not known, the extra amino acids are proteolytically cleaved off 
to leave the normal size VEGFA once the protein has been synthesised 
(Rosenbaum-Dekel et al., 2005). The function of this pathway may be associated 
with the storage of VEGFA or with the rapid generation of the molecule in 
response to hypoxic stimuli (Storkebaum et al., 2004).  
In general, cells respond to hypoxia by decreasing protein synthesis rates 
(Pettersen et al., 1986). One mechanism used to accomplish this in the short term, 
LQYROYHV WKH SKRVSKRU\ODWLRQ RI WKH WUDQVODWLRQ LQLWLDWLRQ IDFWRU H,)ǂ 
(Koritzinsky et al., 2007). When hypo-SKRVSKRU\ODWHGWKHIXQFWLRQRIH,)ǂLVWR
assist in the binding of the initiator tRNA to the 40S ribosomal subunit by 
forming a ternary complex with guanosine triphosphate (GTP). Phosphorylation of 
H,)ǂLQKLELWVWKLVSURFHVVWKHUHE\DFWLQJDVDEUDNHRQJOREDOWUDQVODWLRQUDWHV
(Koritzinsky et al., 2006; Koumenis et al., 2002). 
Exposure to chronic hypoxia causes cells to adopt an additional mechanism of 
translational suppression (Koritzinsky et al., 2006). The mammalian target of 
rapamycin (mTOR) becomes attenuated in response to hypoxia by multiple 
pathways that have yet to be fully described (Brugarolas et al., 2004; Liu et al., 
2006; Schneider et al., 2008). When active, mTOR is involved in a number of 
pathways associated with transcription, proliferation, cell growth and migration 
(Hay and Sonenberg, 2004). One of its functions is to phosphorylate eukaryotic 
initiation factor 4E-binding protein 1 (4E-BP1 RU ¶(,)(%3·) (Beretta et al., 
1996; Brunn et al., 1997; Gingras et al., 2001). eIF4E is the component of the 
eIF4)FRPSOH[UHVSRQVLEOH IRUUHFRJQLVLQJDQGELQGLQJ WKH· FDSRIDP51$ LQ
preparation for the formation of the pre-initiation complex (page 16) (Banerjee, 
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1980; Mathews et al., 2000). Under hypoxic conditions, the mTOR-mediated 
phosphorylation of 4E-BP1 decreases, thereby permitting it to bind eIF4E which 
leads to the suppression of cap-dependent translation initiation (Brugarolas et al., 
2004; Liu et al., 2006; Schneider, 2008). Since IRES-mediated translation 
LQLWLDWLRQGRHVQRWLQYROYHWKHELQGLQJRIWKH·FDSLWLVIDYRXUHGXQGHUFRQGLWLRQV
that inhibit eIF4E function (Hellen and Sarnow, 2001; Prevot et al., 2003; 
Stoneley and Willis, 2004). 
 
2YHUYLHZRIWKH·875VRIWKHJHQHVLQYHVWLJDWHGDVSDUWRIWKH oncogenes section 
of this project 
Name 
Length 
(nucleotides) 
 
GC 
Content 
(%) 
 
Predicted 
Free 
Energy 
(kcal/mol) 
uORF(s) IRES(s) 
Ⱦ 84 74 -15.50 0 0 
Ⱦ 127 47 -30.10 0 0 
GAPDH  102 61 -21.90 0 0 
ODC1 334 66 -157.50 1 1 
EGFR 246 78 -107.50 0 1* 
VEGFA 491 57 -193.30 1 2 
Table 6. Details of the 5' UTRs of the oncogenes and housekeeping genes 
studied as part of this project. * data supporting the existence of an IRES in the 
EGFR ¶875DUHSUHVHQWHGLQWKLVWKHVLV 
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CUG 
  ȕ$FWLQ (84 nucleotides) 
ȕ7XEXOLQ (127 nucleotides) 
GAPDH (102 nucleotides) 
ODC1 (334 nucleotides) 
EGFR (246 nucleotides) 
VEGFA (491 nucleotides) 
AUG IRES 
IRES 
IRES A IRES B 
RNA Hairpin 
Figure 1.26. 7KH¶875VRIWKHJHQHVLQYHVWLJDWHGDVSDUWRIWKHRQFRJHQHVVHFWLRQRIWKLV
project. 7KH¶875VRIWKHFRQWUROKRXVHNHHSLQJJHQHVDUHVKRZQLQblue DQGWKH¶875VRIWKH
proto-oncogenes are shown in red. The sequences are shown to scale. 
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1.4.  Aims  
The aim of this section is to investigate further the translational control of a 
QXPEHURIWKHJHQHVLQYROYHGLQFDQFHU7KH·875VRIWKHJHQHVVKRZQ on the 
previous page were cloned into luciferase reporter plasmids. This collection of 
reporters was used to estimate the inhibitory or stimulatory nature of the 
sequences on the expression of the downstream reporter gene. The eIF4A 
UHTXLUHPHQWRIHDFKRIWKH·875VZas determined by treating cells transfected 
with the reporter plasmids with hippuristanol.  
  
74 
 
Chapter 2. Materials and 
Methods 
 
2.1. PCR and Primers 
All polymerase chain reactions (PCRs) performed to generate sequences that 
would eventually be cloned used Phusion Hot Start High Fidelity DNA 
polymerase (Finnzyme, Cat # F-540S) together with its recommended buffer (20 
mM Tris-HCl (pH 7.4 at 25°C), 0.1 mM EDTA, 1 mM DTT, 100 mM KCl, 
stabilizers and 200 µg/ml BSA) and dNTPs (200 µM). All PCR colony screens used 
Taq polymerase (Roche, Cat # 11146165001) and its buffer (100 mM Tris-HCl, 15 
mM MgCl2 and 500 mM KCl, pH 8.3 (20°C)). Template concentration was 
approximately 1 ng for plasmids and 100 ng for cDNA. Primer concentration was 
0.5 µM. Components were added to the reaction vessel on ice in the order shown 
below (Table 7.). 
 
 
Table 7. The components of the PCR reaction, their concentrations and the 
order in which they were added to the reaction vessel. 20 µl reactions were used 
for colony screens and 50 µl reactions were used if the product was intended for 
cloning. 
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The reaction vessels were put into a PCR machine (BIOER GenePro). This was 
programmed with the following parameters (Table 8.). 
 
Cycle Step Temperature Time(s) Cycles 
Initial 
Denaturation 
98°C 30 1 
Denaturation 98°C 10 
35 Annealing X°C 30 
Extension 72°C 30 
Final Extension 72°C 600 1 
Hold 4°C Hold 1 
Table 8. The program that was run on the PCR machine. X = primer 
annealing temperature (see below). 
 
The primer annealing temperatures used were established using the online 
SURJUDP ¶2OLJR &DOF· (Kibbe, 2007) to determine the salt-adjusted melting 
temperatures (Tm) of the forward and reverse primers for a single reaction, the 
temperature used was 5°C below the lowest value. Once the PCR machine 
programme had completed, the products were visualised using agarose gel 
electrophoresis (see 2.3. DNA agarose gel electrophoresis). 
The sequences of the primers used in this project are shown on the following page 
(Table 9.). 
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Table 9. Sequences of the PCR primers used in this project 
  
Primer Name ȋ ?ǯȂ  ?ǯȌ 
CMV KpnI F TTTGCGGTACCTCGCGATGTACGGG 
CMV HindIII R CTGGACTAGTGGATCCGAGC 
HP HindIII F GATTACAAAGCTTCTCGAGGGGCGAATACGAATTCGTCA 
HP HindIII R GATTACAAAGCTTTTAATTAAGGATCCGTCTTCCCGCCGCC 
HP SpeI F GATTACAACTAGTCTCGAGGGGCGAATACGAATTCGTCA 
HP NcoI R GATTACACCATGGTTAATTAAGGATCCGTCTTCCCGCCGCC 
eIF4AI XhoI F TGCGCTCGAGCAGGCGGGGCCGGGGCGGC 
eIF4AI PacI R ACTGATTAATTAAGATCCTTAGAAACTAGGGCG 
eIF4AII XhoI F TGCGCTCGATCGGCAGCGGCACAGCGAGG 
eIF4AII PacI R ACTGATTAATTAAGATTCAGAGTCCGCGGAAGA 
SOD1 XhoI F GATACACTCGAGGTTTGGGGCCAGAGTGGGCG 
SOD1 PacI R GATACATTAATTAAAACTCGCTAGGCCACGCCGA 
TXN XhoI F GATACACTCGAGTTTGGTGCTTTGGATCCATT 
TXN PacI R GATACATTAATTAACTTGGCTGCTGGAGTCTGAC 
Ace SpeI F GATTACAACTAGTGGGGTGTGTGCGGGGGGCCG 
Ace NcoI R GATTACACCATGGGGCTGCAGGGCAGGCGGCGTC 
Tub SpeI F GATTACAACTAGTGCACCTCGCTGCTCCAGCCTCTGG 
Tub NcoI R GATTACACCATGGGGTTAAAATTTAATTTTTTTGC 
EGFR SpeI F GATTACAACTAGTCCCCGGCGCAGCGCGGCCGC 
EGFR NcoI R GATTACACCATGGCGCTGCTCCCCGAAGAGCTCG 
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 Restriction digestion 
Enzyme Name 
Buffer 
Composition 
BSA1  / SAM2  NEB3  Cat # 
BamHI 
50 mM Tris-HCl 
100 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
BSA R0136S 
EcoRI 
100 mM Tris-HCl 
50 mM NaCl 
10 mM MgCl2 
0.025 % Triton X-100 
pH 7.5 @ 25°C 
No R0101S 
HindIII 
10 mM Tris-HCl 
50 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
No R0104S 
PacI 
10 mM Bis-Tris-
Propane-HCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.0 @ 25°C 
BSA R0547S 
XhoI 
20 mM Tris-acetate 
50 mM potassium 
acetate 
10 mM Magnesium 
Acetate 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
BSA R0146S 
SpeI 
20 mM Tris-acetate 
50 mM potassium 
acetate 
10 mM Magnesium 
Acetate 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
BSA R0133S 
NcoI 
50 mM Tris-HCl 
100 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
No R0193T 
KpnI 
10 mM Bis-Tris-
Propane-HCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.0 @ 25°C 
BSA R0142S 
AhdI 
20 mM Tris-acetate 
50 mM potassium 
acetate 
10 mM Magnesium 
Acetate 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
BSA R0584S 
AseI 
50 mM Tris-HCl 
100 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
No R0526S 
BglII 
50 mM Tris-HCl 
100 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
No R0144S 
Table 10. The restriction endonuclease enzymes used as part of 
this project. 1. BSA = bovine serum albumin, SAM = S-
adenosylmethionine and NEB = New England Biolabs 
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Reaction Component Amount (in a 50 µl Reaction) 
Buffer 5 µl 
BSA or SAM 0.5 µl 
DNA 200 ng (~ 1 µl) 
Enzyme 1 µl 
H2O 42.5 µl (42 µl without BSA/SAM) 
Table 11. A typical restriction digestion reaction 
 
Reactions were assembled as above (Table 11.) and incubated at 37°C. Digestion 
reactions used for the preparation of cloning vectors were incubated overnight 
whereas colony screen diagnostics were incubated for approximately two hours. If 
the digestion product was intended for ligation then the vector was 
dephosphorylated by adding 1 µl Calf Intestinal Alkaline Phosphatase (CIAP NEB 
Cat# M0290L) to the completed reaction which was then left to incubate at 37°C 
for a further five minutes. 
 
 DNA agarose gel electrophoresis 
The products of PCRs and restriction digests were visualised by horizontal 
agarose gel electrophoresis. In order to make these gels 1 g agarose (Melford, Cat 
# MB1200) was added to a Pyrex beaker containing 100 ml 1× TAE (Tris base, 
acetic acid and ethylenediaminetetraacetic acid (EDTA)) to give a final agarose 
concentration of 1%. This beaker was incubated at full power in a 650 W 
microwave for two minutes before being placed in a 42 °C water bath to cool for 
one minute. SYBR Safe (Invitrogen, Cat # S33102) was added to the mixture to 
give a final volume of 0.04% (4 µl). A comb was added to a gel tray and the ends of 
the tray were sealed using autoclave tape. The gel mixture was poured into the 
tray and allowed to set at room temperature. Once set, the gel was immersed in a 
solution of 1× TAE running buffer. DNA was mixed in a 10:1 ratio with loading 
buffer (the master mix of loading buffer consisted of: 6.25 ml of H2O, 0.025 g 
xylene cyanol, 0.025 g bromophenol blue, 1.25 ml 10% SDS and 12.5ml glycerol). 
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The DNA was added to the submerged wells together with a DNA size-marker 
ladder. For large bands, such as digested plasmids, a HighRanger DNA ladder 
(Norgen Biotek, Cat # 11900) was loaded while a 100 bp Ladder (NEB, Cat # 
N3231L) was used for smaller bands such as PCR products. Gels were usually run 
for approximately one hour (using a power pack (Bio-Rad Basic) set to 120 V) 
before visualisation using a ChemiDoc XRS Molecular Imager (Bio-Rad). DNA 
samples were prepared by the addition of loading buffer which consisted of xylene 
cyanol and bromophenol blue dyes and glycerol.  
 
 Gel extraction 
$OO H[WUDFWLRQV RI '1$ IURP DJDURVH JHOV ZHUH SHUIRUPHG XVLQJ WKH ¶)UHH]H-
6TXHH]H· PHWKRG. A scalpel was used to excise DNA bands from the gel and 
transfer them to 1.5 ml microcentrifuge tubes. These were frozen to -80 °C. Tubes 
were centrifuged at 13, 000 rpm for 10 minutes. The liquid was removed and 
transferred to new tubes. An equal volume of water to the liquid removed was 
added to the tubes containing the gel slices, these were then vortexed for 30 
seconds before being re-frozen to -80 °C. The tubes were then centrifuged again 
and the liquid fractions were added to the previous liquid removed from the gel 
slices. Equal volumes of phenol were added to this liquid. These mixtures were 
vortexed and centrifuged at 13, 000 rpm for one minute. The upper fractions were 
transferred to new tubes to which equal volumes of 1:1 phenol : chloroform 
(containing 4% isoamyl alcohol) were added. These mixtures were vortexed and 
centrifuged at 13, 000 rpm for one minute. The upper fractions were transferred 
to new tubes to which equal volumes of chloroform were added. These mixtures 
were vortexed and centrifuged at 13, 000 rpm for one minute. 2.5 volumes of 100% 
ethanol and 0.2 volumes of 5M NaAc (sodium acetate) were added to the tubes 
which were then frozen to -80 °C. The tubes were then centrifuged at 13, 000 rpm 
for 30 minutes at 4 °C. All the supernatant was removed. The pellets were dried 
at room temperature and resuspended in 20 µl H2O. Yield and purity were 
quantified by Nanodrop (Thermo Scientific) analysis. 
 
 Ligation 
All ligations used T4 DNA ligase (NEB, Cat # M0202L) with the supplied buffer 
(50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM Dithiothreitol, pH 7.5 @ 
25°C). A typical ligation reaction contained the following components (Table 12.). 
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Reaction Component Amount (in a 10 µl Reaction) 
Buffer 1 µl 
Vector 100 ng (~ 0.5 µl) 
Insert X ng (0 ng in control) 
Enzyme 0.5 µl 
H2O 8 µl 
 
Table 12. The components of a standard ligation reaction. X = insert 
concentration, this was such that the ratio of vector to insert was 3:1. Reactions 
containing 0 ng insert were performed in parallel to regular reactions, in order to 
ascertain the rate of vector self-ligation.  
 
Reactions were assembled as above in 0.5 ml microcentrifuge tubes. Blunt-end or 
A-tail ligations were incubated overnight at 4°C while sticky-end ligations were 
incubated at room temperature for at least two hours. 
 
2.6 Preparation of Heat-&RPSHWHQW'+ǂEscherichia coli 
A plate was poured that contained LB with no selective agent. 20 µl of one of the 
DOLTXRWV RI WKH SUHYLRXV EDWFK RI '+ǂ ZDV VSUHDG RQ WKLV SODWH )ROORZLQJ
incubation overnight at 37 °C, a single colony was used to inoculate 2.5 ml liquid 
LB (also without antibiotic). This starter culture was incubated at 37 °C overnight 
with agitation before being poured into a 250 ml volume of liquid LB containing 
20 mM MgSO4. This volume was incubated at 37 °C with agitation for 5 ² 6 hours 
until the A600 was between 0.4 and 0.6. At this point, the culture was centrifuged 
at 4000 rpm for ten minutes at 4 °C. In the cold room (maintained at 4 °C), the 
supernatant was discarded and cell pellets were resuspended in 100 ml ice cold 
Buffer 1 (30 mM potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl 
and 15% glycerol, adjusted to pH 5.8 with acetic acid) before being incubated on 
ice for five minutes and centrifuged as before. The supernatant was discarded and 
the pellets were resuspended in 10 ml ice cold Buffer 2 (10 mM 3-(N-
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morpholino)propanesulfonic acid), 75 mM CaCl2, 10 mM RbCl and 15% glycerol, 
adjusted to pH 6.6 with KOH) and incubated on ice for 45 minutes. This mixture 
was transferred to 0.5 ml microcentrifuge tubes in 200 µl aliquots. These tubes 
were flash frozen in liquid nitrogen and stored at -80 °C. 
 
7 Transformation and plasmid preparation 
Heat-FRPSHWHQW '+ǂ Escherichia coli were used to transform plasmids and 
completed ligations. Cells were incubated with ~ 10 ng DNA on ice before being 
subject to heat shock at 42°C. The cells were then incubated at 37°C in non-
selective liquid media for one hour with agitation. This suspension was spread on 
Luria-Bertani (LB) plates containing a  ǍJPO ampicillin. Plates were 
incubated overnight at 37°C.  
Resulting colonies were either screened for successful ligation by PCR (in which a 
scraping from each colony was used as the template) or screened by diagnostic 
digest. If the latter, scrapings from a range of colonies were used to inoculate 10 
ml liquid LB containing  ǍJPO ampicillin, these mixtures were grown 
overnight at 37°C with agitation. The plasmids were purified from the resulting 
cultures using Promega Wizard® Plus SV Miniprep DNA Purification Columns 
(Cat# A1460). Briefly, this protocol involves the lysis of cells using a solution of 
0.2M NaOH and 1% SDS followed by the addition of resuspension solution (50mM 
Tris-+&O S+  P0 ('7$ DQG ǍJPO 51DVH $ &HOOXODU SURWHLQV DUH
degraded by the addition of alkaline phosphatase and the incubation of the 
reaction for five minutes at room temperature. Neutralisation solution (4.09M 
guanidine hydrochloride, 0.759M potassium acetate and 2.12M glacial acetic acid 
(pH 4.2)) was added to stop this reaction. Tubes were centrifuged at 13, 000 rpm 
for ten minutes before the supernatant was eluted and transferred to one of the 
DNA binding columns provided with the Miniprep kit. This was centrifuged at 13, 
000 rpm for one minute. The supernatant was discarded and 750 µl column wash 
solution (60% ethanol, 60mM potassium acetate, 8.3mM Tris-HCl, 0.04mM EDTA) 
was added to the top of the column. The column was then centrifuged again at 13, 
000 rpm for one minute. The supernatant was discarded and replaced with 250 µl 
column wash solution. The column was centrifuged for a further one minute at 13, 
000 rpm. The upper part of the column (to which the DNA was bound) was placed 
in a new 1.5 ml microcentrifuge tube. Nuclease free water (100 µl) was added to 
the column which was then left for five minutes at room temperature to allow the 
DNA to dissolve into the water. The tube containing the column was then 
centrifuged one final time at 13, 000 rpm for one minute to collect the suspended 
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DNA in the microcentrifuge tube. Yield and purity of DNA were determined by 
Nanodrop (Thermo Scientific) analysis. 
 
8. mRNA extraction 
Total RNA was extracted from confluent T75 flasks of SH-SY5Y cells using TRI 
Reagent® (Sigma-Aldrich, Cat # T9424). The growth medium was removed from 
flasks and cells were washed twice in PBS solution. 1.5 ml TRI Reagent® was 
added to the cells and allowed to incubate at room temperature for five minutes. 
This mixture was then transferred to microcentrifuge tubes and 0.3 ml chloroform 
was added. Tubes were shaken, left to stand at room temperature for 15 minutes 
then centrifuged at 13, 000 rpm for 15 minutes at 4 °C. The clear, upper phase 
was carefully transferred to new tubes and 0.75 ml 100% isopropanol was added. 
The tubes were inverted four times, left to stand at room temperature for ten 
minutes and then centrifuged at 13, 000 rpm for ten minutes at 4 °C. The 
supernatant was discarded and the RNA pellet was resuspended in 1.5 ml 75% 
ethanol. Tubes were vortexed then centrifuged at 7, 500 rpm for five minutes at 4 
°C. The pellet was air-dried then suspended in 50 µl nuclease free water. Yield 
and purity of RNA were quantified by Nanodrop (Thermo Scientific) analysis. 
Polyadenylate RNA was extracted from the total RNA using Oligo-dT Dynabeads® 
(Invitrogen, Cat # 610-02). 75 µl of the total RNA was made up to 100 µl by the 
addition of 25 µl nuclease free water. 100 µl Binding Buffer (20 mM Tris-HCl pH 
7.5, 1.0 M LiCl and 2 mM EDTA) was added and the mixture was heated to 65 °C 
for two minutes before being placed on ice. 200 µl of the Dynabeads were washed 
in Binding Buffer and suspended in a further 100 µl of Binding Buffer. This 
suspension of beads was added to the RNA mixture. The RNA / Dynabeads 
suspension was inverted several times before being left on a rotating stand at 
room temperature for ten minutes to allow the RNA poly(A) tails to anneal to the 
poly(T) projections on the beads. A magnet was used to separate the Dynabeads 
(to which the mRNA was bound) from the total mRNA (Figure 2.1.). 
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Figure 2.1. The basic principle of mRNA extraction using Oligo-dT Dynabeads. 
 
Magnet was removed from the tube and 200 µl Washing Buffer B (10 mM Tris 
HCl pH 7.5, 0.15 M LiCl and 1 mM EDTA) was added. The mixture was pipetted 
several times before the magnet was placed next to the tube again. This washing 
procedure was repeated. With the beads attracted to the side of the tube, the 
supernatant was removed and replace with 20 µl 10 mM Tris-HCl. The magnet 
was removed and the tube was heated to 80 °C for two minutes. The magnet was 
then placed next to the tube and the eluted mRNA was transferred to a new tube. 
Yield and purity of mRNA were quantified by Nanodrop (Thermo Scientific) 
analysis. 
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2.9. Reverse transcription 
Extracted poly(A) RNA was used as a template in reverse transcription reactions 
using SuperScript® III Reverse Transcriptase (Invitrogen, Cat # 11754-050). The 
following reaction was assembled on ice (Table 13.). 
 
Reaction Component Amount (in a 20 µl Reaction) 
5×  ?* 4 µl 
10× SuperScript® Enzyme Mix 2 µl 
mRNA 2.5 ng (~ 4 µl) 
H2O 11.5 µl 
Table 13. A typical SuperScript® III Reverse Transcriptase 
reaction. * VILO Reaction Mix contains random primers, MgCl2, and 
dNTPs.  
 
The reaction was incubated for ten minutes at 25 °C then for 60 minutes at 42 °C 
then for five minutes at 85 °C. Five units (1 µl) of RNase H (NEB, Cat # M0297S) 
were then added to degrade the mRNA template and the reaction was incubated 
for a further 15 minutes at 37 °C. An equal volume of phenol to the reaction 
volume (20 µl) was added at this point. This mixture was vortexed and centrifuged 
at 13, 000 rpm for one minute. The upper fraction was transferred to a new tube 
to which 20 µl of 1:1 phenol : chloroform (containing 4% isoamyl alcohol) were 
added (i.e. 10 µl of each). This mixture was vortexed and centrifuged at 13, 000 
rpm for one minute. The upper fraction was transferred to a new tube to which an 
equal volume of chloroform was added. This mixture was vortexed and centrifuged 
at 13, 000 rpm for one minute. 2.5 volumes of 100% ethanol and 0.2 volumes of 5M 
NaAc (sodium acetate) were added to the tube which was then frozen to -80 °C. 
The tube was then centrifuged at 13, 000 rpm for 30 minutes at 4 °C. All the 
supernatant was removed. The pellet was dried at room temperature and 
resuspended in 20 µl H2O. The yield and purity of the cDNA were quantified by 
Nanodrop (Thermo Scientific) analysis. 
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2.10. In vitro transcription 
The RNA duplexes for the in vitro screen and the helicase assay were synthesised 
using in vitro transcription. DNA oligonucleotides were ordered (Table 14.) 
(Invitrogen). 
 
Oligo Name Sȋ ?ǯȂ  ?ǯȌ 
13 Sense F TAATACGACTCACTATAGGGAGAGGCTAATGCTATG 
13 Sense R CATAGCATTAGCCTCTCCCTATAGTGAGTCGTATTA 
13 Antisense F GGCTAATGCTATGTCTCCCTATAGTGAGTCGTATTA 
13 Antisense R TAATACGACTCACTATAGGGAGACATAGCATTAGCC 
44 F 
TAATACGACTCACTATAGGGAGAGGGAGAAAAACAAA
ACAAAACAAAACTAGCACCGTAAAGCACGC 
44 R 
GCGTGCTTTACGGTGCTAGTTTTGTTTTGTTTTGTTT
TTCTCCCTCTCCCTATAGTGAGTCGTATTA 
11 F TAATACGACTCACTATAGGGAGAGGGAGAAAAACAA 
11 R TTGTTTTTCTCCCTCTCCCTATAGTGAGTCGTATTA 
 
Table 14. The oligonucleotides used as template for the in vitro transcription of 
RNA duplexes used as part of this project. The T7 promoter sequence is shown in 
red. 
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5LER0$;/DUJH6FDOH51$3URGXFWLRQ6\VWHP.LWVZHUHused (Promega, Cat # 
P1300). The following reaction components were assembled on ice (Table 15.). 
 
 
Table 15. The components of a typical in vitro transcription 
 
Reactions were incubated at 37 °C for four hours. At the end of this reaction, 1 µl 
RQ1 RNase-Free DNase (Promega, Cat # M6101) was added and the reaction was 
incubated at 37 °C for a further 15 minutes.  
An equal volume of phenol to the reaction volume (100 µl) was added at this point. 
This mixture was vortexed and centrifuged at 13, 000 rpm for one minute. The 
upper fraction was transferred to a new tube to which 20 µl of 1:1 phenol : 
chloroform (containing 4% isoamyl alcohol) were added (i.e. 50 µl of each). This 
mixture was vortexed and centrifuged at 13, 000 rpm for one minute. The upper 
fraction was transferred to a new tube to which an equal volume of chloroform 
was added. This mixture was vortexed and centrifuged at 13, 000 rpm for one 
minute. 2.5 volumes of 100% ethanol and 0.2 volumes of 5M NaAc (sodium 
acetate) were added to the tube which was then frozen to -80 °C. The tube was 
then centrifuged at 13, 000 rpm for 30 minutes at 4 °C. All the supernatant was 
removed. The pellet was dried at room temperature and resuspended in 100 µl 
H2O. The yield and purity of the RNA were quantified by Nanodrop (Thermo 
Scientific) analysis. 
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2.11. Denaturing gel 
In order to check that the RNA molecules described in the previous section had 
synthesised successfully, samples of each were run on vertical denaturing gels. 0.5 
µg RNA was mixed in a 10:1 ratio with loading buffer (the master mix of loading 
buffer consisted of: 6.25 ml of H2O, 0.025 g xylene cyanol, 0.025 g bromophenol 
blue, 1.25 ml 10% SDS and 12.5ml glycerol) along with 10× MOPS (1:10), 
formaldehyde (1.75:10) and formamide (1:1). Gels consisted of 6.36 g Urea, 3 ml 
5× TBE, 3.75 ml 40% 19:1 polyacrylamide (made up to 15 ml with H2O). This 
mixture was poured between two glass plates placed 2.5 mm apart and a comb 
was placed into the unset gel in order to define the wells. The gel was allowed to 
set and the comb was removed.  
Gels were pre-run (in 1× MOPS running buffer) at 200 V at 4°C then for a further 
30 minutes following loading, the gel was visualised by ethidium bromide staining 
DQG 89 H[FLWDWLRQ XVLQJ D &KHPL'RF ;56 V\VWHP %LR-Rad). RNA size was 
estimated using a single stranded RNA ladder (NEB, Cat # N0362S).  
 
 
 
  
88 
 
2.12. ATP Usage Quantification  6, 8-difluoro-4-methylumbelliferyl phosphate 
(DiFMUP) 
DiFMUP (Invitrogen, Cat # D6567) was one of the reagents used for 
quantification of ATP usage by eIF4A in vitro. 200 µl reactions consisted of 20 mM 
HEPES (pH 7.2), KCl 70 mM, 2 mM dithiothreitol, 1 mg/ml bovine serum 
albumin, 1 mM magnesium acetate, 1 mM ATP, 1.8 nM RNA duplex, 0.4 mM 
eIF4A (0 in control) 100 µM DiFMUP and 10 µl H2O (11 µl in control). Reactions 
were incubated at 37°C for 15 minutes before being cooled to 4°C. Colourimetric 
analysis was performed using a BioTeK PowerWave XS Microplate 
Spectrophotometer (Figure 2.2.).  
 
 
Figure 2.2. The principle of DiFMUP activity 
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2.13. ATP Usage Quantification  3L&RORUORFN 
3L&RORUORFN1RYXV%LRORJLFDOV&DW-0030) was the other reagent used for 
colourimetric ATPase activity assay.  
 
 
Figure 2.3. The principle of PiColorlock activity 
 
The reaction components were the same as for DiFMUP, as were the incubation 
conditions. After the completion of the reactions, 80 µl of PiColorlock reagent and 1%  Ǯǯ ȋ    ?  Kit) were added. The mixtures 
were incubated for 30 minutes at room temperature before colourimetric analysis was 
performed using a BioTeK PowerWave XS Microplate Spectrophotometer (Figure 2.3..).  
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2.14. Western Blot 
Two glass plates were placed 2.5 mm apart separated by plastic dividers. A 10% 
gel was prepared with the following components: 
x 1.25 ml resolving buffer (1.5 M Tris pH 8.8 and 1% SDS)  
x 2.1 ml H2O 
x 1.67 ml 19:1 acrylamide 
x 50 µl 25% APS (ammonium persulphate) 
x 3 µl TEMED (tetramethylethylenediamine) 
 
This mixture was poured between the glass plates and left to set at room 
temperature for ten minutes. A layer of 100 µl butanol was added to the surface of 
the set gel. The stacking buffer was prepared as follows: 
x 2.5 ml stacking buffer (0.25 M Tris pH 6.8 and 1% SDS) 
x 1.8 ml H2O 
x 0.67 ml 19:1 acrylamide 
x 50 µl 25% APS 
x 3 µl TEMED 
 
The stacking gel was poured on top of the 10% gel layer and a comb was inserted. 
The stacking gel was left to set at room temperature for ten minutes. The comb 
was then removed and the gel was immersed in running buffer (25 mM Tris pH 
8.3, 0.192 M glycine and 1% SDS). 
Cells were washed twice in PBS before being lysed using sample buffer (100 mM 
7ULVS+JO\FHURO6'6ǃ-mercaptoethanol, 2 mM EDTA and 0.2 
% bromophenol blue). Lysate was transferred to 1.5 ml microcentrifuge tubes, 
heated to 95 °C for five minutes and loaded into the wells of the immersed gel. A 
protein ladder (Bio-Rad, Cat # 161-0373) was also loaded. The gel was run at 150 
V for two hours. 
Six sheets of Whatman filter paper were soaked in blotting buffer (50 mM Tris, 
192 mM glycine and 20% methanol). Three of these were placed on the positive 
electrode of a Semi-Dry Electrophoretic Transfer Cell (BioRad Trans-Blot®, Cat # 
170-3940).  A piece of PVDF (polyvinylidene fluoride) membrane just larger than 
the gel (BioRad, Cat # 162-0174) was soaked in 100% methanol then H2O then 
blotting buffer. This was then placed on the three sheets of Whatman paper on the 
transfer cell. The gel was placed on top of this and another three sheets of blotting 
buffer-soaked Whatman paper were placed on top of the gel. The negative 
electrode was placed on top of the stack and the lid was put on
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voltage of 10 V was applied for one hour. The gel and the Whatman paper were 
discarded and the membrane was placed in 20 ml TBST (tris-buffered saline and 
tween) containing 5% Marvel powdered milk (Tesco). This was incubated at room 
temperature for one hour with agitation. This mixture was removed and replaced 
with 5 ml primary antibody diluted in TBST and 5% Marvel powdered milk. The 
primary and secondary antibodies used in this project are shown in  
Table 16.  
 
Affinity 
Raised 
In 
Dilution Cat # 
Secondary 
Raised In 
Secondary 
Dilution 
Secondary 
Cat# 
eIF4AI Rabbit 1:50 ab31217 Goat 1:1000 ab6012 
eIF4AII Rabbit 1:50 ab31218 Goat 1:1000 ab6012 
eIF4AIII Rabbit 1:250 ab32485 Goat 1:1000 ab6012 
PDCD4 Rabbit 1:5000 ab51495 Goat 1:1000 ab6012 
p53 Mouse 1:1500 ab26 Goat 1:500 ab9165 
EGFR Rabbit 1:200 ab2430 Goat 1:1000 ab6012 Ⱦ Rabbit 1:200 ab6046 Goat 1:1000 ab6012 
 
Table 16. The antibodies used as part of this project 
 
The membrane was left exposed to the primary antibody overnight at 4 °C with 
agitation. The following day, the membrane was washed three times in TBST for 
five minutes with agitation. The membrane was exposed to the secondary 
antibody (also dissolved in TBST and 5% Marvel) for one hour at room 
temperature before being washed in TBST a further three times. 1 ml western 
blotting reagent (GE Healthcare, Cat # RPN2232) was added to the membrane 
which was then wrapped in cling film and placed inside a western imaging 
cassette along with a piece of Kodak X-Omat photographic film (Sigma-Aldrich, 
Cat # F1274). The membrane was left exposed to the film for approximately 30 
seconds before the film was developed.   
Completed blots were scanned at a resolution of 600 dpi and bands were 
quantified using ImageJ (Abramoff et al., 2004). The Rolling Ball algorithm was 
used to subtract the background of the images and the Watershed algorithm was 
used to quantify the intensity of the bands (Hanson, 1992; Vincent and Soille, 
1991). 
At least two replicates were performed for each. Standard deviations are shown as 
HUURUEDUVRQJUDSKVDQGSYDOXHVZHUHJHQHUDWHGE\6WXGHQW·V7WHVW 
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2.15. eIF4A Manufacture 
The ORF of human eIF4AI was cloned into the multi-cloning site of the plasmid 
pMAL (NEB, Cat # E8200S) by Nicola Phillips, a former member of the RNA 
Biology Group, University of Nottingham (Figure 2.4.). This plasmid was 
transformed into heat-competent BL21 E. coli which were then grown overnight 
on an LB plate containing 100 µg/ml ampicillin at 37°C. A single colony was 
picked and used to inoculate a 10ml volume of liquid LB containing 100 µg/ml 
kanamycin. This culture was incubated overnight at 37°C with agitation before 
being decanted into a 1l volume of selective medium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eIF4AI 
eIF4AI 
eIF4AI 
eIF4AI 
eIF4AI 
Cleavage with 
tobacco etch 
viral protease 
Figure 2.4. The principle of eIF4AI 
expression and purification. 
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The 1l culture volume was incubated until A560 reached approximately 0.5 (after 3 
² 4 hours). 1mM IPTG ,VRSURS\Oǃ-D-1-Thiogalactopyranoside) was added at this 
point to induce protein expression. This volume was incubated for a further 10 
hours before being centrifuged at 7000 rpm to pellet the cells. This pellet was 
resuspended in lysis buffer (20 mM Tris-HCl (pH 7.5), 200 mM NaCl and 1 mM 
EDTA) and allowed to drip through a 2.5 ml affinity column that was previously 
prepared by the passage of 50 ml 50% amylose resin and 10 ml lysis buffer. The 
eIF4AI protein was eluted in six aliquots in elution buffer (20 mM Tris-HCl (pH 
7.5), 10 mM maltose, 200 mM NaCl and 1 mM EDTA). The column was washed 
using wash buffer. Each of the elutions was run on an SDS PAGE gel (see 
previous section). This gel was visualised using Coomassie brilliant blue. 
 
 
 
 
Figure 1.5. Elution iterations from the eIF4AI manufacture process. Lanes 1 ± 6 
contain the elutions from the binding column followed by the crude lysate in lane 7, 
and the wash buffer in lane 8. The gel is a 10% western blot gel stained with 
Coomassie. A protein of the expected size for eIF4A in is present in lanes 4 and 5. 
 
 
Glycerol was added to quantities of solution taken from the tubes containing the 
elution iterations from lanes four and five at a 1:1 concentration (Figure 1.5.). 
Nanodrop analysis revealed that the combined protein concentration of tubes four 
and five was 16 mg/ml. 
 
  
 Lane:       1    2     3    4     5     6   7     8 
50 kDa 
75 kDa 
37 kDa 
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2.16. Cell Culture 
Four different human cell lines were used as part of this project, HeLa (cervical 
cancer), SH-SY5Y (neuroblastoma), MCF7 (breast cancer) and Huh7 (hepatocyte 
cellular carcinoma). These were cultured using standard laboratory practice. The 
growth medium used was High Glucose Dulbecco's modified Eagle medium 
(DMEM) (Invitrogen, Cat # 10938-025). This was stored at 4°C when not in use. 
Prior to its addition to the flasks, foetal bovine serum was added to the medium 
(to a final proportion of 10%), as was L-Glutamine. Foetal calf serum (FCS) was 
also added to the growth medium for the SH-SY5Y cells. 
Cells were grown in T75 (75 cm2) TPP cell culture flasks with ventilated lids 
(Sigma-Aldrich®, Cat # Z707546). 
When in use, these flasks were kept in a Thermo Electron HeraCell 150 incubator 
at 37°C in an atmosphere containing 5% carbon dioxide (CO2). Hypoxic 
incubations were carried out in a ProOx 110 (BioSpherix Ltd.) using an oxygen 
concentration of 1%. 
1XPEHUVRIFHOOVZLWKLQDQLQGLYLGXDOIODVNZHUHPDQDJHGE\UHJXODU ¶VSOLWWLQJ·
i.e. enzymatically dissociating the cells from the surface of the flask, to which they 
normally adhere, and discarding a proportion of the resulting suspension before 
replacing the media.  
Dissociation of the cells from the flask was achieved by using the serine protease 
trypsin. The medium was removed from the flask and replaced with 5 ml (in a 
T75) of phosphate buffered saline (PBS) in order to wash the cells. This would 
then be replaced with 5 ml trypsin dissolved in PBS (0.25% (w/v)) and the flask 
incubated for 60 seconds at 37°C (in 5% CO2). Dissociation of the cells was 
confirmed by microscopy.  
The procedure outlined above was used in the seeding of 24 well plates. The 
majority of the experiments performed as part of this project used 24 well plates. 
These were seeded at a density of 50, 000 cells per well. 
Cell viability was estimated using WST-1 reagent (Roche, Cat # 11 644 807 001) 
following standard protocols.  
 
2.17. Cell Preparation 
Before either DNA or RNA transfections, 24 well plates were seeded with cells to 
a density of 50, 000 cells per well and allowed to settle for at least eight hours, 
usually overnight. 
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2.18. DNA Transfection 
Plasmid transfection was performed using Fugene 6 (Roche, Cat # 05061377001) 
using the recommended protocol. For the CMV promoter-based plasmids, 100 ng 
of DNA was transfected into each 24 well plate well using 0.3 µl Fugene and for 
the SV40-based plasmids, 200 ng was used (suspended in 0.6 µl Fugene). DNA 
was suspended in water and the Fugene in serum free media before being 
combined and incubated at room temperature for 30 minutes. The combined DNA 
and Fugene mixture was added to fresh media and vortexed before being used to 
replace the existing media. Luciferase assays were performed on CMV-based 
transfections 24 hours after DNA addition unless otherwise stated. 24 hours 
following SV40 transfections, the medium was changed and the cells incubated for 
a further 24 hours before luciferase assays were performed. 
 
2.19. RNA Transfection 
INTERFERin (Polyplus Transfection, Cat # 409-01) was used to transfect the 
siRNA molecules targeting the paralogs of eIF4A. 21 ng of siRNA per well was 
dissolved in 100 µl Opti-MEM® serum free media (Gentaur, Cat # 31985-070). 4 µl 
INTERFERin was added and the mixture was vortexed for ten seconds and 
incubated at room temperature for 15 minutes. This volume was added to 200 µl 
growth medium.  
eIF4A siRNAs were purchased from InvitrogHQ &DW ·V H,)$, +66
(sequence: GCCCAAUCUGGGACUGGG), eIF4AII HSS103144 (sequence: 
TGCCACAATGCCAACTGA) and eIF4AIII HSS103148 (sequence: 
AGCAGATCATCAAAGGGA), control 12935-300 (sequence: Medium GC). Cells were 
incubated for 24 hours following initial transfection. Transfections were repeated 
at this point to add a second hit and make the knockdown more effective. If 
required, luciferase reporters were co-transfected with the second hit (see DNA 
Transfection). 
 
2.20. Luciferase Assay 
Growth medium was removed from cells and replaced with phosphate buffered 
saline; this was removed after a few seconds and the dry plates were frozen at -
80°C. 40 µl of 1× passive lysis buffer was added to each well of a 24 well plate and 
cells were dissociated from the base by scraping with a 1250 µl pipette tip. 10 µl 
aliquots of this suspension from each well were transferred to individual wells of a 
black 96 well plate.  
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Data were collected using a Promega GloMax Microplate Luminometer and 
associated GloMax software. The luciferase reagents were LarII and Stop & Glo 
(Promega, Cat # E1980). The software directed the addition of 25 µl of each 
reagent to each well and the resulting signal was integrated over 10 seconds. 
At least three replicates were performed for each. Standard deviations are shown 
as error bars on graphs and p values were generated by T test. 
 
2.21. Northern Blot 
Total RNA was extracted from confluent HeLa cells using TRI Reagent® (Ambion, 
Cat # AM9738). These cells had been transfected with either pRF, pREGFRF or 
pRtubF 48 hours earlier (Figure 2.6.).  
 
 
 
 
 
 
 
 
A horizontal gel tray and a comb were wiped with RNase ZAP (Ambion, Cat # 
AM9780). A 1% denaturing gel was prepared using the following components: 
x 1 g agarose 
x 75 ml H2O 
x 17.5 ml formaldehyde 
x 10 ml 10× MOPS (3-(N-morpholino)propanesulfonic acid) 
The gel was poured and left to set in a fume hood under a layer of cling film. The 
mRNA samples were prepared by the addition of the following chemicals: 
x 5 µl RNA  
x 2 µl 10× MOPS 
x 3.5 µl formaldehyde  
x 10 µl formamide 
x 2 µl formaldehyde gel-loading buffer 
Firefly Luciferase SV40 Promoter Renilla Luciferase 
Firefly Luciferase 
(*)5¶875 
SV40 Promoter Renilla Luciferase 
pRF 
pREGFRF 
Firefly Luciferase 
7XEXOLQ¶875 
SV40 Promoter Renilla Luciferase 
pRtubF 
Figure 2.6. The constructs of the plasmids transfected into HeLa 
cells and assayed for mRNA integrity by northern blot. 
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This mixture was incubated at 65 °C for 15 minutes before being centrifuged for 
five seconds. The gel was submerged in 1× MOPS running buffer and the samples 
were loaded. A voltage of 100 V was applied to the gel for two hours. The gel was 
then placed above a tank of 20× SSC (saline-sodium citrate) buffer and below a 
sheet of Zeta Probe membrane (BioRad, Cat # 162-0159) in the configuration 
shown below (Figure 2.7.). 
 
 
 
 
 
 
 
 
 
 
 
 
The capillary action of the paper towels draws the RNA out of the gel overnight 
and the RNA becomes bound to the Zeta-Probe membrane. The membrane was 
subject to UV crosslinking using a Stratalinker (Stratagene, Cat # 400072) set to 
1200.  
The membrane was then stained with methylene blue (1 ml 1% methylene blue in 
H2O, 0.02% methylene, 5 ml NaAc, 0.3 M acetate pH 5.2 made up to 50 ml with 
H2O)  to visualise the RNA. Pencil marks were made to indicate the position of the 
18S rRNA and 28S rRNA bands. The dye was washed off using 1× SSC containing 
1% SDS.  
The template was generated by amplifying a section of the firefly luciferase ORF 
from pRF using the following primers:  
GGAACCGCTGGAGAGCAACTGC; upstream  
GCATGCGAGAATCTCACGCAGGC; downstream 
Stack of paper towels 
Whatman paper soaked in SSC 
Gel 
Zeta probe Cling film 
Sheet of glass 
Whatman paper soaked in SSC 
Plastic tank 
20× SSC 
Figure 2.7. The mechanism by which the RNA was 
transferred to the Zeta Probe membrane 
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The PCR product was used as template for a Klenow fragment reaction with the 
following components: 
x 5 µl 5× labelling buffer (10 mM Tris-HCl pH 7.9, 50 mM NaCl, 10 mM MgCl2 
and 1 mM dithiothreitol) 
x 1 µl BSA 
x 0.5 µl dNTPs (dATP, dTTP and dGTP) 
x 2.5 µl Easy Tides® P[32] 'HR[\F\WLGLQH·7ULSKRVSKDWH&LPPRO 
x 3 µl (30 ng) DNA template 
x 12 µl H2O 
x 1 µl Klenow fragment polymerase (NEB, Cat # M0210S) 
The reaction mixture was incubated at 37 °C for one hour before being purified 
using a Sepharose G50 (GE Healthcare, Cat # 17-0043-01) column. 200 ml Church 
Gilberts solution (5.1 g Na2HPO4, 2.19 g NaH2PO4 and 14 g SDS in 200 ml H2O) 
was heated to 65 °C. The membrane was placed inside a hybridisation tube 
together with 5 ml of the warmed Church Gilberts buffer. The probe was heated to 
95 °C for three minutes then cooled on ice for five minutes and added to the 
hybridisation tube with 5 ml fresh Church Gilberts buffer. The tube was 
incubated in a rotating incubator at 65 °C overnight. The following day, the blot 
was washed three times in SSC containing 0.1% SDS. The blot was wrapped in 
cling film and exposed to a Fujifilm imaging plate (Cat # 2340) that had been 
blanked by exposure to bright light for 20 minutes. The following day, the probe 
was discarded and the membrane was washed. The membrane was then exposed 
to a phosphorimaging screen overnight. The screen was developed using a Storm 
825 phosphorimager (GE Healthcare).  
 
2.22. T Vector 
Since the pGEM®-T Easy cloning vector (Promega, Cat # A3600) is supplied as a 
linear sequence, it cannot be replicated by molecular cloning. An alternative T 
cloning vector was designed that could be manufactured in the laboratory as this 
approach would eliminate the considerable financial outlay in the form of future 
purchases of pGEM®-T Easy from Promega. The restriction enzyme AhdI has the 
restriction site:  
·*$&11N / N1*7&·LIWKHnucleotides flanking the cut (/) are thymine then 
these will be left as overhanging ends ready to accept the overhanging adenine 
ends of the insert added by Taq PCR. The chosen plasmid was pBluescript II SK+ 
(Stratagene); a silent mutation was introduced into the pre-existing AhdI site 
within the ampicillin resistance marker gene of this plasmid. With this AhdI site 
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deleted, another was introduced into the multi cloning region of the pBluescript 
vector within the lacZ (ǃ-galactosidase) gene by cloning in a construct amplified 
from pRF containing XhoI-AhdI-AhdI-EcoRI restriction sites in that order. The 
resulting plasmid was digested to completion with AhdI and run on an agarose gel 
with the excision and purification of the larger (~3.0 kbp) fragment. The newly-
created T vector, termed pHM-7IRU¶+RPH0DGH·ZDVWHVWHGE\OLJDWLQJLQWKH
A-overhanging CMV promoter fragment used in the cell-based screen.  
 
2.23. Helicase Assay 
The reaction conditions used in the helicase assay were the same as those used 
previously (Rogers et al., 1999a). Each 20 µl replicate contained the following 
components: 
x 20 mM HEPES (pH 7.2) 
x KCl 70 mM 
x 2 mM dithiothreitol 
x 1 mg/ml bovine serum albumin 
x 1 mM magnesium acetate 
x 1 mM ATP 
x 1.7-1.8 nM RNA duplex  
x 0.4 mM eIF4A (0 in control) 
The RNA duplex consisted of the same sequence used previously (see section: In 
vitro Transcription) (Rogers et al., 1999a). The 44 bp strand in vitro transcription 
SURJUHVVHGDVSHUWKH5LER0$;SURWRFRODVGLGWKHESWUDQVFULSWLRQEXWIRU
the replacement of half of the 100 mM CTP input with Easy Tides®  P[32] Cytidine 
·7ULSKRVSKDWH&LPPRO 
Duplexes were annealed by heating a tube containing a 1:1 mixture of both 
strands to 95 °C in a beaker of water which was then left to slowly cool to room 
temperature. 
The above reactions were incubated at 37 °C for 10 minutes then terminated by 
the addition of 20 µl of stop solution (the master mix consisted of: 5 ml 50% 
glycerol, 2% SDS, 20 mM EDTA, 0.01% bromophenol blue and 0.01% xylene 
cyanol). Polyacrylamide gel electrophoresis was used to visualise strand 
separation (see section: Western Blotting). The protocol was the same as for 
western blotting with the only exception being that gels were pre-run for 30 
minutes at 200 V at 4°C. Samples were loaded and the gels were run at 200 V for 
one hour. The gels were then desiccated and exposed to Fujifilm phosphorimaging 
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plates overnight. The following day, the plates were imaged using a Storm 825 
phosphorimager (GE Healthcare). 
 
siRNA and shRNA Sequences 
 
Target 
si / 
sh 
Sequence Supplier Cat # 
eIF4AI sh 
CCGGGCCGTGTGTTTGATATGCTTACTCG
AGTAAGCATATCAAACACACGGCTTTTTG 
Sigma-Aldrich TRCN0000052193 
eIF4AI si GCCTTCTGATGTGCTTGAGGTGACCAAGA Invitrogen HSS103141 
eIF4AII si CGATGGTGTCATCGAGAGCAACTGGAATG Invitrogen HSS103144 
eIF4AIII si TTGCTCTCGGTGACTACATGAATGTCCAG Invitrogen HSS103148 
PDCD4 sh 
CCGGCTGACCTTTGTGGGACAGTAACTCG
AGTTACTGTCCCACAAAGGTCAGTTTTTG 
Sigma-Aldrich TRCN0000059081 
Control sh 
CCGGCAACAAGATGAAGAGCACCAACTCG
AGTTGGTGCTCTTCATCTTGTTGTTTTT 
Sigma-Aldrich HSS103148 
Control si Medium GC Invitrogen 12935-300 
 
Table 17. The sequences of the si and sh RNA molecules used to knock down 
the three paralogs of eIF4A and PDCD4, together with the controls. 
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Chapter 3. Results  
 
Part 1.  
 
The Cell-Based Screen  
 
 
3.1.  Introduction 
In general, high throughput screens use simple, reproducible reactions that 
generate easily quantifiable results to screen large libraries of molecules for 
biological activity (Bleicher et al., 2003). It is the aim of this section to develop and 
optimise a new screening strategy suitable for detecting inhibition of translation 
initiation in vivo. The cell-based and in vitro screens were originally intended for 
a library of 20, 000 small molecules derived from natural sources purchased from 
ChemBridge (http://www.chembridge.com/index.php). 
In some ways, the approach was similar to that used by previous studies to 
identify small molecule inhibitors of eukaryotic translation (Bordeleau et al., 
2005; Bordeleau et al., 2006; Hwang et al., 2004; Low et al., 2005; Novac et al., 
2004). While the screening strategy described in these papers was able to test for 
termination inhibition and IRES-mediated translation inhibition, the strategy 
outlined here should be more sensitive to eIF4A inhibition (Novac et al., 2004). 
While the construct used to identify hippuristanol and pateamine A contained a 
hairpin predicted to have a free energy of -38.00 kcal/mol, the ODC1 hairpin has a 
predicted free energy of -82.20 kcal/mol (Novac et al., 2004). This means that the 
ODC1 hairpin is predicted to require much more input from eIF4A and therefore 
be more susceptible to a reduction in eIF4A function (Svitkin et al., 2001). It is 
possible however that the stability of the ODC1 hairpin may mean that it is 
refractory to changes in eIF4A activity and display a narrower signal range.  
The following sections describe the construction of the plasmids that included the 
CMV promoter and the hairpin (Figure 3.1.). 
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 Cloning the cytomegalovirus (CMV) promoter  
Two plasmids were purchased from Promega (Madison WI), the first was 
pGL4.15[luc2P/Hygro] and the second pGL4.80[hRlucP/Neo], Catalogue numbers 
E6701 and E6981 respectively (Figure 3.2.). Each plasmid contains a different 
luciferase gene, pGL4.15[luc2P/Hygro] contains the gene derived from Photinus 
pyralis, a species of North American firefly (McDermott, 1911) and 
pGL4.80[hRlucP/Neo] encodes a luciferase protein derived from the Sea Pansy 
Renilla reniformis (Milton J, 1960). The reason for the use of these disparate 
reporter genes is the fact that their products emit light in response to different 
reagents and as such can be expressed in the same cell and their signals detected 
individually. Both of the luciferase genes have been modified to include the PEST 
sequence within their coding regions. Originally identified in the carboxy terminal 
region of murine ornithine decarboxylase, PEST acts to destabilise the protein 
giving it a shorter cellular half-life, thereby making the reporter system more 
sensitive (Loetscher et al., 1991). 
 
Firefly Luciferase 
Figure 3.1. Representations of the mRNA molecules generated by the two 
plasmids to be used as part of the cell-based screen for eIF4A inhibitors. The 
image of the hairpin represents the ODC1 ¶87551$KDLUSLQ WKLVVHTXHQFH ZDV
cloned upstream of a gene encoding firefly luciferase. Since this structure requires 
the activity of eIF4A for the efficient expression of the downstream gene, the 
expression level of the firefly luciferase is proportional to the functionality of eIF4A in 
cells recipient of these constructs (Svitkin et al., 2001). The Renilla luciferase mRNA 
was co-WUDQVIHFWHGDVDFRQWUROLWGRHVQRWFRQWDLQDQ\¶VHTXHQFHSUHGLFWHGWREH
inhibitory.  
Cultured cells were transfected with the plasmids containing these sequences and 
these cells were subject to treatment with different molecules. If a molecule had 
specific eIF4A-inhibitory activity, a drop in firefly luciferase expression was observed 
while the expression of the Renilla gene remained constant. 
Stable hairpin RNA 
secondary structure 
previously shown to 
require eIF4A 
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Figure 3.2. Plasmid maps of pGL4.15 and pGL4.80 
 
In order to drive the expression of the reporter genes, the cytomegalovirus (CMV) 
promoter sequence was cloned into both plasmids using KpnI and HindIII 
restriction sites (Figure 3.2.).  
The CMV promoter sequence was amplified from pcDNA3.1 (Invitrogen, Cat # 
V385-20) using primers containing a KpnI restriction site in the forwards primer 
and a HindIII site in the reverse primer (Table 9.). The PCR was performed using 
Phusion Hot Start High Fidelity DNA polymerase (Finnzyme, Cat # F-540S) with 
recommended conditions. Between the final extension and hold stages of the PCR 
program, 10 units of Taq DNA polymerase (QIAGEN, Cat # 201203) were added 
to the reaction which was incubated for an extra 15 minutes. This additional step 
added single adenosine nucleotides to the ends of the PCR product which was 
purified and ligated into pGEM-T® (Promega, Cat # A3600). The CMV sequence 
was digested out of this plasmid (termed pGEMTCMV) using KpnI and HindIII 
before being cloned into both pGL4.15 and pGL4.80 using these restriction sites. 
Successful cloning was confirmed by sequencing (Appendix 1. Sequencing) and the 
completed plasmids, pGL4.15cmv and pGL4.80cmv are referred to in this thesis 
as p15 and p80 respectively. The plasmids were then tested for activity by 
transfection into SH-SY5Y cells which were incubated overnight and lysed for 
luciferase assay the following day, both generated expected signals. 
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3.1.3. Cloning the ODC1 hairpin into p15 and p80 
A version of the plasmid encoding the Renilla luciferase (p80) was created in order 
to demonstrate that any effects of the hairpin were not specific to the firefly 
luciferase ORF. 
The ODC1 hairpin was previously cloned into the Promega plasmid pGEM®-4Z 
(by Nicola Phillips, a former member of the RNA Biology Group, University of 
Nottingham). Standard PCR was used to amplify the sequence; both primers 
contained HindIII restriction sites (Table 9.). The PCR product was digested, 
purified and cloned into the HindIII site immediately downstream of the CMV 
promoter in both p15 and p80 (Figure 3.4.). Successful cloning was initially 
confirmed by digestion with EcoRI which has a recognition site within the hairpin 
sequence. This diagnostic digestion revealed that the hairpin had cloned into p15 
and p80 successfully and also that some colonies on the p80 ligation plate 
contained plasmids in which the hairpin had cloned backwards (Figure 3.3.). 
Sequencing verified that this was the case. Primers including SpeI and NcoI 
restriction sites were used to amplify the hairpin (Table 9. Figure 3.3.). The 
product was digested to completion with SpeI and NcoI, as was pRF. The hairpin 
was cloned into pRF between these sites which are located between the two 
luciferase cistrons. Transcription from the SV40 promoter in the pRF plasmid 
generates a dicistronic mRNA encoding Renilla luciferase and firefly luciferase 
proteins (Figure 3.3.). This approach has been used for a number of years to test 
sequences for IRES activity (Stoneley et al., 1998), since the downstream firefly 
cistron has no cap structure then it will only be expressed if the sequence 
preceding it is able to initiate translation in a cap-independent manner. It is 
important to show that the hairpin sequence does not exhibit IRES activity as 
such activity may interfere with the results and make interpretation more 
difficult. 
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Figure 3.4. The sequence of the CMV promoter and the ODC1 hairpin in p15 
 
 
 
 
Firefly Luciferase 
Hairpin 
CMV Promoter 
p15HP 
Renilla Luciferase 
Hairpin 
CMV Promoter 
p80HP 
Renilla Luciferase CMV Promoter 
p80HP Backwards 
Firefly Luciferase 
Hairpin 
SV40 Promoter Renilla Luciferase 
pRHPF 
Figure 3.3. Construct diagrams of p15HP, p80HP, p80HP-Backwards and pRHPF 
Transcription Start Site 
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 Initial luciferase and transfection reagent test 
In order to test that the luciferase was working correctly, p15 was transfected into 
HeLa and assayed for luciferase activity. Two different transfection reagents, 
Fugene 6 (Roche, Cat # 05061377001) and Lipofectamine (Invitrogen, Cat # 
15338-500) were used to establish which was most effective (Figure 3.5.). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Initial test of p15 activity in HeLa cells. A 24 well plate was seeded with 
HeLa cells. The following day, three wells were transfected with p15 at a 
concentration of 100 ng per well using either Fugene or Lipofectamine. 24 hours later, 
cells were lysed and luciferase assays were performed. Single experiment, average of 
three repeats, error bars represent standard deviation. The background signal was 
generated by luciferase assay reagents in the absence of test sample. 
 
 
Lipofectamine transfection resulted in a lower luciferase signal (Figure 3.5.). 
Microscopy revealed that wells treated with this reagent tended to contain an 
increased number of dissociated cells (data not shown). This indicates that 
Lipofectamine is not as well tolerated as Fugene and may interfere with the 
cellular processes under investigation. Based on the results of this experiment, 
Fugene 6 was used for DNA transfection throughout this project. Regardless of 
transfection reagent, p15 generates a strong luciferase signal (Figure 3.5.).  
41,092 
2 × 107 
1 × 107 
3 × 107 
4 × 107 
5 × 107 
6 × 107 
7 × 107 
8 × 107 
9 × 107 
107 
 
5. The hairpin is more inhibitory forwards than backwards 
 
In order to test that the Renilla luciferase plasmids were working and that the 
hairpin had inhibitory activity on the expression of the luciferase, the plasmids 
p80, p80HP and p80HP-Backwards were transfected into HeLa and assayed for 
activity 24 hours later. The hairpin caused a decrease in reporter gene expression 
relative to the control and also the hairpin was more than twice as inhibitory in 
the forwards orientation (Figure 3.6.).  
 
 
Figure 3.6. The effect of the hairpin in forwards and reverse orientations on the 
expression of the downstream Renilla luciferase reporter gene in HeLa cells. A 
24 well plate was seeded with HeLa cells. The following day, three wells were 
transfected with p80 (no hairpin), p80HP and p80HP-Backwards at a concentration of 
100 ng of each per well. 24 hours later, cells were lysed and luciferase assays were 
performed. Single experiment, average of three repeats, error bars represent standard 
deviation. 
 
 
This result is unexpected given that the predicted free energy of the hairpin is 
roughly the same for either oritentiation. 
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6 The promoterless reporter 
It was important for the interpretation of the subsequent results to demonstrate 
that the hairpin did not exhibit cryptic promoter activity in this context and 
behaved as an inhibitory structure.  
A promoterless version of p15HP was created by disabling the CMV promoter. The 
restriction enzyme AseI has restriction VLWHVEDVHSDLUVIURPWKH·HQGRIWKH 
744 base pair CMV promoter sequence DQGEDVHSDLUVIURPWKH·HQGQRRWKHU
AseI sites occur in p15HP. p15HP was digested to completion with AseI, excising 
the proximal 644 base pairs of the promoter from the backbone which was then 
ligated back together. 
 
 
Figure 3.7. A. ± the effect of disabling the CMV promoter on the expression of 
the firefly luciferase. A 24 well plate was seeded with HeLa cells. The following day, 
three wells were transfected with p15HP and p15HP-Promoterless at a concentration 
of 100 ng per well. 24 hours later, cells were lysed and luciferase assays were 
performed. Panel B. shows a magnification of the bottom of Panel A. Single 
experiment, average of three repeats, error bars represent standard deviation. The 
background luciferase level was determined using lysate from untransfected cells. 
 
Removal of the function of the CMV promoter in p15HP caused a reduction of 
luciferase expression to background levels (Figure 3.7.). This result confirms that 
the hairpin does not exhibit promoter activity in this context. 
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7. shRNA knockdown of eIF4A has an inhibitory effect on the hairpin reporter  
 
The next stage was to test whether the hairpin reporter responded to eIF4A 
inhibition by suppressing eIF4AI expression in cells transfected with p15HP and 
p80.  
Two pLKO.1-puro plasmids were purchased (Table 18.). One contained a sequence 
designed to target eIF4AI expression while the other contained a control sequence 
confirmed to have no target in human cells (Table 18.). 
 
 
  
Target Sequence Supplier Cat # 
eIF4AI 
CCGGGCCGTGTGTTTGATATGCTTACTCG
AGTAAGCATATCAAACACACGGCTTTTTG 
Sigma-Aldrich TRCN0000052193 
Control 
CCGGCAACAAGATGAAGAGCACCAACTCG
AGTTGGTGCTCTTCATCTTGTTGTTTTT 
Sigma-Aldrich HSS103148 
Table 18. Details of the shRNA plasmids used to test the cell-based screen. 
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The sequences shown above (Table 18.) were located within the plasmids 
downstream of a U6 promoter sequence (Figure 3.8.). 
 
 
Figure 3.8. Map of the pLKO.1-puro plasmid that contained the eIF4AI and 
control shRNA sequences. 
 
Following transfection of the shRNA plasmid into cells, the U6 promoter directs 
RNA polymerase III to generate an uncapped RNA which folds to form the 
shRNA. 
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The shRNA is converted to a single strand by Dicer and the RNA-induced 
silencing complex (RISC) (Reviewed in: (Pratt and MacRae, 2009)). The shRNA is 
structured so that the strand that remains associated with the RISC is 
complementary to the coding sequence of eIF4AI (Figure 3.9.).  
 
 
Figure 3.9. Mechanism of gene silencing using a MISSION shRNA plasmid. 
Source of diagram: Website Reference 11. 
 
The pairing of the shRNA sequence with the eIF4AI mRNA causes both molecules 
to be degraded by the cell (Figure 3.9..) (Reviewed in: (Pratt and MacRae, 2009)).  
The control and eIF4AI shRNA plasmids were transfected into HeLa cells along 
with the p80 (control) and p15HP (hairpin-mediated) reporter plasmids. 
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Figure 3.10. The effect of knockdown of eIF4AI using shRNA. A 24 well plate was 
seeded with HeLa cells. The following day, six wells were transfected with p15HP and 
p80 at a concentration of 100 ng of each per well. Three of these wells were also 
transfected with the non-target Mission Control plasmid (Sigma-Aldrich MISSION 
Control, Cat # SHC002) and three with the shRNA plasmid targeting eIF4A. Single 
experiment, average of three repeats, error bars represent standard deviation. The 
knockdown plasmid used was: Sigma-Aldrich TRCN0000052193, Clone ID: 
NM_001416.1-495s1c1. On the top panel, this plasmid is referred to as shRNA 3, this 
is because it was the best performing of five knockdown plasmids previously tested 
for activity. 24 hours later, cells were lysed and luciferase assays were performed. 
The western blots below the top panel show the protein levels of eIF4A,DQGȕtubulin 
as part of the initial test of each of the knockdown plasmids. Quantification of the 
eIF4A bands relative to the ȕ tubulin bands using ImageJ revealed that the eIF4A 
level in the cells recipient of the knockdown plasmid was approximately 50% lower 
than those transfected with the control plasmid.  
 
Knockdown of eIF4AI using shRNA caused a significant reduction in the 
expression of the firefly luciferase reporter plasmids containing the hairpin 
sequence relative to the control Renilla luciferase reporter (p = 0.032) (Figure 
3.10). 
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8. Hippuristanol has an inhibitory effect on the hairpin reporter  
 
With eIF4A expression attenuation clearly detectible by the reporter system, cells 
transfected with the hairpin-reporter and control plasmids were treated with 
hippuristanol in order to establish whether the system was sensitive enough to 
identify small molecule inhibition of eIF4A. Based on previous literature, it was 
predicted that hippuristanol would cause a large drop in the expression of the 
luciferase preceded by the hairpin (Bordeleau et al., 2006; Svitkin et al., 2001). 
 
 
 
Figure 3.11. The effect of 10 µM hippuristanol treatment on the expression of the 
firefly luciferase encoded by p15HP. A 24 well plate was seeded with HeLa cells. 
The following day, six wells were transfected with p15HP and p80 at a concentration 
of 100 ng of each per well. 24 hours later, the growth medium was changed for fresh 
medium (100 µl per well) containing 10 µM hippuristanol or DMSO (in which the 
hippuristanol was dissolved), three wells were recipient of each. Following a six hour 
incubation, cells were lysed and assayed for luciferase activity. Single experiment, 
average of three repeats, error bars represent standard deviation. 
 
 
Hippuristanol treatment caused a significant reduction in the expression of the 
firefly luciferase encoded by p15HP relative to the DMSO control (p = 0.0046) 
(Figure 3.11.). When this experiment was repeated in SH-SY5Y, similar results 
were generated (data not shown).  
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9. Optimisation of the hairpin reporter using hippuristanol  
10 µM hippuristanol treatment causes a ~50% reduction in hairpin-mediated 
reporter expression (Figure 3.11.). While this result was expected, the magnitude 
of the effect was disappointing. If the hairpin reporter system were to be used in a 
high throughout context then it would be advantageous if it were much more 
sensitive. Like the shRNA directed against eIF4A, hippuristanol treatment 
represents a postive control for the screen. In order to test whether the assay 
would be more sensitive with a shorter recovery time, an experiment was 
performed in which this recovery period was reduced from 24 hours to four hours 
(Figure 3.12.).  
 
Figure 3.12. The effect of 10 µM hippuristanol treatment on the hairpin reporter 
in HeLa after allowing cells only four hours to recover from transfection. The 
experiment was performed exactly as described in the legend to Figure 3.11.. except 
that the 24 hour recovery phase was reduced to four hours. Single experiment, 
average of three repeats, error bars represent standard deviation. 
 
 
The assay was much more sensitive using this approach (Figure 3.122.), the 
addition of 10 µM hippuristanol caused a 94% reduction in normalised luciferase 
expression relative to the control (p = 0.00028). The magnitude of the effect and 
the low standard deviations indicate that the hairpin reporter system RU ¶FHOO-
EDVHG VFUHHQ· would be suitable for use in a high throughput context. It is 
probable that the four hour recovery from transfection did not allow the firefly 
luciferase protein to accumulate to the same level as after the 24 hour recovery. 
There was therefore less of it to degrade following the treatment of the cells with 
hippuristanol  
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. The hairpin reporter system is suitable for screening eIF4E inhibitors 
Since structured mRNAs have a greater requirement for eIF4E as well as for 
eIF4A, it was proposed that the hairpin reporter system may also be suitable for 
screening for eIF4E inhibitors (Graff et al., 2008; Svitkin et al., 2001). The 
SRVLWLYH FRQWURO LQ WKLV H[SHULPHQW ZDV D · FDS DQDORJXH WKHVH PROHFXOHV
competitively bind eIF4E and prevent it from anchoring the translation initiation 
FRPSOH[WRWKHP51$·FDS(Cai et al., 1999). In addition to the cap analogue, it 
was decided that the system should also be used to test 12 small molecules 
identified as potential inhibitors of eIF4E by an in silico screen (undertaken by 
Francois Meullenet, a former member of the RNA Biology Group, University of 
Nottingham). 
 
 
 
 
 
 
 
 
Figure 3.13. The effect of predicted and actual eIF4E inhibitors on the hairpin 
reporter. Four 24 well plates were seeded with HeLa cells. The following day, all of 
the wells were transfected with p15HP and p80 at a concentration of 100 ng of each 
per well. Four hours later, the growth medium was changed for 100 µl fresh medium 
per well. Wells were treated in triplicate with either DMSO, one of the unknown 
molecules predicted to be inhibitory to eIF4E or the positive control (cap analogue). 
Following a six hour incubation, cells were lysed and assayed for luciferase activity. 
Single experiment, average of three repeats, error bars represent standard deviation. 
 
All of the compounds, including the positive control, caused a significant reduction 
in hairpin-mediated firefly luciferase expression relative to both the Renilla 
luciferase and the DMSO controls (Figure 3.13.). This indicates that the cell-based 
screen is able to detect eIF4E inhibition and that all of the 12 molecules identified 
by the in silico screen have biological activity consistent with their predicted 
properties. 
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. Screening FDA approved drugs 
With the cell-based screen demonstrated to be able to detect and quantify eIF4E 
inhibition (Figure 3.13.), it was proposed that it may also be able to detect mTOR 
inhibition. Suppression of mTOR activity results in the dephosphorylation of 4E-
BP1 which then binds eIF4E and sequesters it away from the eIF4F complex 
(Wang et al., 2007). The mTOR signalling pathway also results in the 
phosphorylation, and therefore activation, of eIF4B which is a stimulating co-
factor of eIF4A (Shahbazian et al., 2006). If mTOR were to be inhibited and eIF4B 
became less active then the translation of highly structured mRNAs, like the 
hairpin reporter, is likely to be reduced to a greater extent than non-structured 
messages (Shahbazian et al., 2010). 
Like the assay of the predicted eIF4E inhibitors, molecules predicted to be 
inhibitors of mTOR were identified as part of another project (undertaken by 
Sarah Smalley, a member of the Biochemistry Department, University of Sussex). 
The predicted function of these molecules was not revealed until after the 
experiment so no positive control was included. However, it would be interesting 
to test the effect of rapamycin treatment on the cell-based screen in the future 
(Brown et al., 1994). The identity of the seven molecules provided for assay was 
not revealed but they have all been previously approved by the FDA (Food and 
Drug Administration) and all are able to modulate the expression of the oncogene 
O-6-methylguanine-DNA methyltransferase (MGMT). Any molecule that 
suppresses the activity of MGMT will be of clinical interest but especially so if this 
molecule has already been granted approval for use in humans by the FDA.  
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Figure 3.14. The effect of the FDA-approved drugs on the expression of the 
firefly luciferase in p15HP normalised to the Renilla luciferase control. The 
experiment described in the legend to Figure 3.13 was repeated with the only 
difference being the molecules used to treat the cells. Single experiment, average of 
three repeats, error bars represent standard deviation. 
 
Three of the molecules caused a significant increase in normalised p15HP 
luciferase expression relative to the control (Figure 3.14.). The result for 
compound five is absent due to the fact that treatment with this molecule killed 
the cells. The concentration of compound five was reduced in a repeat experiment 
to 0.500×, 0.250× and 0.125× the quantity that killed the cells. Although reduced 
mortality was observed with reducing concentration, there was no difference 
between treatment and control (data not shown). Without a positive control, no 
confident conclusions can be drawn from this experiment and therefore it is not 
known whether the cell-based screen is able to detect molecules that exhibit this 
activity.  
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Part 2.  
 
In Vitro Screen Results 
 
3.2.1. Introduction 
The high throughput screens that led to the discovery of hippuristanol, pateamine 
A  and silvestrol used in vitro (reticulocyte lysate-based) approaches (White, 
2000). The advantages of in vitro assays include their affordability, simplicity, 
specificity and the fact that they are not subject to inconsistencies arising from 
cell confluency or passage fluctuations (Masimirembwa et al., 2001). The main 
disadvantages of the in vitro approach compared to the cell-based approach are 
that shRNA knockdown cannot be used and that in vitro assays are inherently 
more artificial than those using live cells (Masimirembwa et al., 2001). A good 
example of when the two assays can work in concert in this project is in adjusting 
for cell membrane permeability and toxicity. A molecule may have strong eIF4A-
inhbitory activity but at the concentration used in the cell-based assay, it may not 
pass through the cell membrane or it may be toxic to the cell and therefore 
register only as a hit in the in vitro screen.  
Given the strengths and weaknesses of each, it was decided that both should be 
designed and optimised as part of this project. The previous section describes the 
construction and optimisation of the cell-based screen (using the hairpin reporter 
system) while this section will outline the optimisation stages of the in vitro 
screen. 
Compared to the cell-based screen which involved well established principles, the 
in vitro screen was highly experimental. Two main approaches were assessed for 
their suitability for use in a high throughput context.  
 
2.1.A Ethidium bromide (EtBr) incorporation 
Ethidium bromide binds to DNA by intercalating between the bases of the double 
stranded molecule or to RNA between the nucleotides that are double stranded as 
part of the secondary structure (Gatti et al., 1975). Although EtBr can bind single 
stranded DNA and RNA, crucially, this interaction is significantly weaker than its 
intercalation with double stranded molecules (Cosa et al., 2001). The EtBr-based 
in vitro screen reaction consisted of a short RNA duplex between which, EtBr 
molecules were intercalated, together with eIF4A and the buffers needed for it to 
function and ATP. Incubation of this reaction should allow the eIF4A to unwind 
and separate the duplex, causing a quantifiable drop in EtBr signal proportional 
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to the activity of the eIF4A. The inclusion of RNase T1, which cleaves only single 
stranded RNA, may increase the observed effect of strand separation (Figure 
3.15.) (Czaja et al., 2004).   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RNase T1 RNase T1 has no 
specificity for dsRNA 
RNA Duplex 
Highly fluorescent 
intercalated EtBr 
eIF4A 
Less fluorescent 
released EtBr 
ssRNA 
degraded by 
RNase T1 
Remaining EtBr 
released 
RNase T1 
Released EtBr less 
fluorescent 
eIF4A Duplex 
separated by 
eIF4A  
Some EtBr remains 
associated 
Figure 3.15. The principle of the in vitro screen. If the eIF4A successfully unwinds the 
duplex, a drop in EtBr fluorescence should be observable. The bottom panel shows that 
RNase T1 may increase the dynamic range of this fluorescence change by degrading the 
single stranded RNA.  
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The use of ethidium bromide in this way has been documented previously as part 
of a study that used a similar approach to assay the RNA-cleaving activity of a 
deoxyribozyme (a catalytic DNA motif) (Ferrari and Peracchi, 2002). This study 
concluded that the technique is simple, fast and inexpensive and should up-scale 
easily to multi-well plates (Ferrari and Peracchi, 2002). If the attributes of the 
assay described above are transferable to an assay for eIF4A activity then it is 
likely that this may prove to be a very effective high-throughput screening 
strategy. 
 
2.1.B ATP usage quantification 
Since eIF4A is an ATP-dependent RNA helicase, incubation of the duplex reaction 
described above will be accompanied by a drop in ATP concentration as eIF4A 
converts it to ADP in order to process the duplex. The Materials and Methods 
section outlines the two protocols used to assay ATP availability as part of this 
project.  
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3.2.2. Helicase Assay 
The first stage in the creation of a new in vitro screen for eIF4A activity was to 
check whether the stock of eIF4A was functional. For this purpose, a radioactive 
helicase assay was performed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. In vitro radioactive assay for RNA helicase activity. The reaction 
visualised in the left lane did not contain eIF4A while the reaction on the right did 
contain eIF4A. 
 
Addition of eIF4A caused the separation of a semi-radioactive RNA duplex 
consisting of an unlabelled 44 nucleotide molecule and a radiolabelled 13 
nucleotide molecule (Figure 3.16.). Image quantification using ImageJ (using 
Rolling Ball and Watershed algorithms) (Abramoff et al., 2004) revealed that the 
larger nucleotide sized band decreased by approximately 50% between the two 
treatments indicating that the eIF4A had separated the duplex. The reason for 
the presence of so much separated duplex in the control lane is unknown. 
Performing the helicase assay at a lower temperature may reduce the amount of 
spontaneous duplex separation.  
  
Annealed Duplex (Double Stranded) 
Separated Duplex (Single Stranded) 
eIF4A        ±           +  
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3.2.3. Ethidium bromide incorporation. 
With a stock of eIF4A confirmed to have activity in vitro, the next stage was to 
test the sensitivity of ethidium bromide at detecting the presence of RNA. If the 
assay was to work then double stranded RNA would have to stimulate EtBr 
emission to a level much higher than background. The difference in EtBr signal 
between the presence and absence of RNA is predicted to be greater than the 
difference between double- and single-stranded RNA so the maximum effect 
eIF4A can have on the assay will be less than the difference between plus and 
minus RNA (Figure 3.17.).  
 
 
 
 
 
 
 
 
Figure 3.17. Ethidium bromide is most fluorescent when associated with double 
stranded RNA 
 
dsRNA ± highly 
fluorescent 
ssRNA ± moderately 
fluorescent 
No RNA ± barely 
fluorescent 
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Figure 3.18. Ethidium bromide solution with and without dsRNA. 4.5 µg double stranded 
RNA identical in sequence to the duplex used previously was suspended in 1200 µl of water to 
JLYH D ILQDOFRQFHQWUDWLRQ RI  SPROȝO (Rogers et al., 1999a). A final concentration of 0.01 
µg/µl ethidium bromide (EtBr) was also added. Part A. shows the effect of the addition of RNA 
on the emission of the EtBr solution measured at a wavelength of 640 nm following excitation at 
535 nm. Single experiment, average of three repeats, error bars represent standard deviation. 
Part B. shows the tube containing this solution photographed under UV light adjacent to a tube 
containing only the water and EtBr (no RNA).  
 
The presence of 4.5 µg of double stranded RNA caused an approximate 16% 
increase in EtBr excitation compared to an RNA concentration of 0 µg (p = 0.0279) 
(Figure 3.18. A.). This proportion is mirrored in the image below Panel A. (Figure 
3.18. B.); the tube containing the RNA appears brighter but only marginally. 
It would be interesting to investigate the effect of denaturing the duplex or using 
single stranded RNA. 
In a repeat experiment, the concentration of EtBr was reduced from 0.01 µg/µl to 
0.001 µg/µl. It was predicted that this would reduce the amount of EtBr that is not 
associated with the RNA duplex, thereby lowering the background. 
Disappointingly however, the signal from the replicates containing the RNA 
decreased by the same proportion as the background. Although EtBr has been 
used in solution in other studies (Ferrari and Peracchi, 2002), it must be 
concluded that it is not appropriate for use as part of the in vitro screen protocol.  
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3.2.4. SYBR Safe Incorporation  
Like EtBr, SYBR Safe is commonly used to visualise DNA and RNA as part of gel 
electrophoresis (Martineau et al., 2008). With the previous results indicating that 
EtBr would not be sensitive enough for use in the in vitro assay, SYBR Safe was 
trialled instead. 
 
 
Figure 3.19. Fluorescence of 1000x SYBR Safe (1 µl in 20 µl volume) in the 
presence / absence of 4500 ng dsRNA. The experiment described in the legend to 
Figure 3.18. was repeated with SYBR Safe in place of EtBr. Single experiment, 
average of three repeats, error bars represent standard deviation. 
 
 
A 28% increase in fluorescence was observed in the tube containing the RNA 
relative to the tube without (p = 0.0262) (Figure 3.19.). This was a bigger 
difference than that observed using EtBr (which was 16%). 
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3.2.5. SYBR Safe Incorporation 2. 
With the results on the previous page showing that SYBR Safe was more sensitive 
than EtBr at detecting the presence of RNA, it was decided that it could progress 
to the next stage and it could be added to helicase assay reactions with and 
without either eIF4A or RNase T1. It is not apparent from the literature whether 
SYBR Safe is an intercalating agent in the same way as EtBr; it is therefore not 
possible to predict the effect of the action of eIF4A on an RNA duplex stained with 
SYBR Safe. RNase T1 was also added to some reactions in order to see whether it 
increased the magnitude of the observed effect of eIF4A on the emission signal 
from the reaction. Since RNase T1 only cuts single stranded RNA, it was 
predicted that it would cleave RNA previously separated by the eIF4A, thereby 
reducing the signal from the SYBR Safe. 
 
Figure 3.20. Fluorescence of 1000x SYBR Safe (1 µl in 20 µl volume) and 4500 
ng dsRNA in the presence / absence of eIF4A and RNase T1. SYBR Safe was 
added to the standard helicase assay reaction (see Materials and Methods) which 
contains the RNA duplex, eIF4A and the buffers needed for it to function. Reactions 
were incubated at 37°C for 15 minutes before the stop solution (see Materials and 
Methods) was added. Stopped reactions were subject to light with a wavelength of 
535 nm and their emission at 640 nm was recorded. Single experiment, average of 
three repeats, error bars represent standard deviation. 
 
The presence of eIF4A in the helicase assay reaction containing SYBR Safe caused 
a 28% reduction in fluorescence relative to the non-eIF4A control in the absence of 
RNase T1 (p = 0.0423) and a 15% reduction in the presence of RNase T1 (Figure 
3.20.). Although the results are as expected for eIF4A, there is not a great deal of 
difference between the reactions that did and did not contain eIF4A.  
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3.2.6. ATP usage ² DiFMUP  
 
Since eIF4A is an ATP-dependent RNA helicase, as the helicase assay reaction 
progresses ATP will be used (Grifo et al., 1982). DiFMUP is an ATP analogue that 
becomes fluorescent when it is dephosphorylated (Williams and Scott, 2009). 
Increased fluorescence resulting from a helicase assay containing DiFMUP 
indicates a greater rate of ATP usage.  
 
 
Figure 3.21. The helicase assay reaction containing DiFMUP with and without 
eIF4A. 10 µg/ml DiFMUP was added to the standard helicase assay reaction that 
either contained or did not contain eIF4A. These reactions were incubated at 37°C for 
15 minutes before the stop solution was added. The stopped reactions were excited 
using light with a wavelength of 365 nm and emission was quantified at 640 nm. 
Single experiment, average of three repeats, error bars represent standard deviation. 
 
 
The inclusion of eIF4A in the helicase assay reaction containing DiFMUP caused 
an 8% increase in quantified ATP usage (p = 0.022) (Figure 3.21.). The high 
background fluorescence from the reaction without eIF4A was a problem.  
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3.2.7. ATP usage ² DiFMUP 2. 
 
In order to determine the reaction component responsible for the high background 
observed in the previous figure, the concentrations of RNA, ATP and eIF4A were 
varied independently. 
 
 
Figure 3.22. The effect of varying reaction component concentrations on the 
sensitivity of DiFMUP. The standard helicase assay reaction containing 10 µg/ml 
DiFMUP was repeated using different concentrations of RNA, ATP and eIF4A. The 
standard helicase assay reaction consists of: 20 mM HEPES (pH 7.2), KCl 70 mM, 2 
mM dithiothreitol, 1 mg/ml bovine serum albumin, 1 mM magnesium acetate, 1 mM 
ATP, 1.7-1.8 nM RNA duplex and 0.4 mM eIF4A. Single experiment, one replicate per 
condition. 
 
 
The only condition that caused a noticeable difference (a 15% increase) in 
observed ATP usage relative to the control is the tenfold reduction in ATP 
concentration (Figure 3.22.). This is expected given that DiFMUP is an ATP 
analogue, and reduction of the actual ATP is likely to increase the relative 
concentration of DiFMUP in the reaction meaning that more of it will be 
converted to its fluorescent breakdown product. 
The fact that increasing RNA and eIF4A concentrations cause reduced 
PiColorlock signals may be contrary to expectations but it must be kept in mind 
that just one replicate was performed for each condition.  
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3.2.8. ATP usage ² DiFMUP 3. 
In order to test at which time-point the DiFMUP assay was most sensitive, a 
timecourse experiment was performed using varying ATP concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The reactions containing lower concentrations of ATP (including 0% ATP) were 
more sensitive to the presence of eIF4A than those containing higher 
concentrations of ATP (Figure 3.23.). This result is expected given that lower 
concentrations of ATP increase the relative concentration of DiFMUP in the 
reaction. This means that a greater percentage of DiFMUP is likely to be 
converted to its fluorescent breakdown product. 
The time course made little difference to the fluorescence measured for any of the 
reactions. It would be interesting to repeat this experiment over a range of 
different temperatures. This may reveal that DiFMUP undergoes spontaneous 
breakdown and that lower temperatures may reduce the background level of 
DiFMUP fluorescence.  
  
Figure 3.23. A timecourse of helicase assay reactions containing DiFMUP and varying 
concentrations of ATP. The helicase assay including DiFMUP was repeated using varying 
ATP concentrations, with and without eIF4A over a timecourse of 180 seconds. Colour Key: 
0 ATP, 0 ATP + eIF4A, 1% ATP, 1% ATP + eIF4A, 10% ATP, 10% ATP + eIF4A, 100% 
ATP, 100% ATP + eIF4A, 1000% ATP, 1000% ATP + eIF4A. ATP concentrations are 
expressed as percentages of the concentration in the standard helicase assay reaction. The 
standard helicase assay reaction consists of: 20 mM HEPES (pH 7.2), KCl 70 mM, 2 mM 
dithiothreitol, 1 mg/ml bovine serum albumin, 1 mM magnesium acetate, 1 mM ATP, 1.7-1.8 
nM RNA duplex and 0.4 mM eIF4A. Single experiment, one replicate per condition. 
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3.2.9. ATP Usage ² PiColorlock 1.  
 
Another approach for quantifying ATP usage was tried. PiColorlock increases in 
absorbance at 635 nm in the presence of inorganic phosphate (Pi) which is a 
break-down product of ATP (Freschauf et al., 2010).  
 
 
 
 
 
 
 
The inclusion of eIF4A in the helicase assay reaction caused a 34% increase in Pi 
concentration as quantified by the absorbance of PiColorlock at 635 nm (p = 
0.0036) (Figure 3.24.).  
 
 
  
Figure 3.24. The standard helicase assay reaction containing PiColorlock was 
incubated at 37°C for 15 minutes with and without eIF4A before the absorbance of 
the reaction at 635nm was measured. Single experiment, average of three repeats, 
error bars represent standard deviation. 
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3.2.10. ATP Usage ² PiColorlock 2.  
 
While the approach shown in the previous figure was the most successful so far, 
the background signal is still high. The reaction components were incubated with 
the PiColorlock reagent independently in order to ascertain the cause of the 
background. 
 
 
 
 
 
 
ATP was the only reaction component that caused a noticeable increase in 
background absorbance when assayed in isolation (Figure 3.25.). This was 
expected given that ATP can spontaneously hydrolyse (Galán et al., 1999). 
Although this happens at a low rate below 60°C, it is clearly enough to cause the 
background signal (Figure 3.24.) (Galán et al., 1999).  
  
Figure 3.25. The effect of the helicase assay reaction components on the 
absorbance of PiColorlock. All of the individual reaction components of the helicase 
assay were combined with PiColorlock and incubated at 37°C for 15 minutes before the 
absorbance at 635 nm of each mixture was quantified. Single experiment, one replicate 
per condition. 
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3.2.11. ATP Usage ² PiColorlock 3.  
 
Rather than a high background, it could be that the stock of eIF4A had a low level 
of ATPase activity in the reaction. In order to test this, a positive control was 
used. DnaK (also called Hsp70), a protein involved in the cellular response to 
heat-shock, has been used as a positive control for ATPase activity in previous 
studies (Agranovsky et al., 1997). 
 
 
 
 
 
 
eIF4A and the positive control ATPase DnaK both caused significant increases in 
Pi concentration (Figure 3.26.). If the DnaK had generated a signal significantly 
higher than the control and eIF4A signals, it may have been assumed that the 
eIF4A was not very active. The fact that the control signal is similar to that 
generated by both the eIF4A and the DnaK indicates that it is the background 
that is high rather than the eIF4A having weak ATPase activity (Figure 3.24.).  
  
Figure 3.26. The helicase assay reaction containing PiColorlock and a positive 
control for ATPase activity. Nine reactions were incubated for 15 minutes at 37°C, 
three were without enzyme (control), three contained eIF4A and three contained 0.4 mM 
DnaK. After the reactions were stopped, their absorbance at 635 nm was quantified. 
Single experiment, average of three repeats, error bars represent standard deviation. 
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Part 3. 
 
eIF4A Paralogs Results 
 
There exist three different paralogs of eIF4A in humans. Each mRNA contains a 
5·875WKDWLVGLIIHUHQWLQWHUPVRIOHQJWKGC content and predicted free energy 
(Table 19.). 
 
 
The purpose of this section is to investigate the effect of individual knockdown of 
the three eIF4A paralogs on the hairpin reporter system and also the effect of 
LQGLYLGXDONQRFNGRZQDQGKLSSXULVWDQROWUHDWPHQWRQUHSRUWHUVFRQWDLQLQJWKH·
UTRs of the paralogs themselves.  
 
Name 
 
 
Length 
(nucleotides) 
 
GC Content 
(%) 
 
 
Predicted 
Free Energy 
(kcal/mol) 
 
 
Accession # 
 
eIF4AI 103 66 -39.20 NM_001416.2 
eIF4AII 39 53 -7.00 NM_001967 
eIF4AIII 222 74 -75.90 NM_014740 
Table 19'HWDLOVRIWKH¶875VRIHDFKRIWKHSDUDORJVH,)$ 
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3.3.1. Cloning the eIF4A ·875V 
7KH · 875V RI WKH WKUHH KXPan paralogs of eIF4A were cloned into p15 
downstream of the CMV promoter and upstream of the firefly luciferase gene. 
Primers were designed based on sequences from NCBI, RefSeq IDs NM_001416 
for eIF4AI, NM_001967 for eIF4AII and NM_014740 for eIF4AIII (Table 2., Table 
9.). The eIF4AII ·875ZDVFreated by annealing oligonucleotides as it is only 39 
nucleotides in length. The UTRs for paralogs I and III were amplified from SH-
SY5Y cDNA using standard Phusion PCR. Primers were complementary to the 20 
nucleotides closest to the · RU · ends of the sequences and included PacI and 
XhoI sites which enabled the sequences to be cloned into p15. Digestion of p15HP 
with XhoI and PacI excises the hairpin which can be replaced with any other 
sequence. Successful cloning was confirmed by sequencing.  
Before the eIF4A · 875-reporters were used, the effect of individual paralog 
knockdown on the hairpin reporter system (described in section: 3.1.1. Cell Based 
Screen Introduction) was established. 
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3.3.2. The effect of individual siRNA knockdown of each paralog on the hairpin 
reporter system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
eIF4AI 
eIF4AII 
eIF4AIII 
ȕ7XEXOLQ 
ȕ7XEXOLQ 
ȕ7XEXOLQ 
Antibody Specificity 
siRNA Target* ĺ 
*siRNA Target Key: IC = eIF4AI + Control, IIC = eIF4AII + Control, IIIC = eIF4AIII + Control, I II 
= eIF4AI + eIF4AII, I III = eIF4AI + eIF4AIII, II III = eIF4AII + eIF4AIII, CC = Control + Control, C 
= Control, NT = No shRNA Transfection  
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Although knockdown of eIF4AII and eIF4AIII was successful, only knockdown of 
eIF4AI caused a reduction in the expression of the hairpin reporter (Figure 3.27.).  
 
 
 
 
 
 
  
Figure 3.27. The effect of the individual and combined knockdown of the three 
paralogs of eIF4A in SH-SY5Y. The bar graph (A.) shows the luciferase activity of 
plasmids transfected into cells previously recipient of siRNA knockdown. Single 
experiment, average of three repeats, error bars represent standard deviation. The 
lower part (B.) shows the western blots that confirm the knockdown of each paralog 
ZLWKWKHFRQWUROȕWXEXOLQEORWXQGHUQHDWKWKHRUGHUIURPOHIWWRULJKWLVWKHVDPHDVRQ
the bar graph. The black arrow to the left of the western blots represents 50 kDa. 
Westerns were performed in triplicate but only one (representative) blot is shown. 
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3.3.3. Cell viability in response to individual paralog knockdown as estimated by 
WST-1 Assay 
 
 
Figure 3.28. WST-1 viability assays were performed on SH-SY5Y cells recipient 
of siRNA sequences targeting each of the paralogs of eIF4A in order to quantify 
cell viability. Higher values indicate greater viability. (C = control, NT = no siRNA 
transfection, NC = negative control (empty well)). Single experiment, average of three 
repeats, error bars represent standard deviation. 
 
Although some of the viability assays performed on the cells previously recipient 
of targeted siRNAs seem to be slightly lower than the controls (Figure 3.28.), none 
of the data were statistically significant compared to the CC, C and NT fields ( 
Figure 3.28). Relative to the negative control (NC), there was a strong signal from 
all of the viability assays performed on the cell-containing wells (Figure 3.28.). 
There are many other methods for assessing cell viability besides WST-1. These 
alternatives together with the limitations of the WST-1 will be explored in the 
Discussion section. 
  
eIF4A Paralog siRNA Knockdown Target 
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3.3.H,)$·875UHSRUWHUVDQGparalog knockdown 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29. The effect of eIF4A and eIF4B knockdown on reporters containing 
WKH¶875VRIWKHWKUHHparalogs of eIF4A. A 24 well plate was seeded with SH-
SY5Y cells. The following day, these were transfected simultaneously with siRNAs 
targeted against each paralog of eIF4A (or eIF4B), one of the reporter plasmids 
FRQWDLQLQJWKHWKUHHGLIIHUHQW¶875VRIeIF4A and the control p80 plasmid. 24 hours 
later, the luciferase expression within these cells was quantified. Single experiment, 
average of three repeats, error bars represent standard deviation. 
 
 
In general, between paralog reporters I, II and III, normalised luciferase activity 
increases in a stepwise manner (Figure 3.29.). Knockdown of eIF4AI caused a 
small decrease in the expression of the eIF4AI · 875 UHSRUWHU .QRFNGRZQ RI
eIF4AII and eIF4AIII did not affect the expression of the eIF4AI reporter relative 
to the control. Knockdown of eIF4AI and eIF4AIII and eIF4B had no effect on the 
expression of the eIF4AII · 875 UHSRUWer. However, knockdown of eIF4AII 
caused a significant increase in the expression of the eIF4AII reporter. For the 
eIF4AIII reporter, knockdown of eIF4AI and eIF4AIII caused a reduction and 
knockdown of eIF4AII caused an increase.  
 
 
eIF4AI Reporter 
I     II    III  Control   I     II    III  Control     I     II     III  Control eIF4A Paralog siRNA Target ĺ 
eIF4AII Reporter 
eIF4AIII Reporter 
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3.3.  eIF4A ·875UHSRUWHUVDQGKLSSXULVWDQROWUHDWPHQW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hippuristanol had no effect on the eIF4AI reporter (Figure 3.30. A.). There was a 
small decrease in the expression of the eIF4AII reporter in response to 
hippuristanol (B.) and there was a substantial decrease in the eIF4AIII reporter 
(C.). The control levels for paralogs I, II and III are 0.11, 0.17 and 0.95 
respectively; this is consistent with previous results (Figure 3.29.). 
 
 
 
Figure 3.30. The effect of 10 µM 
hippuristanol on the eIF4A paralog 
reporters. A 24 well plate was seeded with 
SH-SY5Y cells. The following day, cells 
were transfected with one of the eIF4A 
SDUDORJ · 875 UHSRUWHUV )RXU KRXUV
later, 10 µM hippuristanol was added and 
cells were incubated for a further six 
hours before being lysed for luciferase 
assay. Panel A. = eIF4AI, Panel B. = 
eIF4AII and Panel C. = eIF4AIII. Single 
experiment, average of three repeats, 
error bars represent standard deviation.  
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Part 4.  
 
PDCD4 Results 
 
As outlined in the Introduction, PDCD4 is a cellular antagonist of eIF4A that 
regulates its function (Goke et al., 2002; Onishi et al., 1998; Shibahara et al., 
1995; Yoshinaga et al., 1999). Also referred to in the Introduction is the fact that 
loss of PDCD4 impairs the ability of a cell to respond to DNA damage (Bitomsky 
et al., 2008; Singh et al., 2009). 
As part of this project, the effect of PDCD4 knockdown on the hairpin reporter 
system was observed. It was predicted that the loss of this eIF4A inhibitor would 
increase the relative expression of the hairpin-mediated reporter gene relative to 
the control reporter. This result would not reveal anything new about the biology 
of translation initiation as the relationship between eIF4A and PDCD4 has been 
well researched but it would test whether the hairpin reporter system would 
identify molecules that inhibited PDCD4 as part of a high throughput screen 
(Yang et al., 2003). It was also necessary to demonstrate that the shRNA 
knockdown of PDCD4 worked effectively as it would be used to investigate further 
the role of PDCD4 in the DNA damage response. It was predicted that the 
interaction between PDCD4 and eIF4A was the cause of the involvement of 
PDCD4 in this response i.e. eIF4A activity contributes to the severity of DNA 
damage. 
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3.4.  PDCD4 knockdown and the hairpin reporter 
 
Figure 3.31. The effect of PDCD4 knockdown on the hairpin reporter system. A 
24 well plate was seeded with SH-SY5Y cells. The following day, six wells were 
transfected with p15HP and p80, three of these were also transfected with a PDCD4 
knockdown plasmid (Sigma-Aldrich, TRCN0000059081, NM_014456.3-914s1c1) and 
the other three were also transfected with a control plasmid (Sigma-Aldrich MISSION 
Control, Cat # SHC001). 24 hours later, cells were lysed for luciferase activity assay 
and western blot. Single experiment, average of three repeats, error bars represent 
standard deviation.  
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PDCD4 knockdown caused a 2.78 fold increase in p80 Renilla luciferase activity (p 
= 0.005) but a 3.16 fold increase in p15HP activity (p = 0.003) (Figure 3.31.). 
However, when the response to PDCD4 knockdown of the control (p80) was 
compared to that of the hairpin-containing reporter (p15HP), the data were found 
to be statistically non-significant (p = 0.180). Western blots for PDCD4 revealed 
that the knockdown worked successfully. There was a 39% reduction in PDCD4 
level in the cells recipient of the shRNA knockdown plasmid relative to the control 
DQG UHODWLYH WR WKH OHYHO RI ǃ WXEXOLQ (Figure 3.31.) (westerns quantified using 
ImageJ (Abramoff et al., 2004)). 
With the knockdown plasmid demonstrated to work (Figure 3.31.), the next stage 
was to investigate the effect of the reduction of PDCD4 protein level on cell 
viability and the number of dissociated cells in response to ultraviolet (UV) light. 
UV treatment is a well characterised stimulator of DNA damage and it is used to 
study the phenomenon in the laboratory (Sinha and Hader, 2002). 
The following section outlines the experiments that were performed to ascertain 
the tolerance of SH-SY5Y and HeLa to DNA damage when their PDCD4 protein 
level was reduced. Two cell lines, originating from different human tissues, were 
used to try to exclude any potential cell line specific effects. 
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3.4.  -SY5Y cell viability following UV exposure and PDCD4 knockdown 
 
 
Figure 3.32. The effect of PDCD4 knockdown on SH-SY5Y viability following UV 
irradiation. Two 24 well plates were seeded with SH-SY5Y cells. The following day, 
six wells of each were transfected with the PDCD4 knockdown plasmid and six with 
the control plasmid. 24 hours later, one plate was exposed to 275 J/m2 UV light while 
the other was mock irradiated. The plates were allowed to recover for a further 24 
hours before WST-1 viability assays were performed. Single experiment, average of 
six repeats, error bars represent standard deviation. 
 
 
There was a significant increase in SH-SY5Y viability following PDCD4 
knockdown under control conditions (p = 0.025) (Figure 3.32.). The opposite was 
true for cells irradiated with UV, PDCD4 knockdown caused a significant 
decrease in viability (p = 0.00003). In general, UV treatment caused viability to 
reduce by over half.  
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3.4.  -SY5Y dissociated cell count following UV exposure and PDCD
knockdown 
 
 
Figure 3.33. The effect of PDCD4 knockdown on the number of dissociated SH-
SY5Y cells following UV irradiation. Two 24 well plates were seeded with SH-SY5Y 
cells. The following day, six wells of each were transfected with the PDCD4 
knockdown plasmid and six with the control plasmid. 24 hours later, one plate was 
exposed to 275 J/m2 UV light while the other was mock irradiated. The plates were 
allowed to recover for a further 24 hours before the dissociated cells were counted by 
haemocytometry. Single experiment, average of six repeats, error bars represent 
standard deviation. 
 
There is no statistical difference between the number of dissociated cells under 
normal conditions following PDCD4 knockdown (p = 0.3785) (Figure 3.33.). This 
was in contrast to the dissociated cells in UV treated wells which were 
statistically more prevalent in wells also recipient of PDCD4 knockdown shRNA 
(p = 0.0076). There was also an approximate 15 fold increase in dissociated cells 
between control and UV-treated wells respectively.  
The number of dissociated cells in a tissue culture vessel is often regarded as an 
unreliable measure of viability as floating cells may not necessarily be dead and 
dead cells may remain attached or have disintegrated. It is important therefore to 
interpret these data alongside the WST-1 proliferation assay data. Comparison of 
these two assays gives a more reliable representation of cell death and health 
than either alone.  
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3.4.  Confirmation of knockdown in SH-SY5Y cells 
 
 
 
 
 
Figure 3.34. Western blots for PDCD4 that confirm the success of the 
knockdown. The SH-SY5Y cells used for the previous two experiments were lysed 
and the protHLQOHYHOVRI3'&'SDQGȕWubulin were estimated by western blot in 
order to confirm that the knockdown was successful. The black arrow indicates 50 
kDa on the protein ladder. 
 
 
PDCD4 protein levels fell in response to the transfection of shRNA plasmids 
targeted against it while they remained constant following treatment with the 
control, non-target shRNA (Figure 3.34.). PDCD4 protein levels seem to increase 
LQUHVSRQVHWR89WUHDWPHQW3URWHLQOHYHOVRISDQGǃ tubulin did not change in 
response to UV treatment or PDCD4 knockdown. The p53 blot was performed 
because it was presumed that this protein is involved in the PDCD4-mediated 
DNA damage response by a previous study (Bitomsky et al., 2008).  
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3.4.  HeLa cell viability following UV exposure and PDCD4 knockdown 
 
 
 
Figure 3.35. The effect of PDCD4 knockdown on HeLa viability following UV 
irradiation. Two 24 well plates were seeded with HeLa cells. The following day, six 
wells of each were transfected with the PDCD4 knockdown plasmid and six with the 
control plasmid. 24 hours later, one plate was exposed to 275 J/m2 UV light while the 
other was mock irradiated. The plates were allowed to recover for a further 24 hours 
before WST-1 viability assays were performed. Single experiment, average of six 
repeats, error bars represent standard deviation. 
 
 
There was a slight but significant reduction in HeLa viability following PDCD4 
knockdown under control conditions (p = 0.0176) (Figure 3.35.). This effect was 
accentuated in cells irradiated with UV, PDCD4 knockdown caused a much 
greater decrease in viability (p = 0.00007). In general, UV treatment caused little 
reduction in viability in HeLa cells. 
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3.4.  HeLa dissociated cell count following UV exposure and PDCD4 knockdown 
 
 
Figure 3.36. The effect of PDCD4 knockdown on the number of dissociated 
HeLa cells following UV irradiation. Two 24 well plates were seeded with HeLa 
cells. The following day, six wells of each were transfected with the PDCD4 
knockdown plasmid and six with the control plasmid. 24 hours later, one plate was 
exposed to 275 J/m2 UV light while the other was mock irradiated. The plates were 
allowed to recover for a further 24 hours before the dissociated cells were counted by 
haemocytometry. Single experiment, average of six repeats, error bars represent 
standard deviation. 
 
 
There was a slight statistical drop between the number of dissociated cells in the 
control wells and the PDCD4-knockdown wells under normal conditions (p = 
0.0199) (Figure 3.36.). There was no statistical difference between the data for 
plus and minus shRNA in UV treated wells (p = 0.1027). In general, there was an 
approximate two-fold increase in the number of dissociated cells between minus 
and plus UV treatment respectively.  
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3.4.  Confirmation of knockdown in HeLa  
 
 
 
 
Figure 3.37. Western blots for PDCD4 that confirm the success of the 
knockdown. The HeLa cells used for the previous two experiments were lysed and 
the protHLQ OHYHOV RI 3'&' S DQG ȕ Wubulin were estimated by western blot in 
order to confirm that the knockdown was successful. The black arrow indicates 50 
kDa on the protein ladder. 
 
 
PDCD4 protein levels fell in response to the transfection of shRNA plasmids 
targeted against it while they remained constant following treatment with the 
non-target control shRNA (Figure 3.37.). 3URWHLQ OHYHOVRISDQGǃ tubulin did 
not change either in response to UV treatment or PDCD4 knockdown.  
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Part 5. 
 
Alzheimer's Disease 
 
 
3.5.1. Introduction to the Alzheimer's Disease Results Section 
Prior to the start of this project, a microarray was performed on lysate from HeLa 
cells previously treated with hippuristanol (by Andrew Bottley). This identified 
APP, MAPT and acetylcholinesterase expression as being susceptible to eIF4A 
inhibition. It was confirmed by western blot that hippuristanol treatment reduced 
the expression of these three genes.  
This was the original reason for investigating the relationship between eIF4A 
activity modulation and Alzheimer's disease. A database of all the genes reported 
as being involved in Alzheimer's disease in the literature was compiled. A number 
RIWKHVHJHQHVZHUHVHOHFWHGDQGWKHLU·875VZHUHFORQHGLQWRUHSRUWHUSODVPLGV
The genes investigated are shown in Table 3 and their properties are discussed in 
the Introduction.  
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3.5.2. Cloning the Alzheimer's-DVVRFLDWHG·875VLQWRS 
7KH·875VRISOD1 and TXN were amplified from cDNA using primers shown 
in the Materials and Methods section (Table 9.). TKH · 875V RI PS1, PS2, 
BACE1, Clu2, CR1, MAPT, AChE and APP were ordered from GenScript based on 
contemporary data from the NCBI (National Center for Biotechnology 
Information) website. These sequences were cloned into p15 using XhoI and PacI 
(Figure 3.38.). 
 
  
Firefly Luciferase 
SOD1 ¶875 
CMV Promoter 
p15SOD1 
Figure 3.38. Construct diagrams showing the 
FORQLQJ VLWH LQ S DQG WKH ¶ 875V RI WKH
Alzheimer's-associated genes 
Renilla Luciferase 
TXN ¶875 p15TXN 
PS1 ¶875 p15PS1 
PS2 ¶875 p15PS2 
BACE1 ¶875 p15BACE1 
Clu2 ¶875 p15Clu2 
CR1 ¶875 p15CR1 
MAPT ¶875 p15MAPT 
AChE ¶875 p15AChE 
APP ¶875 p15APP 
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3.5.3. 7KH · 875 VHTXHQFHV RI genes predicted to play harmful roles in 
Alzheimer's disease are inhibitory to reporter expression 
 
It was suspected that eIF4A suppression could be an effective mechanism for 
treating Alzheimer's disease. Overexpression of certain genes e.g. APP, MAPT and 
BACE1 contributes to the severity of AD; these genes are referred to in this 
SURMHFWDV ¶KDUPIXO· Given that these genes possess longer and potentially more 
KLJKO\ VWUXFWXUHG · 875V WKDQ WKH JHQHV LQYROYHG LQ WKH GHIHQFH DJDLQVW
oxidative stress, it was predicted that they would have a greater eIF4A 
requirement. 
 
 
Figure 3.39.  The reporter plasmids containing the Alzheimer's-associated 5' 
UTRs were transfected into SH-SY5Y cells. 5HSRUWHUVFRQWDLQLQJ¶875Vof genes 
predicted to play a harmful role in Alzheimer's are shown in red, those predicted to be 
beneficial are shown in dark blue, the hairpin control is shown in purple and the p15 
control is shown in charcoal. Single experiment, average of six repeats, error bars 
represent standard deviation. 
 
In SH-SY5Y cells, reporters containing · UTRs belonging to genes predicted to 
play harmful roles in Alzheimer's generated much lower signals than those 
FRQWDLQLQJ WKH · 875V RIJHQHV predicted to be beneficial. The p15 control (B.) 
generated a much stronger signal than the reporters containing ectopic sequence. 
The hairpin reporter generated DVLPLODUVLJQDOWRWKH¶KDUPIXO·UHSRUWHUV 
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3.5.4. Promoterless reporter plasmids generate no signal 
 
In order to test for cryptic promoter activity, the promoterless versions of the 
reporters were assayed for luciferase activity. 
 
 
Figure 3.40. Versions of the Alzheimer's reporters without the CMV promoter 
were created and assayed for activity in SH-SY5Y cells. The p15 control included 
a functional promoter. Single experiment, average of three repeats, error bars 
represent standard deviation. 
 
 
Removal of the promoter sequence (by excision using AseI) from the reporters 
reduced their activity to the same level as the activity observable in untransfected 
cells (Figure 3.40). The slight effect observed from the promoterless PS2 reporter 
was generated by a single outlier in the data, the fact that the other replicates 
generate background signals suggests that this is not cryptic promoter activity or 
it would be ubiquitous among PS2 reporters. 
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3.5.5 +LSSXULVWDQRO UHGXFHV WKH H[SUHVVLRQ RI UHSRUWHUV FRQWDLQLQJ · 875V RI
genes predicted to play harmful roles in AD 
 
To test the eIF4A requirement of each of the reporters, SH-SY5Y cells transfected 
with one of each were treated with hippuristanol, an inhibitor of eIF4A. 
 
 
 
 
 
 
 
 
 
 
Figure 3.41. The effect of 10 µM hippuristanol on the Alzheimer's-associated  ¶ 
UTR-mediated expression of reporters in SH-SY5Y cells. Three 24 well plates 
were seeded with SH-SY5Y cells. The following day, six wells were transfected with 
each of the Alzheimer's reporter plasmids (in addition to p80). Four hours later, three 
wells of each were treated with either 10 µM hippuristanol or DMSO. Six hours later, 
cells were lysed for luciferase assay. The charcoal, red, purple or dark blue bars were 
generated from cells recipient of only DMSO while those in orange were generated 
from cells recipient of 10 µM hippuristanol. Panel B shows the full image while the 
Panel A shows a close up of the lower part of the same image. Single experiment, 
average of three repeats, error bars represent standard deviation. 
 
Hippuristanol had no effect on the p15 control reporter (Figure 3.41. B.). All of the 
UHSRUWHUV FRQWDLQLQJ · 875V IURP JHQHV DVVRFLDWHG ZLWK WKH KDUPIXO HIIHFWV RI
Alzheimer's and the hairpin reporter yielded significantly reduced levels of 
activity in response to hippuristanol treatment (Figure 3.41.. A. and B.). There 
was no significant effect on the SOD1 reporter but a slight statistical reduction 
was observed in the data for the TXN reporter (p = 0.0168).  
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DMSO Hippuristanol 0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
5.5.6. The effect of hippuristanol on the ADAM10 reporter 
Since the ADAM10 ·875 LV FXUUHQWO\EHLQJ LQYHVWLJDWHGE\DQRWKHU ODE (Sven 
Lammich (Ludwig Maximilians Universität)), it was not cloned as part of the 
reporter collection. However, Dr Lammich kindly provided his ADAM10 reporter 
plasmid for use in this project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ADAM10 reporter was provided cloned into the plasmid pcDNA6/V5-His 
which had been modified to include the firefly luciferase open reading frame 
(Figure 3.43.). These results could not be directly compared to the rest of the data 
which were generated using the p15 reporter system created as part of this 
project.  
 
 
 
Hippuristanol caused a statistically significant 31% reduction in the expression of 
the reporter containing the ADAM10 ·UTR (Figure 3.42.).  
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Figure 3.42.  The effect of 10 µM hippuristanol treatment on cells transfected 
with a reporter plasmid containing the 5' UTR of ADAM10. A 24 well plate was 
seeded with SH-SY5Y cells. The following day, six wells were transfected with the 
$'$0¶875UHSRUWHUDQGVL[ZLWKLWVDVVRFLDWHGFRQWUROLQDGGLWLRQWRS)RXU
hours later, three wells of each were treated with either 10 µM hippuristanol or DMSO. 
Six hours later, cells were lysed for luciferase assay. Firefly luciferase counts were 
normalised to Renilla luciferase counts. The ratio of firefly luciferase activity to Renilla 
luciferase activity of the reporter containing the ADAM1¶875ZDVQRUPDOLVHG WR
the ratio of the control. Single experiment, average of six repeats, error bars represent 
standard deviation. 
Firefly Luciferase 
ADAM10 ¶875 
CMV Promoter 
pcDNA6/V5-HisADAM10 
Figure 3.43. The ADAM10 reporter construct 
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5.5.7 Hippuristanol causes a significant reduction in AChE reporter expression 
 
 
 
 
 
 
 
 
 
 
Hippuristanol treatment caused a significant reduction in the expression of the 
luciferase gene in the reporter containing the acetylcholinesterase · 875 S  
0.00001) (Figure 3.44.). 
 
 
  
Figure 3.447KHHIIHFWRIKLSSXULVWDQRORQWKHUHSRUWHUFRQWDLQLQJWKH¶875RI
acetylcholinesterase. A 24 well plate was seeded with SH-SY5Y cells. The 
following day, six wells were transfected with p15AChE. Four hours later, 10 µM 
hippuristanol (or the equivalent amount of DMSO) was added to the cells. Six hours 
later, cells were lysed and luciferase assays were performed. Single experiment, 
average of three repeats, error bars represent standard deviation. 
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5.5.8. The promoterless AChE reporter 
 
The result from pRAceF is unexpected given that the acetylcholinesterase ·875
is predicted to form a hairpin. It was expected that the sequence would suppress 
reporter expression like the ODC1 hairpin, rather than stimulate it. In order to 
establish whether the sequence had promoter activity, the CMV promoter was 
removed from the reporter and the experiment was repeated. 
 
 
 
Figure 3.45. The effect of removing the promoter sequence from the 
acetylcholinesterase $FH¶UTR reporter. A 24 well plate was seeded with SH-
SY5Y cells. The following day, three wells were transfected with p15AChE and three 
with PlessAChE (promoterless). 24 hours later, cells were lysed and luciferase assays 
were performed. The panel shows the normalised expression levels of the control and 
promoterless reporters. Single experiment, average of three repeats, error bars 
represent standard deviation.  
 
Removal of the CMV promoter sequence from the acetylcholinesterase reporter (to 
create the plasmid Plessp15AChE) caused a reduction of luciferase activity to 
background levels (Figure 3.45.). 
  
p15AChE PlessAChE 
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Part 6. 
 
Cancer Results 
 
3.6.1. Introduction to the Cancer Results Section 
Unlike in Alzheimer's disease, there exists a moderate amount of evidence 
implicating eIF4A in cancer. In order to further investigate this relationship, the 
· 875V RI WKUHH RQFRJHQHV DQG WKUHH KRXVHNHHSLQJ JHQHV were cloned into the 
OXFLIHUDVH UHSRUWHU V\VWHPFUHDWHGDVSDUWRI WKLVSURMHFW7KH·875V of ODC1 
has been studied extensively and shown to contain a stable hairpin, a uORF and 
an IRES, as has the VEGFA ·875ZKLFKZDVVKRZQWRFRQWDLQDX25)DQGWZR
IRES elements (see Introduction). Although a well studied oncogene, there is little 
PHQWLRQRIWKH·875RIEGFR in the literature. The housekeeping genes are ǃ
actin, ǃWXEXOLQ and GAPDH. 
7KHGHWDLOVRIWKHVL[·875VVWXGLHGDVSDUWRIWKLVVHFWLRQDUHVKRZQLQTable 20 
and each gene is discussed in the Introduction. 
 
 
Name 
Length 
(nucleotides) 
 
GC 
Content 
(%) 
 
Predicted 
Free 
Energy 
(kcal/mol) 
uORF(s) IRES(s) 
Ⱦ 84 74 -15.50 0 0 
Ⱦ 127 47 -30.10 0 0 
GAPDH  102 61 -21.90 0 0 
ODC1 334 66 -157.50 1 1 
EGFR 246 78 -107.50 0 1* 
VEGFA 491 57 -193.30 1 2 
 
Table 207KHGHWDLOVRIWKH¶875VRIWKHKRXVHNHHSLQJJHQHVDQGRQFRJHQHV
investigated in this section. 
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Firefly Luciferase 
ȕWXEXOLQ¶875 
SV40 Promoter Renilla Luciferase 
EGFR ¶875 
pRtubF 
pREGFRF 
Firefly Luciferase 
ȕDFWLQ¶875 
CMV Promoter 
p15Actin 
ȕWXEXOLQ¶875 p15Tubulin 
GAPDH ¶875 p15GAPDH 
ODC1¶875 p15ODC1 
EGFR ¶875 p15EGFR 
VEGFA ¶875 p15VEGFA 
Figure 3.47. Construct diagrams of the cancer-DVVRFLDWHG¶875UHSRUWHUV 
SV40 Promoter 
Renilla luciferase ORF 
Firefly luciferase ORF 
Multi-cloning site 
Figure 3.46. Map of the pRF parent vector 
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3.6.2. Plasmid construction 
7KHVHTXHQFHVRIWKH·875VRIKXPDQǃDFWLQ, ǃWXEXOLQ, GAPDH, ODC1, EGFR 
and VEGFA as they appeared on the NCBI website (August 2010) were ordered as 
complete sequences from GenScript and cloned into p15 (Figure 3.47.). 
Promoterless variants were constructed by excising the proximal 80% of the CMV 
promoter sequence by AseI digest. Primers for the ǃWXEXOLQ and EGFR ·875V
were designed which included SpeI (upstream) and NcoI (downstream) restriction 
sites (Table 9.). These sequences were amplified using standard Phusion PCR and 
cloned into pRF (Figure 3.46.) in between the two luciferase cistrons. A truncated 
mutant version of the EGFR ·875ZDVFUHDWed by NotI digestion. The plasmid 
that contained this mutant version was termed pREGFRFNotIMut (see page 174 
for diagram). 
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3.6.3. Hippuristanol causes a greater reduction in oncogene reporter expression 
than housekeeping gene reporter expression in -SY5Y cells. 
7KHHIIHFWRIWKH·875VHTXHQFHVRQWKHOXFLIHUDVHUHSRUWHUVZDVHVWDEOLVKHGE\
transfecting the collection of reporter into SH-SY5Y cells. The eIF4A requirement 
of each of the reporters was established using hippuristanol treatment. 
 
Figure 3.48. The effect of 10 µM hippuristanol on the oncogene ¶875-mediated 
expression of reporters in SH-SY5Y cells. Two 24 well plates were seeded with 
SH-SY5Y cells. The following day, six wells were transfected with each of the 
oncogene reporter plasmids (in addition to p80). Four hours later, three wells of each 
were treated with either 10 µM hippuristanol or DMSO. Six hours later, cells were 
lysed for luciferase assay. The red bars (representing proto-oncogenes) and the dark 
blue bars (representing housekeeping genes) were generated from cells recipient of 
only DMSO while those in orange were generated from cells recipient of 10 µM 
hippuristanol. Single experiment, average of three repeats, error bars represent 
standard deviation. 
 
Although the actin, tubulin and GAPDH reporters generate similar expression 
levels, hippuristanol only caused a reduction in the expression of the GAPDH 
reporter (p = 0.0018) (Figure 3.48.). There was no statistical difference between 
the firefly luciferase / Renilla luciferase ratios generated by the ODC1 reporter 
and the housekeeping controls but hippuristanol caused a 72% reduction in its 
expression (p = 3.41E-06). The firefly luciferase / Renilla luciferase ratio generated 
by the EGFR reporter were statistically higher than any of the controls (p = 
0.0010), hippuristanol also caused a reduction in the expression of the EGFR 
reporter (p = 0.0003). The VEGFA reporter generated a much weaker signal than 
the controls, approximately 87% lower (p = 2.19E-08). Hippuristanol caused a 
substantial decrease in the expression of the VEGFA reporter (p = 3.53E-05). 
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3.6.4 Hippuristanol has no effect on cell viability in SH-SY5Y cells as estimated 
by WST-1 assay 
 
If eIF4A is to be an effective drug target in the treatment of cancer, suppression of 
its function must not be overly toxic to the cell. As part of this project, cell 
viability following eIF4A suppression using hippuristanol was quantified using 
WST-1 reagent. 
 
 
 
Figure 3.49. The viability of SH-SY5Y cells treated with hippuristanol. WST-1 
viability assays were performed on SH-SY5Y cells transfected with the oncogene 
reporters and treated with hippuristanol or DMSO (Figure 3.4.). Before cells were 
lysed for luciferase assay, WST-1 reagent was added to the media and plates were 
incubated for a further one hour. After this incubation, 100 µl of the media / WST-1 
mixture was assessed by spectrophotometry. The interpretation of this graph is the 
same as for the previous figure with the exception of the y axis which represents 
arbitrary viability units (absorbance at 440 nm). The control was performed on wells 
containing no cells. Single experiment, average of three repeats, error bars represent 
standard deviation. 
 
 
Relative to the control, all of the cells appeared viable (Figure 3.49.). There is no 
statistical difference between the data for plus and minus hippuristanol (p = 
0.051).  
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3.6.5. Hippuristanol causes a greater reduction in oncogene reporter expression than 
housekeeping gene reporter expression in HeLa cells 
 
 
 
Figure 3.50. The effect of 10 µM hippuristanol on the oncogene reporter 
collection in HeLa cells. Two 24 well plates were seeded with HeLa cells. The 
following day, six wells were transfected with each of the oncogene reporter plasmids 
(in addition to p80). Four hours later, three wells of each were treated with either 10 
µM hippuristanol or DMSO. Six hours later, cells were lysed for luciferase assay. The 
red or dark blue bars were generated from cells recipient of only DMSO while those in 
orange were generated from cells recipient of 10 µM hippuristanol. Single experiment, 
average of three repeats, error bars represent standard deviation. 
 
 
The results of the experiment conducted in HeLa (Figure 3.48.) were broadly 
similar to those generated using SH-SY5Y (Figure 3.50.). The main difference 
between cell lines is the substantial difference between the EGFR reporter and 
the controls (p = 0.0010). In HeLa, the EGFR reporter activity also differed in that 
it responded more strongly to hippuristanol treatment, reducing by 79% (p = 
0.0003) compared to 28% in SH-SY5Y (p = 0.0003). 
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3.6.6. Hippuristanol has no effect on cell viability in HeLa cells 
 
 
Figure 3.51. The viability of HeLa cells treated with hippuristanol. WST-1 viability 
assays were performed on HeLa cells transfected with the oncogene reporters and 
treated with hippuristanol or DMSO (Figure 3.50.). Before cells were lysed for 
luciferase assay, WST-1 reagent was added to the media and plates were incubated 
for a further one hour. After this incubation, 100 µl of the medium / WST-1 mixture 
was assessed by spectrophotometry. The interpretation of this panel is the same as 
for the previous figure with the exception of the y axis which represents arbitrary 
viability units (absorbance at 440 nm). The control was performed on wells containing 
no cells. The interpretation of this panel is the same as for the previous figure with the 
exception of the y axis which represents arbitrary viability units (absorbance at 440 
nm). The control was performed on wells containing no cells. Single experiment, 
average of three repeats, error bars represent standard deviation.  
 
Hippuristanol had a similar effect on the viability of HeLa (Figure 3.549.) as it did 
on SH-SY5Y (Figure 3.51.). There was a slight but non-significant increase in 
viability in response to hippuristanol treatment (p = 0.2581). 
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3.6.7. Hippuristanol causes a reduction in EGFR protein level 
 
In order to ascertain whether the effect of eIF4A inhibition on the EGFR reporter 
is biologically relevant, the protein level of EGFR in HeLa recipient of 
hippuristanol treatment (or control treatment) was estimated by western blot. 
Bands were quantified using ImageJ (Abramoff et al., 2004). 
 
 
 
 
 
 
 
10 µM hippuristanol treatment caused a significant reduction in EGFR protein 
level in HeLa (p = 0.0106) Figure (3.52.). 
  
Figure 3.52. The effect of hippuristanol on EGFR protein level. HeLa cells were 
treated for 24 hours with either 10µM hippuristanol or DMSO, lysates from these cells 
ZHUH ZHVWHUQ EORWWHG IRU (*)5 %ORWV ZHUH UXQ LQ WULSOLFDWH TXDQWLILHG UHODWLYH WR D ȕ
tubulin loading control and averaged. The size marker on the EGFR blot represents 150 
kDa, the marker on the tubulin blot represents 50 kDa. Representative blots are shown, 
single experiment, average of three repeats, error bars represent standard deviation. 
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3.6.8. Promoterless oncogene reporters are not functional 
 
Promoterless versions of the oncogene reporters were used to test for cryptic 
promoter activity. 
 
 
 
Figure 3.53. Versions of the oncogene reporters without the CMV promoter were 
created and assayed for activity in SH-SY5Y cells. The p15 control included a 
functional promoter. Single experiment, average of three repeats, error bars represent 
standard deviation. 
 
 
Removal of the CMV promoter from the reporters caused a reduction in luciferase 
activity to background levels in SH-SY5Y cells (Figure 3.5.). The experiment was 
repeated in HeLa cells with the same result (data not shown). 
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3.6.9. The EGFR · 875 LQ S5) S5(*)5) allows the expression of the 
downstream cistron 
 
In order to test for IRES activity, the EGFR ·875ZDVFORQHGLQWRWKHGLFLVWURQLF
reporter pRF. 
 
 
 
 
Figure 3.54. The EGFR ¶875LQDGLFLVWURQLFFRQWH[WA 24 well plate was seeded 
with SH-SY5Y cells. The following day, eight wells were transfected with pREGFRF 
and eight with pRtubF. 48 hours later, cells were lysed and luciferase assays were 
performed. Panel A shows the levels of Renilla luciferase activity of pRtubulinF and 
pREGFRF transfected into SH-SY5Y cells. Panel B shows the firefly luciferase activity 
of the same constructs.  Single experiment, average of eight repeats, error bars 
represent standard deviation. 
 
There was no significant difference between Renilla luciferase expression levels 
between the two plasmids (p = 0.2690) (Figure 3.5. A.). Panel B shows that the ǃ
tubulin reporter pRtubF generated only background levels of firefly luciferase 
expression (25) while the EGFR reporter generated a signal of almost 10,000 
(9,729).  
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5.6.10 The EGFR ·875LQSURPRWHUOHVVS5)generates  signal 
 
In order to establish whether the apparent IRES activity of the EGFR · 875
(Figure 3.5.) was due to cryptic promoter activity in the dicistronic context, the 
experiment was repeated using a promoterless version of the plasmid.  
 
 
 
Figure 3.55. The EGFR ¶875 LQDSURPRWHUOHVVGLFLVWURQLFFRQWH[W A 24 well 
plate was seeded with SH-SY5Y cells. The following day, eight wells were transfected 
with pREGFRF and eight with Promoterless-pREGFRF. 48 hours later, cells were 
lysed and luciferase assays were performed. Panel A shows the levels of firefly 
luciferase activity of pREGFRF and Promoterless-pREGFRF transfected into SH-
SY5Y cells. Panel B shows the Renilla luciferase activity of the same constructs. 
Single experiment, average of eight repeats, error bars represent standard deviation. 
 
 
With no promoter sequence driving the transcription of the dicistronic 
RenillaORF-(*)5·UTR-fireflyORF sequence, there was a reduction in both 
Renilla luciferase and firefly luciferase expression (Figure 3.55..). 
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11. Northern analysis revels that the EGFR ·875does not induce splicing 
 
The firefly luciferase signal from pREGFRF may be the result of the EGFR ·
UTR acting as a splice site for the dicistronic mRNA (Figure 3.5.). This may 
potentially result in a capped, functional firefly luciferase-encoding mRNA (Figure 
3.56.). 
 
 
 
 
Figure 3.56. The mRNA that may result from the EGFR ¶ 875 IDFLOLWDWLQJ WKH
splicing of the mRNA generated by pREGFRF. The size of the full-length transcript 
is 3.5 kb (top construct); a spliced variant of this will be shorter in length.  
 
 
In order to determine whether the luciferase signal from pREGFRF is a result of 
IRES activity or splicing events, a northern blot was performed (see Materials and 
Methods). The probe was complementary to the firefly luciferase open reading 
frame so if the spliced transcript shown above were being generated then an extra 
band would be apparent on the gel.  
 
 
 
 
Less than 3.5 kilobases but no 
smaller than 1.8 kilobases 
3.5 kilobases 
The minimum length of the firefly 
luciferase ORF is 1,827 bases 
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The EGFR ·875SUREDEO\GRHVQRW LQGXFHVSOLFLQJJLYHQWKDWWKHWUDQVFULSWRI
pREGFRF generates a single mRNA of the expected size. 
 
 
 
  
28S rRNA 
18S rRNA 
pRF pREGFRF pRmycF 
Figure 3.57. Northern blot using a probe complementary to the firefly luciferase 
open reading frame. The 18S rRNA is approximately 1.9 kilobases and the 28S 
rRNA is approximately 4.9 kilobases. All the lanes contain a transcript of the expected 
size. Experiment repeated with the same result (data not shown) 
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5.6.12. The EGFR ·875has IRES activity four in different cell lines 
 
In order to test whether the IRES activity of the EGFR ·875REVHUYHGLQSH-
SY5Y cells was an artefact unique to these cells, the experiment was repeated in a 
further three laboratory cancer cell lines. 
 
 
 
Figure 3.58. The IRES activity of the EGFR ¶875LQGLIIHUHQWFHOOOLQHV24 well 
plates were seeded with HeLa, Huh7, MCF7 and SH-SY5Y cells. The following day, 
six wells of each were transfected with pREGFRF. 48 hours later, luciferase assays 
were performed on the cellular lysates. Single experiment, average of six repeats, 
error bars represent standard deviation. 
 
 
IRES activity was apparent in all four cell lines (Figure 3.58.). There was a 
difference in normalised pREGFRF expression (firefly luciferase activity / Renilla 
luciferase activity) between different cell lines. All differences are statistically 
significant (HeLa vs Huh7 data p = 0.0169).  
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5.6.13. Mapping of the EGFR IRES using upstream start codons 
 
In order to establish where the ribosome enters the EGFR · 875, mutant 
versions of the sequence were generated and cloned into pRF. The principle of the 
out-of-frame upstream AUG mutant mapping is shown below (Figure 3.5.). 
 
 
 
 
 
 
 
 
 
,I WKH ULERVRPHHQWHUV WKH·875XSVWUHDPRI WKH LQWURGXFHGAUG and initiates 
translation at this point, it will encounter a stop codon 114 nucleotides 
downstream and produce a 38 amino acid peptide (Figure 3..). If the ribosome 
enters downstream of the introduced AUG, the wild-type firefly luciferase protein 
will be expressed (Figure 3..).  
 
 
 
 
 
 
 
 
 
 
EGFR ¶875 
If the ribosome enters here 
then a nonsense protein will 
result 
If the ribosome enters here, a 
functional firefly luciferase will 
be expressed 
SV40 Promoter Firefly Luciferase 
Upstream AUG 
Renilla Luciferase 
Figure 3.59. Representation of the mutant EGFR sequence containing the 
introduced upstream AUG sequence (out of frame of the firefly luciferase 
cistron) and the consequences of the ribosome entering either side. 
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Mutant Peptide:  
GVRPSPRLAANATTTAHGPLTPSSIDRESRSELFGEQR 38 
 
 
Wild-type firefly luciferase: 
MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYAEYFEMS  60 
VRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGI  120 
SQPTVVFVSKKGLQKILNVQKKLPIIQKIIIMDSKTDYQGFQSMYTFVTSHLPPGFNEYD  180 
FVPESFDRDKTIALIMNSSGSTGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSV  240 
VPFHHGFGMFTTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTL  300 
IDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAILITPEGDDKPG  360 
AVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHS  420 
GDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGEL  480 
PAAVVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILI  540 
KAKKGGKIAVNSHGFPPEVEEQAAGTLPMSCAQESGMDRHPAACASARINV  591 
 
 
 
 
 
Figure 3.61. Mutant versions of the EGFR ¶ 875 FRQWDLQLQJ LQWURGXFHG AUG 
sequences. Two 24 well plates were seeded with SH-SY5Y cells. The following day, 
six wells of each were transfected with mutant versions of the EGFR reporter and the 
wild-type pREGFRF plasmid. 48 hours later, cells were lysed and luciferase assays 
were performed. The sequences of the mutant versions are shown on the next page. 
Single experiment, average of six repeats, error bars represent standard deviation. 
 
Mutants 3 ² 14 permitted the successful expression of the firefly luciferase gene 
whereas mutants 17 and 19 did not (Figure 3.61.). This indicates that the 
ribosome entry site of the IRES is between 61 ² 25 nucleotides from the wild-type 
start codon; this region is highlighted in purple in the wild-type sequence on the 
following page. 
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Figure 3.60. Amino acid sequences of the mutant peptide resulting from the 
ribosome entering the EGFR ¶ 875 XSVWUHDP RI WKH RXW-of-frame AUG and 
the wild-type firefly luciferase. 
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Wild-type 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGAC
GCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCG
GACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCAC
AACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGA
GCTCTTCGGGGAGCAGCG 
 
Mut 3 (changed base 115 bases from wild type start codon) 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGAC
GCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCG
GAtGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCAC
AACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGA
GCTCTTCGGGGAGCAGCG 
 
Mut 12 (130) 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGAC
GCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCG
GACGACAGGCCACCTCaTgGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCAC
AACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGA
GCTCTTCGGGGAGCAGCG 
 
Mut 14 (187) 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGAC
GCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCG
GACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCAC
AACCACCGCGCACGGCatgCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGA
GCTCTTCGGGGAGCAGCG 
 
Mut 17 (223) 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGAC
GCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCG
GACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCAC
AACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAtgGA
GCTCTTCGGGGAGCAGCG 
 
Mut 19 (241) 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGAC
GCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCG
GACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCAC
AACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGA
GCTCTTCGGGGAGatGCG 
 
 
 
 
  
Figure 3.62. The wild-type and mutant forms of the EGFR ¶875WKDW
were cloned into pRF. The mutant start codons are shown underlined 
and in green, the bases that were changed are shown in lower case. 
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3.6.14. An upstream AUG mutant in a monocistronic context 
One of the mutant versions of the EGFR · 875 ZDV FORQHG LQWR S ZKLFK
encodes firefly luciferase in a monocistronic context. This would test whether 
translation initiation progresses in a cap-dependent or cap-independent manner 
(Figure 3.63.). 
 
 
 
 
 
 
 
 
 
Figure 3.64. A mutant version of the EGFR ¶875LQDPRQRFLVWURQLFUHSRUWHUA 
24 well plate was seeded with SH-SY5Y cells. The following day, six wells were 
transfected with p15EGFRMut12 and six with p15EGFR (wild-type). All 12 wells were 
transfected with the p80 control. 24 hours later, cells were lysed and luciferase assays 
were performed. Single experiment, average of four repeats, error bars represent 
standard deviation. 
 
The introduction of an AUG start codon approximately in the middle of the EGFR 
· 875 RXW RI IUDPH RI D GRZQVWUHDP PRQRFLVWURQLF UHSRUWHU JHQH KDG QR
statistical effect on the data generated by this reporter (p = 0.3427) (Figure 3.64.). 
EGFR ¶875 
If the ribosome enters here, 
e.g. by binding the cap, then a 
nonsense protein will result 
If the ribosome enters here, a 
functional firefly luciferase will 
be expressed 
CMV Promoter Firefly Luciferase 
Upstream AUG 
Figure 3.63. A mutant version of the EGFR ¶ 875 LQ WKH PRQRFLVWURQLF S
reporter plasmid. If the pre-LQLWLDWLRQ FRPSOH[ ELQGV WR WKH ¶ FDS WKHQ D QRQ-
functional version of the luciferase will result and luciferase activity in cells transfected 
with this plasmid will be the same as the background. However, if the ribosome enters 
the sequence usLQJ WKH ,5(6 ZKLFK LV SUHGLFWHG WR EH LQ WKH ¶ VHFWLRQ RI WKH
sequence (Figure 3.61..), then a functional luciferase protein will result. 
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3.6.15 Truncation of the EGFR ·875has no effect on IRES activity 
 
 
Figure 3.65. $WUXQFDWHGYHUVLRQRIWKH(*)5¶875LQDdicistronic reporter. A 
24 well plate was seeded with SH-SY5Y cells. The following day, six wells were 
transfected with pREGFRFNotIMut and six with p15EGFR (wild-type). All 12 wells 
were transfected with the p80 control. 24 hours later, cells were lysed and luciferase 
assays were performed. Single experiment, average of four repeats, error bars 
represent standard deviation. 
 
 
The removal of the red bases (below) by NotI digestion caused no decrease in 
firefly luciferase expression (Figure 3.65.). This indicates that this region is not 
involved in the IRES activity of the sequence.  
 
 
-type 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGC
CCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCC
GCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCT
CGCCGCCAACGCCACAACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATT
GATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCG 
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3.6.16. Hippuristanol significantly reduces firefly luciferase expression generated 
 pREGFRF 
The signal from the monocistronic EGFR ·875UHSRUWHUGHFUHDVHVLQUHVSRQVHWR
hippuristanol treatment. The following experiment was performed in order to 
establish whether the same was true if the sequence was in a dicistronic context.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.66. The effect of hippuristanol on pREGFRF. A 24 well plate was seeded 
with SH-SY5Y cells. The following day, six wells were transfected with pREGFRF (A.) 
and another six were transfected with p15HP and p80 (B.). 24 hours later, 
hippuristanol (or DMSO) was added to the cells. After incubation for a further 24 
hours, cells were lysed for luciferase assay. Single experiment, average of three 
repeats, error bars represent standard deviation. 
 
Hippuristanol treatment caused a significant reduction in firefly luciferase 
activity in both the pREGFRF reporter (p = 0.0002) (Figure 3.66. A.) and the 
hairpin control (p = 6.72689E-06) (Figure 3.66. B.).  
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3.6.17. The EGFR IRES maintains reporter expression in hypoxia 
 
In order to establish whether the previously observed upregulation of EGFR in 
response to hypoxia was translationally controlled, the EGFR reporter plasmid 
was assayed for activity in cells incubated under hypoxic conditions (Franovic et 
al., 2007).  
 
 
 
 
 
 
 
 
 
Figure 3.67. The effect of hypoxia on pREGFRF. Two 24 well plates were seeded 
with SH-SY5Y cells. The following day, six wells from each were transfected with pRF, 
pRtubulinF, pREGFRF or pRmycF. One plate was incubated in a normoxic 
(atmospheric) oxygen concentration and the other in hypoxic (1% O2) conditions. 24 
hours later, cells were lysed for luciferase assay. Single experiment, average of six 
repeats, error bars represent standard deviation. 
 
Hypoxia caused a ~50% reduction in levels of Renilla luciferase expression (p = 
1.18E-22) (Figure 3.6.). In both hypoxic and normoxic conditions, pRF and 
pRtubulinF generated only background levels of firefly luciferase activity while 
pREGFRF and pRmycF generated strong firefly luciferase signals which are 
maintained in hypoxic conditions (Figure 3.6.).  
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3.6.18. Hypoxia has little effect on cell viability 
 
 
 
Figure 3.68. The effect of a 24 hour incubation under hypoxic conditions on the 
viability of SH-SY5Y cells. WST-1 assays for cell viability were performed on the 
cells incubated in hypoxic and normoxic conditions. Single experiment, average of six 
repeats, error bars represent standard deviation. 
 
 
Hypoxia had no significant effect on SH-SY5Y cell viability (p = 0.1620) when 
assayed over the 30 minutes immediately following 24 hour incubations in hypoxic 
and normoxic conditions (Figure 3.68.). 
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3.6.19. Iron response activity in different cell lines and the effect of the truncation 
mutant 
  
In order to test whether the iron-responsive nature of the EGFR reporter was an 
artifact unique to SH-SY5Y cells, it was repeated in different cell lines. The 
plasmid containing the truncated version of the EGFR sequence (page 174) was 
also assayed for activity in the three different cell lines. 
 
 
Figure 3.69. The effect of iron on the wild-type and mutated EGFR ¶ 875
reporters in three different cell lines. 24 well plates were seeded with SH-SY5Y, 
Huh7 or HeLa cells. 12 wells of each plate were transfected with either pREGFRF or 
pREGFRFNotIMut. Six wells of each of these were either treated with 250 µM 
ammonium iron citrate or an equal volume of H22µFRQ¶Single experiment, average 
of six repeats, error bars represent standard deviation. 
 
Removal of the bases shown in red on page 174 did not cause a loss of the iron-
responsive property of the sequence in either SH-SY5Y, Huh7 or HeLa cells 
(Figure 3.69.). Both the wild-type EGFR sequence and the mutant had iron-
response activity in all three cell lines. 
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3.6.20. The EGFR ·875LQDSK\ORJHQHWLFFRQWH[W 
 
 
Common Name 
 
Latin Name 
 
E value 
% Homology 
with Human 
EGFR  ?ǯ 
Common chimpanzee Pan troglodytes 4e-120 99% 
Sumatran orang-utan Pongo abelii 2e-116 98% 
Rhesus macaque Macaca mulatta 3e-103 95% 
Common marmoset Callithrix jacchus 0.002 93% 
Table 21. A BLAST search was performed referencing the human EGFR ¶875
sequence against the non-redundant (nr) database of sequences (29/10/2011) 
(Altschul et al., 1997) 
 
 
In addition to performing a BLAST search for similarity to the human sequence, 
WKH WHUP ¶HJIU·ZDVXVHG WR VHDUFK genome sequences of all species on the NCBI 
Gene database (http://www.ncbi.nlm.nih.gov/gene/?term=egfr, 2/11/2011). This 
identified matches in species not listed above (Table 21.), these sequences were 
compiled into a new database in addition to the sequences identified by the 
BLAST search. A ClustalW2 alignment was performed (using 
http://www.ebi.ac.uk/Tools/msa/clustalw2/, 2/11/2011 with default parameters 
(Larkin et al., 2007)). This alignment was then visualised using ClustalX v2.1 
(Larkin et al., 2007) (Figure 3.70.). 
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7KH ¶ KDOI RI WKH KXPDQ EGFR ¶ 875 VHTXHQFH DOLJQHG WR WKDW RI WHQ
different species 
 
 
7KH¶KDOI 
 
Figure 3.70. ClustalX v2.1 visualisation of a ClustalW2 alignment of the EGFR ¶
UTR of 12 different species. The sequence belonging to the common marmoset 
(Calithrix jaccus) is not included as it is only 40 bases in length and is probably only a 
fragment of the full-length sequence belonging to this organism. There is a much 
KLJKHU GHJUHH RI VHTXHQFH FRQVHUYDWLRQ LQ WKH ¶ KDOI RI WKH VHTXHQFH &DQRQLFDO
bases are indicated by asterisks. 
 
 
The significance of the conservation of the EGFR ·875VHTXHQFHUHmains to be 
determined as the ǃ DFWLQ and ǃ WXEXOLQ · 875 VHTXHQFHV DUH DOVR KLJKO\
conserved (Figure 3.71.). 
 
 
The ȕDFWLQ ¶875VHTXHQFHDOLJQHGWRWKDWRIILYHGLIIHUHQWVSHFLHV 
 
 
The ȕWXEXOLQ ¶875VHTXHQFHDOLJQHGWRWKDWRIGLIIHUHQWVSHFLHV 
 
Figure 3.71. ClustalX v2.1 visualisation of a ClustalW2 alignment of the EGFR ¶
UTR of 12 different species. 
 
181 
 
Chapter  Discussion 
 
Part 1. 
 
Screens for eIF4A Activity 
 
4.1.1. Conclusions from the Optimisation of the In Vitro and Cell-Based Screens 
x The most successful in vitro screen approach was only moderately 
responsive to the activity of eIF4A (Figure 3.24.). 
x However, the optimised cell-based screen was highly sensitive to a 
reduction in eIF4A function (using hippuristanol (Figure 3.12.) and RNAi 
(Figure 3.10., 3.27.)) and eIF4E function (using a cap analogue, Figure 
3.13.)). 
x It is interesting that eIF4E suppression has a greater effect on the 
hairpin-mediated reporter than it does on the control reporter. The mRNA 
discriminatory effect of eIF4E inhibition has been documented (Graff et 
al., 2008) but it remains to be explained why it occurs.  
x Promoterless and dicistronic variants of the hairpin reporter plasmid 
revealed that the hairpin did not exhibit cryptic promoter or IRES activity 
(Figure 3.3., Figure 3.7.). It may be possible that the hairpin acts as a 
cryptic enhancer in the context of the reporter plasmid but this is unlikely 
as the luciferase expression level from the hairpin-containing plasmid 
(p15HP) is much lower than that of the control plasmid (p15) (Figure 3.6.). 
x This means that the hairpin reporter system could form the basis of a 
high-throughput screen for new small molecule inhibitors of translation. 
x Alongside the radioactive helicase assay (Figure 3.16.), the in vitro screen 
may prove to be useful in the low throughput assessment of eIF4A 
function in vitro. It may be particularly useful in identifying false positive 
hits generated by the high throughput cell-based screen. For example, if a 
molecule in the library had activity similar to that of pifithrin-ǂ ZKLFK
inhibits firefly luciferase activity (but not Renilla luciferase), this would be 
registered as a positive for translation initiation inhibition by the cell-
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based screen but would be revealed as a negative by the in vitro assay 
(Rocha et al., 2003). 
 
4.1.2. Limitations of the screens 
x The optimised cell-based screen approach involved the transfection of the 
reporter plasmids into the cell using Fugene 6 followed by a short (four 
hour) recovery period before the eIF4A inhibitor was added to the cells 
(Figure 3.12.). 
x The problem with up-scaling this approach is the cost and inconsistency 
associated transiently transfecting a large number (potentially >100, 000 
wells) of cells. 
 
4.1.3. Future work on the screens 
x One solution to the problem of up-scaling the cell-based screen would be to 
create a stable cell line which constitutively expresses the control Renilla 
luciferase gene and the hairpin-mediated firefly luciferase gene. 
x This would be theoretically easy to create as the plasmids contain 
hygromycin (pGL4.15) and neomycin (pGL4.80) resistance genes. 
x The problem with this solution is that there would be a perpetually high 
concentration of firefly luciferase protein within the cells. An eIF4A 
inhibitor added to these cells would only curtail de novo luciferase 
expression. The accumulated protein would have to degrade for the effects 
of the inhibition to be observable. 
x An inducible expression vector could be used to combine both these 
approaches. For example, the hairpin and the luciferase ORF could be 
cloned into the plasmid below (Figure 4.1., Clontech, Cat # 631168) 
between the Tet-On 3G sequence and the SV40 polyA signal. Tetracycline 
would be added along with the candidate molecule. This would mean that 
all the subsequent firefly luciferase expression would be proportional to 
the functionality of the eIF4A in the cells.  
 
 
  
Figure 4.1. An example of a tetracycline-inducible 
plasmid that already contains a CMV promoter 
sequence. 
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Part 2. 
 
eIF4A Paralogs 
 
4.2.1. The effect of individual siRNA knockdown of each paralog on the hairpin 
reporter system 
x Consistent with the data generated using shRNA, knockdown of eIF4AI 
using siRNA causes a reduction in hairpin-mediated luciferase expression 
(Figure 3.27.). 
x Interestingly, knockdown of eIF4AII (confirmed to be successful by 
western blot) does not cause a significant reduction in hairpin-mediated 
luciferase expression relative to the control (Figure 3.27.). 
x The consensus in the literature is that paralogs I and II perform the same 
function (see 1.2.2. Paralogs). The fact that eIF4AII is not detectibly 
involved in the unwinding of the secondary structure of the hairpin-
containing luciferase mRNA (Figure 3.27.) strongly supports the theory 
that it is functionally distinct from eIF4AI under these conditions.  
x Individual or combined knockdown of each of paralog of eIF4A has little 
effect on cell viability (estimated using WST-1) or the number of 
dissociated cells (Figure 3.28.). 
x This may be a surprising result given the apparent importance of these 
proteins in gene expression. Although surprising, cellular tolerance to 
eIF4A suppression has been documented in the literature (see 1.4.5. 
eIF4A and Cancer). 
 
4.2.2. Limitation of the data generated by the hairpin reporter in response to 
eIF4A knockdown 
x The western blots confirming the successful knockdown of each of the 
paralogs of eIF4A (Figure 3.27.) must be repeated if these data are to be 
published. The unconvincing appearance of some of the knockdowns limits 
the confidence with which conclusions may be drawn from this 
experiment. 
x In mouse cells, it has been shown that eIF4AII is more highly expressed 
during quiescent phases of growth whereas eIF4AI is constitutively 
expressed (Williams-Hill et al., 1997). A confluent flask of cells was used 
for the experiment in this project that determined that knockdown of 
eIF4AII had no effect on the expression of the hairpin-mediated firefly 
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luciferase gene. No general conclusions can therefore be made until the 
experiment is repeated using a range of different cell densities so that the 
effect of the differential expression of the two different paralogs can be 
established. 
x WST-1 (Roche, Cat # 11 644 807 001) is a tetrazolium salt that is cleaved 
by mitochondrial dehydrogenases which generates formazan (which 
changes the colour of the media). This assay therefore does not measure 
cell viability directly. As such, care must be taken when making 
conclusions regarding overall viability based on WST-1 assay alone. 
x Alongside WST-1 assay, floating cell counts can give an indication of the 
health of the population of cells. However, this approach is also flawed if it 
is used to make general inferences regarding cell viability as dead cells 
may not float and floating cells may not be dead. 
 
4.2.3. Future work focusing on the effect of knocking down each paralog on the 
hairpin reporter system 
x The western blots must be repeated. 
x The experiment should be repeated using cells at different densities. 
x It would be interesting to determine the effect of individual eIF4A paralog 
knockdown on sequences other than the hairpin. For example, expression 
from the Alzheimer's disease- or cancer- associated reporter plasmids may 
be different in response to individual knockdown compared to 
hippuristanol treatment.  
 
4.2.4 The response of the eIF4A · 875 UHSRUWHUV  paralog knockdown and 
hippuristanol treatment 
x In order to establish whether the genes encoding the three paralogs of 
eIF4A are translationally controlled by a feedback mechanism, cells 
transfected with reporter SODVPLGVFRQWDLQLQJWKH·875VRIWKHHDFKRI
the genes were treated with siRNAs directed against the three proteins 
(Figure 3.29.). 
x As expected, knockdown of eIF4AI caused reductions in the signals of all 
three reporters roughly proportional to the amount of predicted secondary 
structure (Figure 3.29.). 
x Despite being highly structured, the eIF4AIII ·875VWLPXODWHVUHSRUWHU
gene expression and has a less than expected requirement for eIF4AI 
function (Figure 3.29.). The function of this reduced requirement may be 
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to preserve eIF4AIII expression under conditions that are inhibitory to 
eIF4AI (and possibly eIF4E). Since eIF4AIII is involved in mRNA splicing 
and other processes associated with mRNA turnover, it may be necessary 
for cell survival (Ferraiuolo et al., 2004; Holzmann et al., 2000). While it 
has previously been shown that knockout of eIF4AIII is lethal during 
development, knockdown in mature cells is tolerated (Haremaki et al., 
2010). The stimulatory effect of the eIF4AIII · 875 WRJHWKHU ZLWK LWV
resistance to eIF4AI suppression and the importance of the gene in 
development specifically, indicate that translational control of the 
sequence is likely to be important in immature organisms. 
x Somewhat surprisingly, hippuristanol treatment causes a different effect 
to the knockout of eIF4AI on the reporters containing the eIF4A ·875
sequences (Figure 3.30.). Hippuristanol is thought to inhibit paralogs I 
and II but not III (Bordeleau et al., 2006). The eIF4AIII reporter behaves 
like the hairpin reporter following hippuristanol treatment, a significant 
drop in reporter gene expression is observed (Figure 3.30.). The similarity 
of the data generated by combined eIF4AI and eIF4AII knockdown and 
hippuristanol treatment is consistent with the idea that hippuristanol 
inhibits eIF4AII in addition to eIF4AI (Figure 3.29., Figure 3.27., Figure 
3.30.).  
 
4.2.5. Limitations of the data generated by the eIF4A ·875UHSRUWHUV 
x The main difficulty in interpreting these findings is that fact that 
eIF4AIII has multiple roles, none of which is fully understood (see 1.2.2. 
Paralogs). 
 
4.2.6. Future work inhibiting each paralog of eIF4A in cells transfected with 
UHSRUWHUSODVPLGVFRQWDLQLQJWKH·875VRIHDFKSDUDORJ 
x As with the previous experiment, it would be interesting to establish 
whether there are any cell-growth dependent effects on the expression of 
the eIF4A ·875UHSRUWHUV 
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Part 3. 
 
PDCD4 
 
4.3.1. Conclusions from the response of the hairpin reporter to PDCD4 knockdown 
x PDCD4 knockdown causes an increase in the expression of the control 
Renilla luciferase protein but a more significant increase in the expression 
of the hairpin-mediated firefly luciferase protein (Figure 3.31.). This 
differential is expected given the previously demonstrated requirement of 
the hairpin reporter for eIF4A activity. 
x Although there is no statistical difference between the control and the 
PDCD4 knockdown-treated hairpin reporters (Figure 3.31.), optimisation 
of the knockdown and the reporter system may eventually lead this 
difference to become significant. 
 
4.3.2. The limitations of the experiment in which the response of the hairpin 
reporter to PDCD4 knockdown was observed 
x The fact that PDCD4 knockdown is not statistically detectible (Figure 
3.31.) is a major limitation to the use of the cell-based screen to identify 
new small molecule inhibitors of PDCD4.  
 
4.3.3. Future work on the detection of PDCD4 activity using the hairpin reporter 
x A reporter plasmid containing a much more highly structured sequence 
preceding the luciferase ORF may be more sensitive to changes in PDCD4 
activity.  
x Ideally this sequence would require the maximum eIF4A activity of the 
cell. Inhibition of PDCD4 would be predicted to cause an increase in this 
activity. 
 
4.3.4. PDCD4 knockdown and the response to DNA damage by UV light 
x Under normal conditions, PDCD4 knockdown does not significantly affect 
viability or the number of dissociated SH-SY5Y cells or HeLa cells UV 
treatment decreases cell viability and increases the number of dissociated 
cells, knockdown of PDCD4 in combination with UV exposure further 
decreases viability and further increases the number of dissociated cells in 
SH-SY5Y and in HeLa (Figure 3.32., Figure 3.33., Figure 3.34., Figure 
3.35., Figure 3.36., Figure 3.37.). 
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x These data support the idea that PDCD4 is important in the DNA damage 
response in human cells as well as in chicken cells, as has been previously 
demonstrated (Bitomsky et al., 2008; Singh et al., 2009). 
x Experiments performed by other members of our laboratory (mainly 
Andrew Bottley and Alexander Kondrashov) involved the treatment of 
cells with hippuristanol prior to UV exposure or chemically-induced DNA 
damage. It was found that eIF4A inhibition caused a significant increase 
in viability in HeLa and SH-SY5Y cells in both these cases. In JB6+ cells, 
which lack PDCD4, a marked increase in viability was observed in 
response to DNA damage when eIF4A was suppressed. 
x These data suggest that the involvement of PDCD4 in the response to 
DNA damage may be due to its inhibitory relationship with eIF4A. 
 
4.3.5. Limitations of the experiments ascertaining the effect of PDCD4 knockdown 
on the DNA response 
x The limitations of using WST-1 assay and floating cell counts to estimate 
cell viability are discussed previously. 
 
4.3.6. Future work investigating the relationship between PDCD4 and DNA 
damage 
x In order to get a more complete picture of cell viability following DNA 
damage and PDCD4 knockdown, other techniques could be applied 
alongside the WST-1 assay and the floating cell counts. For example, 
bromodeoxyuridine (BrdU) labelling which is used to quantify the rate at 
which DNA is synthesised in a cell or a cytolysis assay which is used to 
estimate cell membrane stability. 
x It would also be interesting to investigate the response of PDCD4-
impaired cells to a range of different UV intensities and durations of 
exposure. 
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Part 4. 
 
Alzheimer's Disease 
 
4.4.1. Conclusions from the Alzheimer's disease-associated reporter collection 
x It has been previously shown that the expression of a luciferase gene is 
VXSSUHVVHG ZKHQ LWV P51$ FRQWDLQV WKH · 875V EHORQJLQJ WR APP, 
BACE1, ADAM10 or MAPT. The data presented in this thesis corroborate 
these findings (Figure 3.39.). 
x 7KH·875VRIClu1, CR1, the presenilins, SOD1 and TXN also suppress 
reporter gene expression (Figure 3.39.).  
x ,QWHUHVWLQJO\WKH·875VRISOD1 and TXN are less inhibitory than the 
rest (Figure 3.39.). This indicates that suppression of eIF4A would not 
impair the cellular defence against oxidative stress (Pappolla et al., 1992; 
Wollman et al., 1988). 
x 7KH UHSRUWHUV FRQWDLQLQJ WKH · 875V RI WKH JHQHV SUHGLFWHG WR SOD\
harmful roles in Alzheimer's disease had significantly elevated eIF4A 
UHTXLUHPHQWVUHODWLYHWRWKHUHSRUWHUVFRQWDLQLQJWKH·875VRIADAM10, 
SOD1 and Txn (Figure 3.41, Figure 3.42.). 
x The eIF4A requirement of the · 875 RI ADAM10 is much lower than 
expected based on its length and predicted free energy (Figure 3.42., 
Figure 5.1.).  
x The eIF4A requirement of the AChE ·875is much higher than expected 
based on its length and predicted free energy (Figure 3.44., Figure 5.1.). 
This is consistent with the fact that the sequence is very (81%) GC rich and 
predicted to form a hairpin (Figure 4.2.).  
x The existence of this hairpin may serve to regulate acetylcholinesterase 
expression in neuronal cells, in which translational control is heavily 
relied upon to modulate gene expression away from the nucleus e.g. at the 
far end of an axon (Costa-Mattioli, 2009).  
x It is possible that the high eIF4A requirement of the sequence is overcome 
in neuronal cells by HuD which stimulates the activity of eIF4A is only 
expressed in neuronal cells and has previously been shown to bind to the 
·875RIacetylcholinesterase (Deschênes-Furry et al., 2006). 
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Figure 4.2. The predicted 
secondary structure of the 
entire acetylcholinesterase 
¶875 
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4.4.2 Limitations of the data generated by the Alzheimer's disease-associated 
reporter collection 
x The data from the ADAM10 reporter cannot be directly compared to the 
rest as they were generated using a different reporter system (Figure 
3.42.). 
 
4.4.3. Future work investigating the effect of Alzheimer's disease-DVVRFLDWHG ·
UTR sequences on the expression of downstream luciferase genes 
x It is necessary to demonstrate that the AChE · UTR forms a hairpin 
structure in reality using in vitro structure mapping as it is currently only 
predicted (by mfold) to do so. 
x It would be interesting to expand the collection of Alzheimer's disease-
associated reporter plasmids. 
 
4.4.4. eIF4A as a drug target in Alzheimer's disease 
x The dependency of the expression of APP and MAPT on eIF4A function 
has been demonstrated at the protein level by Andrew Bottley, a member 
of the RNA Biology Group, University of Nottingham (Bottley et al., 2010). 
x The data from the reporter library also support the idea that eIF4A may 
prove to be a useful drug target for the treatment of Alzheimer's disease 
(Figure 3.41.). 
x WST-1 assays revealed that eIF4A suppression (using hippuristanol) 
treatment was very well tolerated (Figure 3.49.). 
 
4.4.5. Limitations of using eIF4A as a drug target in Alzheimer's disease 
x The claim that eIF4A could be used as a drug target for the treatment of 
Alzheimer's disease can only be made with a limited amount of confidence. 
The potential physiological effects of eIF4A suppression in humans cannot 
be anticipated based on the data presented in this thesis. 
 
4.4.6. Future work into the involvement of eIF4A in Alzheimer's disease 
x The collection of Alzheimer's disease-associated reporters is currently 
being used to investigate further the properties of the UTR sequences (e.g. 
using mutagenesis etc). 
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Part 5. 
 
Cancer 
 
4.5.1. Conclusions from the oncogene reporter collection 
x In HeLa and SH-SY5Y cells, the ODC1 reporter generates a signal similar 
to the control reporters, the EGFR reporter generates a stronger signal 
than the controls and the VEGFA reporter generates a weaker signal 
(Figure 3.48., Figure 3.50.). 
x The signal from the ODC1 reporter may be regarded as resulting from a 
balance between the stimulatory effect of the IRES and the inhibitory 
effects of the hairpin and the uORF (Figure 3.48., Figure 3.50.) (Danner, 
2002). 
x Although the VEGFA ·875FRQWDLQVWZR,5(6HOHPHQWVLWLVOLNHO\WKDW
the combined stimulatory effect of these is not sufficient to overcome the 
inhibitory effect of the long, highly structured sequence (Figure 3.48., 
Figure 3.50.) (Huez et al., 1998).  
x Like the reporters containing the Alzheimer's-associated sequences, the 
UHSRUWHUV FRQWDLQLQJ WKH · 875V RI JHQHV LQYROYHG LQ FDQFHU JHQHUDWHG
lower signals in response to hippuristanol treatment than those 
FRQWDLQLQJ·875VRIKRXsekeeping genes (Figure 3.48., Figure 3.50.). The 
results for the ǃ DFWLQ, ǃ WXEXOLQ, GAPDH, ODC1 and VEGFA reporters 
were as expected based on the predicted secondary structures of the 
sequences and the current literature (Figure 3.48., Figure 3.50.).  
 
4.5.2. The EGFR ·875 
x The EGFR · 875 VHTXHQFH ZDV IRXQG WR permit the expression of the 
downstream cistron in pRF in four different human cell lines without 
exhibiting cryptic promoter activity or induce splicing (Figure 3.54, Figure 
3.55., Figure 3.56., Figure 3.57., Figure 3.58.). 
x The ribosome is predicted to enter the sequence close to the start codon 
(Figure 3.59., Figure 3.60., Figure 3.61., Figure 3.62., Figure 3.63., Figure 
3.64., Figure 3.65.) 7KLV SRWHQWLDOO\ H[SODLQV ZK\ WKH · 875 LV OHVV
inhibitory to reporter gene expression than predicted. 
x 7KH SUHVHQFH RI DQ ,5(6 LQ WKH · 875 RI EGFR is consistent with the 
translational upregulation of the expression of EGFR expression in 
hypoxic conditions (in which cap-independent translation initiation is 
favoured).  
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x Expression of the downstream firefly cistron within cells transfected with 
pREGFRF remained constant following exposure to hypoxic conditions 
(Figure 3.67.). This is consistent with the translational upregulation of 
EGFR expression being mediDWHGE\WKH·875  
x Providing very strong evidence for the presence of an IRES in the EGFR ·
UTR is the fact that knockdown of a number of IRES trans acting factors 
(ITAFs) reduces EGFR expression (Lindsay Wilson, personal 
communication, 2011).  
x The EGFR · 875 H[KLELWV D VLJQLILFDQW UHTXLUHPHQW IRU H,)$ LQ
monocistronic and dicistronic contexts in HeLa and SH-SY5Y cells (Figure 
3.48., Figure 3.50., Figure 3.66.). The fact that the sequence behaves in 
almost exactly the same way in response to hippuristanol in a 
monocistronic context (in which the ribosome has the option of entering at 
the cap) and a dicistronic context (in which the ribosome must enter at the 
IRES) supports the idea that the IRES is favoured (Figure 3.66.).  
x Since the ribosome appears to enter the sequence between 25 and 61 
nucleotides away from the start codon (Figure 3.61.), it would be expected 
that the EGFR ·875VKRXOGKDYHDQH,)$UHTXLUHPHQWFRPSDUDEOHWR
that of a much shorter sequence. The predicted secondary structure of the 
full length EGFR ·875DQGWKHUHJLRQLGHQWLILHGDVWKHULERVRPDOHQWU\
site is shown on the following page (Figure 4.3.). 
x If the region of the EGFR ·875XSVWUHDPRIWKHULERVRPHHQWU\VLWHZDV
subject to sequence drift, probability suggests that the sequence would 
contain approximately three AUG codons (Enard et al., 2002; King and 
Wilson, 1975). The fact that there are no upstream AUGs in the EGRF ·
UTR is consistent with the sequence having some function.  
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Figure 4.3. mfold prediction of the full length EGFR ¶875VHFRQGDU\
structure. The region indicated in red is the predicted ribosomal entry site. 
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x The ribosomal entry site within the EGFR ·875 is predicted to form a 
hairpin (Figure 4.3.). This short hairpin only has a free energy of -18.2 
kcal/mol (mfold (Zuker, 2003)). This level of structure is similar to that of 
WKH ǃ DFWLQ · 875 ZKLFK KDV D ORZ H,)$ UHTXLUHPHQW (Figure 3.48., 
Figure 3.50.). The existence of this hairpin is therefore not sufficient by 
itself to explain the high eIF4A requirement of the EGFR ·875 
x The explanation for the discrepancy between this eIF4A requirement and 
the fact that that the IRES allows the majority of the sequence to be 
bypassed is probably the fact that the IRES itself requires eIF4A. The 
IRESs belonging to the human genes c-myc, N-myc and BiP have a strong 
requirement for eIF4A (Bordeleau et al., 2006; Spriggs et al., 2009; Thoma 
et al., 2004). It has been suggested that this requirement indicates that 
WKHVWUXFWXUHRIWKHVH,5(6VQHHGV¶UHPRGHOOLQJ·E\H,)$EHIRUHWKH\DUH
able to function (Kolupaeva et al., 2003; Komar and Hatzoglou, 2011; 
Pause et al., 1994b; Spriggs et al., 2009). However, experimental 
confirmation of these predicted structures is required to support this 
model.  
x Across the full length of WKHKXPDQ(*)5·875WKHUHLVDKLJKGHJUHH
of conservation in other species (Figure 3.70.). This result is expected 
given that EGFR is functionally important. Functional importance is 
usually associated with evolutionary conservation (Boffelli et al., 2004; 
Dermitzakis et al., 2005). However, interestingly, the majority of the 
YDULDWLRQ EHWZHHQ VSHFLHV RFFXUV LQ WKH · UHJLRQ (Figure 3.70.) 7KH ·
region, which is expected to contain ribosomal entry site in humans, 
exhibits a higher degree of conservation across these 13 varied species 
with five bases in this region the same for all species (Figure 3.70.). This 
suggests that the IRES may have an important role in the expression of 
EGFR. Evolutionary conservation is particularly significant in 
untranslated regions as these sequences are generally freer to diversify 
than coding regions and still perform the same function (Enard et al., 
2002; King and Wilson, 1975).  
x Hippuristanol significantly suppressed the expression of the EGFR 
protein, reducing it by 93% compared to the control (Figure 3.52.). 
x Expression of the firefly luciferase cistron in three different cell lines 
transfected with pREGFRF was reduced following treatment of these cells 
with 250 µM iron (Figure 3.69.).  
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4.5.3 Limitations of the data generated by the oncogene reporter collection  
x The dicistronic EGFR reporter was assayed for activity in four different 
cell lines (HeLa, Huh7, MCF7 and SH-SY5Y) but the rest of the reporter 
plasmids were only tested in two (HeLa and SH-SY5Y) (Figure 3.58., 
Figure 3.58., Figure 3.60.). 
x The mutant monocistronic EGFR reporter transcript may be subject to 
reinitiation i.e. the mutant start codon directs the synthesis of a nonsense 
peptide that is short enough that the ribosome may reinitiate and 
translate the luciferase ORF (Figure 3.60.). This is unlikely however as 
expression levels from the mutant plasmid are statistically 
indistinguishable from those generated by the non-mutated plasmid 
(Figure 3.64.). This indicates that, in both cases the ribosome is entering 
at the IRES in the ·KDOIRIWKHEGFR ·875VHTXHQFH 
x No firm conclusions can be made regarding the response of the pREGFRF 
reporter to iron treatment as the concentration of iron added may not be 
biologically relevant (250 µM was added to the ~1.8-3.5 µM already 
present in the medium). 
 
4.5.4 Future work on the oncogene reporter collection  
x There is sufficient evidence for the existence of an IRES element within 
WKH · 875 RI KXPDQ EGFR to submit for peer review and (subject to 
approval) publication. 
x It would be interesting to use the monocistronic and dicistronic EGFR ·
UTR reporter plasmids to further investigate the relationship between 
EGFR expression and ITAF knockdown (discovered by Lindsay Wilson). 
 
4.5.5. eIF4A as a drug target in cancer 
x EGFR, ODC1 and VEGFA are all being investigated for their feasibility as 
drug targets, each with a range of candidate drugs at various stages in the 
clinical trials process (2005; Folkman, 2007; Kobayashi et al., 2005; Seiler, 
2003). Clearly, targeting these proteins individually is expected to be 
therapeutically beneficial in the treatment of cancer. The results 
presented in this thesis suggest that suppression of eIF4A would reduce 
the expression and therefore the activity of all three of these oncoproteins 
(Figure 3.48., Figure 3.50.).  
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x It may prove that eIF4A inhibition could be useful in curtailing the 
aberrantly high expression of certain oncogenes (including EGFR) in the 
hypoxic conditions often associated with the tumour environment.  
x A previous study into the effect of silvestrol (another small molecule 
inhibitor of eIF4A) on healthy and tumour-bearing mice found this 
treatment to be also well tolerated (Cencic et al., 2009). Levels of 
aminotransferase toxicity markers in the blood of these mice were 
measured and found to either remain constant or fall (Cencic et al., 2009). 
As outlined in the Introduction, the mice used in this study were closely 
monitored and displayed no noticeable side effects to the eIF4A-
suppressive treatment (Cencic et al., 2009). A more recent study into the 
effects of silvestrol by a different group concluded that the molecule has a 
favourable pharmacokinetic profile in mice and an excellent level of 
bioavailability when administered inter-peritoneally (Saradhi et al., 2011). 
 
4.5.6 Limitations of using eIF4A as a drug target in cancer  
x While mutations that directly affect eIF4A in cancer have never been 
documented, it is possible that cancer cells may become resistant to eIF4A 
inhibitors. 
x Tables 4 and 5 show that tumour suppressor JHQHVRIWHQSRVVHVV·875V
with properties that suggest that they may have a high eIF4A 
requirement. This may mean that inhibition of eIF4A could result in the 
reduction of tumour suppressor proteins in the cell, potentially making the 
cancer more aggressive. 
x More general considerations regarding the use of eIF4A as a drug target 
are discussed in the Alzheimer's disease section. 
 
4.5.7 Future work investigating eIF4A as a drug target in cancer  
x The studies investigating the feasibility of using eIF4A as a drug target 
are discussed in the Introduction.  
x It would be necessary to quantify the levels of the tumour suppressor 
proteins in cells previously treated with eIF4A inhibitors or subject to 
eIF4A knockdown. This may be useful in anticipating the potential 
detrimental effects of therapeutic eIF4A inhibition.  
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Part 6.  
 
Overall Summary 
 
 
4.6.1. Overall Conclusions from the project 
x The hairpin reporter system is suitable for identifying new eIF4A 
inhibitors by high-throughput screening  
x eIF4AII has an apparently distinct function to eIF4AI. 
x The cellular DNA damage response is impaired if PDCD4 is lacking. This 
is possibly due to the interaction of PDCD4 with eIF4A. 
x 7KH H[SUHVVLRQ RI UHSRUWHU JHQHV SUHFHGHG E\ WKH · 875 VHTXHQFHV RI
genes predicted to play harmful roles in Alzheimer's disease have a 
greater UHTXLUHPHQW IRU H,)$ IXQFWLRQ WKDQ JHQHV SUHFHGHG E\ WKH ·
UTRs of genes involved in the defence against oxidative stress. 
x 7KH H[SUHVVLRQ RI UHSRUWHU JHQHV SUHFHGHG E\ WKH · 875 VHTXHQFHV RI
oncogenes also have a greater requirement for eIF4A function than genes 
SUHFHGHGE\WKH·875VRIKRXVHNHHSLQJJHQHV 
x The EGFR · 875 FRQWDLQV DQ ,5(6 WKDW DOORZV WKH ULERVome to enter 
near the start codon and maintains the expression of the downstream 
gene in hypoxic conditions. 
 
4.6.2. Limitations of the project and future work 
x The biggest limitation of applying the conclusions generated using the 
reporters to living cells is that the UTR sequence cloned into the 
plasmids may not be the same as that found in nature. This is 
particularly true of highly structured sequences as the reverse 
transcriptase enzyme (used to make a cDNA copy of the RNA for 
sequencing) may detach from the RNA at regions of very stable 
structure (Buell et al., 1978; Bustin, 2000). 
x To address this potential inaccuracy, ·5ACE (rapid amplification of 
F'1$ HQGV SULPHUV IRU WKH · 875 VHTXHQFHV RI D QXPEHU RI WKH
genes studied as part of this project are currently being used by 
members of the RNA Biology Group. 
x The Alzheimer's disease reporter collection was only transfected into 
SH-SY5Y; it would be interesting to investigate the expression pattern 
of the luciferase genes in different neuronal cell lines. 
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x 2QO\ (*)5 DQG ǃ WXEXOLQ SURWHLQ OHYHOV ZHUH HVWLPDWHG IROORZLQJ
hippuristanol treatment. It would be interesting to ascertain whether 
the levels of ODC1 and VEGFA protein fall in response to eIF4A 
suppression to the same extent as the luciferase genes preceded by 
WKHLU·875VHTXHQFHV 
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Chapter 5 Overall Analysis 
  
   
Figure 5.1. The length and predicted free energy of the sequences 
cloned into the reporter plasmids were compared to their eIF4A 
requirement. This requirement is defined as the percentage drop in 
reporter expression following treatment of the cells transfected with the 
reporter with 10 µM hippuristanol. The data-points indicated in yellow 
represent acetylcholinesterase and the data-points indicated in blue 
represent ADAM10.  
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Name 
 
Length 
(bases) 
 
GC Content 
(%) 
 
Predicted 
Free Energy 
(kcal/mol) 
 
 
% Drop (eIF4A 
requirement) 
eIF4AI 103 66 -39.20 -7.40688 
eIF4AII 39 53 -7.000 23.47715 
eIF4AIII 222 74 -75.90 86.78376 
Hairpin 137 74 -82.20 98.19891 
APP 194 76 -101.1 78.88428 
BACE1 461 76 -226.7 86.26154 
Clu 305 59 -128.6 82.83702 
CR1 140 50 -35.10 86.859 
PS1 284 56 -99.60 78.13176 
PS2 427 57 -157.5 95.60934 
MAPT 320 74 -132.5 91.65273 
SOD1 148 64 -58.70 25.02442 
TXN 80 54 -24.50 24.03096 
ADAM10 444 68 -215.9 31.41395 
AChE 139 81 -78.50 82.7139 
HTT 145 73 -70.60 34.99489 
Ⱦ 84 74 -15.50 6.14119 
Ⱦ Tubulin 127 47 -30.10 4.409291 
GAPDH 102 61 -21.90 28.248 
ODC1 334 66 -157.5 64.72523 
EGFR 246 78 -107.5 79.08524 
VEGFA 491 57 -193.3 76.85123 
Table 22. 7KHFKDUDFWHULVWLFVRIHDFK¶875FORQHGLQWRWKHUHSRUWHUV\VWHP
were compiled, together with the percentage drop in their expression 
following hippuristanol treatment (10 µM) in SH-SY5Y cells. This percentage 
drop may be regarded as proportional to the requirement of the sequence for 
eIF4A function. 
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